|
Mayne Pharma Group Limited is a specialty pharmaceutical company focused on commercialising branded and generic drugs in women’s health and dermatology. The company develops and manufactures oral and topical dose forms, including modified-release products and poorly soluble compounds, through its contract development and manufacturing organisation (CDMO) services. Key products include NEXTSTELLIS and IMVEXXY. Mayne Pharma serves markets in Australia and the United States, with a product development and manufacturing facility in Salisbury, Australia. The company partners with clients worldwide for pharmaceutical development, analytical testing, and commercial manufacturing. It maintains a 40-year track record in oral drug delivery systems. Summarised from the company's own disclosures, fiscal year ended Jun 2026 |
Industry Pharmaceuticals, Biotechnology & Life Sciences | Homepage maynepharma.com |
| Sector Healthcare | IR page investors.maynepharma.com | |
|
Tags
women's health, dermatology, oral drug delivery, cdmo, branded pharmaceuticals, generic pharmaceuticals, topical formulations, modified-release products, NEXTSTELLIS, IMVEXXY, DistributeRx, Adelaide Apothecary
|
Press page maynepharma.com/news |
Metrics
| Valuation | |
|---|---|
| Market cap | A$ 277.61M |
| Market cap (USD) | $ 186.868M |
| P/E | 8.90 |
| PEG | — |
| P/BV | 1.24 |
| P/S | 0.72 |
| P/OCF | 20.02 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 8.2% |
| ROI | 7.2% |
| ROIC | 7.2% |
| Profit margin | 8.1% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | -35.7% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | — |
| Diluting (TTM) | Yes |
| Debt/Equity | 11.0% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 2 |
| Quality score | 20.0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 383.676M | 408.095M | 388.399M | 183.586M | 157.147M | 400.781M | 456.985M | 525.208M | 530.313M | 572.595M | 267.28M | 60.664M | 143.254M | 84.071M | 52.546M | 50.101M | 36.713M |
| Net profit | 31.198M | -90.071M | -211.555M | 117.249M | -281.286M | -17.943M | -92.789M | -279.203M | -133.984M | 88.567M | 37.355M | 10.199M | 21.29M | -2.843M | 6.153M | — | — |
Podcast Mentions
Announcements lodged with ASX, newest first, routine forms (director and substantial-holding notices, daily buy-back and quotation notices) included. The link opens the announcement on ASX. Press releases from the company's own website, newest first.
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:02 AM
Released 29 Oct 2026 - 8:02 AM
LikeFollowShare
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 1 / 6 Announcement Summary Entity name MAYNE PHARMA GROUP LIMITED Date of this announcement Thursday October 29, 2026 The +securities the subject of this notification are: Total number of +securities to be issued/transferred ASX +security code Security description Total number of +securities to be issued/transferred Issue date MYXAN PERFORMANCE RIGHTS 1,285,036 22/10/2026 Refer to next page for full details of the announcement +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 2 / 6 Part 1 - Entity and announcement details 1.1 Name of entity MAYNE PHARMA GROUP LIMITED We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities. 1.2 Registered number type ABN Registration number 76115832963 1.3 ASX issuer code MYX 1.4 The announcement is 1.5 Date of this announcement 29/10/2026 New announcement
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 3 / 6 Part 2 - Issue details 2.1 The +securities the subject of this notification are: 2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which: has an existing ASX security code ("existing class") +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 4 / 6 Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B Additional +securities in an existing class issued under an +employee incentive scheme ASX +security code and description MYXAN : PERFORMANCE RIGHTS Date the +securities the subject of this notification were issued 22/10/2026 Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Were any of the +securities issued to +key management personnel (KMP) or an +associate? Provide details of the KMP or +associates being issued +securities. Name of KMP Name of registered holder Number of +securities Aaron Gray Aaron Gray 286,180 Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms
- Rights are eligible for vesting on 1 September 2029, subject to achievement of specific vesting condition hurdles.
- The number / proportion of Rights that vest is based on the absolute Total Shareholder Return (TSR) over the period with 20% vesting if a TSR Compound Annual Growth (CAGR) of 8% is achieved, rising to 100% vesting for achievement of a TSR CAGR of 15%. Any other information the entity wishes to provide about the +securities the subject of this notification
- The base test date for Rights is set as 1 September 2026 and the expiry date is 1 September 2031.
- The Base Test Price for the Rights is $3.14
- If the Rights are not exercised before the expiry date they will automatically lapse
- There are no voting rights or rights to dividends whilst the participant holds a Right Issue details Number of +securities 1,285,036 Yes Yes
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 5 / 6 Part 4 - +Securities on issue Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise: The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing. 4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX) ASX +security code and description Total number of +securities on issue MYX : ORDINARY FULLY PAID 81,890,887 4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX) ASX +security code and description Total number of +securities on issue MYXAA : CONVERTIBLE NOTES 27,950 MYXAN : PERFORMANCE RIGHTS 5,531,578
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 6 / 6 Part 5 - Other Listing Rule requirements 5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1? 5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1? 5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? 5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? 1,285,036 5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? No Yes No No
Ask a question
100%
/ 6
1 / 6
Announcement PDF Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 1 / 6 Announcement Summary Entity name MAYNE PHARMA GROUP LIMITED Date of this announcement Thursday October 29, 2026 The +securities the subject of this notification are: Total number of +securities to be issued/transferred ASX +security code Security description Total number of +securities to be issued/transferred Issue date MYXAN PERFORMANCE RIGHTS 1,285,036 22/10/2026 Refer to next page for full details of the announcement +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 2 / 6 Part 1 - Entity and announcement details 1.1 Name of entity MAYNE PHARMA GROUP LIMITED We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities. 1.2 Registered number type ABN Registration number 76115832963 1.3 ASX issuer code MYX 1.4 The announcement is 1.5 Date of this announcement 29/10/2026 New announcement Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 3 / 6 Part 2 - Issue details 2.1 The +securities the subject of this notification are: 2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which: has an existing ASX security code ("existing class") +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 4 / 6 Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B Additional +securities in an existing class issued under an +employee incentive scheme ASX +security code and description MYXAN : PERFORMANCE RIGHTS Date the +securities the subject of this notification were issued 22/10/2026 Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Were any of the +securities issued to +key management personnel (KMP) or an +associate? Provide details of the KMP or +associates being issued +securities. Name of KMP Name of registered holder Number of +securities Aaron Gray Aaron Gray 286,180 Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms - Rights are eligible for vesting on 1 September 2029, subject to achievement of specific vesting condition hurdles. - The number / proportion of Rights that vest is based on the absolute Total Shareholder Return (TSR) over the period with 20% vesting if a TSR Compound Annual Growth (CAGR) of 8% is achieved, rising to 100% vesting for achievement of a TSR CAGR of 15%. Any other information the entity wishes to provide about the +securities the subject of this notification - The base test date for Rights is set as 1 September 2026 and the expiry date is 1 September 2031. - The Base Test Price for the Rights is $3.14 - If the Rights are not exercised before the expiry date they will automatically lapse - There are no voting rights or rights to dividends whilst the participant holds a Right Issue details Number of +securities 1,285,036 Yes Yes Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 5 / 6 Part 4 - +Securities on issue Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise: The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing. 4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX) ASX +security code and description Total number of +securities on issue MYX : ORDINARY FULLY PAID 81,890,887 4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX) ASX +security code and description Total number of +securities on issue MYXAA : CONVERTIBLE NOTES 27,950 MYXAN : PERFORMANCE RIGHTS 5,531,578 Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 6 / 6 Part 5 - Other Listing Rule requirements 5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1? 5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1? 5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? 5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? 1,285,036 5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? No Yes No No
Open panelView summary and Q&As
Share your feedback
How likely is it that you would recommend Mayne Pharma Group Limited to another investor?
Likely
Neutral
Unlikely
0 responses
Questions (0)
Post question
Your question will be sent privately to Mayne Pharma Group Limited. The company may choose to make this question public.
Start the conversation
Ask Mayne Pharma Group Limited a question about this announcement.
Discover
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:04 AM](https://investors.maynepharma.com/announcements/69glBo-notification-regarding-unquoted-securities-myx)
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:03 AM](https://investors.maynepharma.com/announcements/RQVGgB-notification-regarding-unquoted-securities-myx)
[![]()
Investor presentation
Released 25 Oct 2026 - 9:50 PM](https://investors.maynepharma.com/announcements/7bQw6o-investor-presentation)
Summary
Summary
Questions (0)
Provide feedback to Mayne Pharma Group Limited. Complete survey to view results.
How likely is it that you would recommend Mayne Pharma Group Limited to another investor?
Likely
Neutral
Unlikely
0 responses
Post question
Your question will be sent privately to Mayne Pharma Group Limited. The company may choose to make this question public.
Start the conversation
Ask Mayne Pharma Group Limited a question about this announcement.
Share your feedback
How likely is it that you would recommend Mayne Pharma Group Limited to another investor?
Likely
Neutral
Unlikely
0 responses
Discover
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:04 AM](https://investors.maynepharma.com/announcements/69glBo-notification-regarding-unquoted-securities-myx)
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:03 AM](https://investors.maynepharma.com/announcements/RQVGgB-notification-regarding-unquoted-securities-myx)
[![]()
Investor presentation
Released 25 Oct 2026 - 9:50 PM](https://investors.maynepharma.com/announcements/7bQw6o-investor-presentation)
We value your privacy
We use cookies, including those from select third parties, to enhance your experience on our website and to help improve our services as specified in our Privacy Policy.
By clicking "Accept all", you consent to our use of cookies.
Our cookie notice lists every cookie we set, what it does and how long it lasts.
Closing this window accepts our default settings. You can change them at any time from cookie settings.
Accept allReject allCustomise settings
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:03 AM
Released 29 Oct 2026 - 8:03 AM
LikeFollowShare
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 1 / 6 Announcement Summary Entity name MAYNE PHARMA GROUP LIMITED Date of this announcement Thursday October 29, 2026 The +securities the subject of this notification are: Total number of +securities to be issued/transferred ASX +security code Security description Total number of +securities to be issued/transferred Issue date MYXAN PERFORMANCE RIGHTS 444,346 22/10/2026 Refer to next page for full details of the announcement +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 2 / 6 Part 1 - Entity and announcement details 1.1 Name of entity MAYNE PHARMA GROUP LIMITED We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities. 1.2 Registered number type ABN Registration number 76115832963 1.3 ASX issuer code MYX 1.4 The announcement is 1.5 Date of this announcement 29/10/2026 New announcement
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 3 / 6 Part 2 - Issue details 2.1 The +securities the subject of this notification are: 2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which: has an existing ASX security code ("existing class") +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 4 / 6 Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B Additional +securities in an existing class issued under an +employee incentive scheme ASX +security code and description MYXAN : PERFORMANCE RIGHTS Date the +securities the subject of this notification were issued 22/10/2026 Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Were any of the +securities issued to +key management personnel (KMP) or an +associate? Provide details of the KMP or +associates being issued +securities. Name of KMP Name of registered holder Number of +securities Aaron Gray Aaron Gray 143,069 Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms
- Rights are eligible for vesting on 1 September 2029, subject to continued employment by the relevant participant.
- The expiry date for the rights is 1 September 2031. If the Rights are not exercised before the expiry date they will automatically lapse.
- There are no voting rights or rights to dividends whilst the participant holds a Right. Any other information the entity wishes to provide about the +securities the subject of this notification Issue details Number of +securities 444,346 Yes Yes
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 5 / 6 Part 4 - +Securities on issue Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise: The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing. 4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX) ASX +security code and description Total number of +securities on issue MYX : ORDINARY FULLY PAID 81,890,887 4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX) ASX +security code and description Total number of +securities on issue MYXAA : CONVERTIBLE NOTES 27,950 MYXAN : PERFORMANCE RIGHTS 4,690,888
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 6 / 6 Part 5 - Other Listing Rule requirements 5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1? 5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1? 5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? 5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? 444346 5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? No Yes No No
Ask a question
100%
/ 6
1 / 6
Announcement PDF Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 1 / 6 Announcement Summary Entity name MAYNE PHARMA GROUP LIMITED Date of this announcement Thursday October 29, 2026 The +securities the subject of this notification are: Total number of +securities to be issued/transferred ASX +security code Security description Total number of +securities to be issued/transferred Issue date MYXAN PERFORMANCE RIGHTS 444,346 22/10/2026 Refer to next page for full details of the announcement +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 2 / 6 Part 1 - Entity and announcement details 1.1 Name of entity MAYNE PHARMA GROUP LIMITED We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities. 1.2 Registered number type ABN Registration number 76115832963 1.3 ASX issuer code MYX 1.4 The announcement is 1.5 Date of this announcement 29/10/2026 New announcement Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 3 / 6 Part 2 - Issue details 2.1 The +securities the subject of this notification are: 2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which: has an existing ASX security code ("existing class") +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 4 / 6 Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B Additional +securities in an existing class issued under an +employee incentive scheme ASX +security code and description MYXAN : PERFORMANCE RIGHTS Date the +securities the subject of this notification were issued 22/10/2026 Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Were any of the +securities issued to +key management personnel (KMP) or an +associate? Provide details of the KMP or +associates being issued +securities. Name of KMP Name of registered holder Number of +securities Aaron Gray Aaron Gray 143,069 Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms - Rights are eligible for vesting on 1 September 2029, subject to continued employment by the relevant participant. - The expiry date for the rights is 1 September 2031. If the Rights are not exercised before the expiry date they will automatically lapse. - There are no voting rights or rights to dividends whilst the participant holds a Right. Any other information the entity wishes to provide about the +securities the subject of this notification Issue details Number of +securities 444,346 Yes Yes Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 5 / 6 Part 4 - +Securities on issue Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise: The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing. 4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX) ASX +security code and description Total number of +securities on issue MYX : ORDINARY FULLY PAID 81,890,887 4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX) ASX +security code and description Total number of +securities on issue MYXAA : CONVERTIBLE NOTES 27,950 MYXAN : PERFORMANCE RIGHTS 4,690,888 Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 6 / 6 Part 5 - Other Listing Rule requirements 5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1? 5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1? 5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? 5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? 444346 5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? No Yes No No
Open panelView summary and Q&As
Share your feedback
How likely is it that you would recommend Mayne Pharma Group Limited to another investor?
Likely
Neutral
Unlikely
0 responses
Questions (0)
Post question
Your question will be sent privately to Mayne Pharma Group Limited. The company may choose to make this question public.
Start the conversation
Ask Mayne Pharma Group Limited a question about this announcement.
Discover
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:04 AM](https://investors.maynepharma.com/announcements/69glBo-notification-regarding-unquoted-securities-myx)
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:02 AM](https://investors.maynepharma.com/announcements/46zl4q-notification-regarding-unquoted-securities-myx)
[![]()
Investor presentation
Released 25 Oct 2026 - 9:50 PM](https://investors.maynepharma.com/announcements/7bQw6o-investor-presentation)
Summary
Summary
Questions (0)
Provide feedback to Mayne Pharma Group Limited. Complete survey to view results.
How likely is it that you would recommend Mayne Pharma Group Limited to another investor?
Likely
Neutral
Unlikely
0 responses
Post question
Your question will be sent privately to Mayne Pharma Group Limited. The company may choose to make this question public.
Start the conversation
Ask Mayne Pharma Group Limited a question about this announcement.
Share your feedback
How likely is it that you would recommend Mayne Pharma Group Limited to another investor?
Likely
Neutral
Unlikely
0 responses
Discover
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:04 AM](https://investors.maynepharma.com/announcements/69glBo-notification-regarding-unquoted-securities-myx)
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:02 AM](https://investors.maynepharma.com/announcements/46zl4q-notification-regarding-unquoted-securities-myx)
[![]()
Investor presentation
Released 25 Oct 2026 - 9:50 PM](https://investors.maynepharma.com/announcements/7bQw6o-investor-presentation)
We value your privacy
We use cookies, including those from select third parties, to enhance your experience on our website and to help improve our services as specified in our Privacy Policy.
By clicking "Accept all", you consent to our use of cookies.
Our cookie notice lists every cookie we set, what it does and how long it lasts.
Closing this window accepts our default settings. You can change them at any time from cookie settings.
Accept allReject allCustomise settings
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:04 AM
Released 29 Oct 2026 - 8:04 AM
LikeFollowShare
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 1 / 6 Announcement Summary Entity name MAYNE PHARMA GROUP LIMITED Date of this announcement Thursday October 29, 2026 The +securities the subject of this notification are: Total number of +securities to be issued/transferred ASX +security code Security description Total number of +securities to be issued/transferred Issue date MYXAN PERFORMANCE RIGHTS 445,777 22/10/2026 Refer to next page for full details of the announcement +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 2 / 6 Part 1 - Entity and announcement details 1.1 Name of entity MAYNE PHARMA GROUP LIMITED We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities. 1.2 Registered number type ABN Registration number 76115832963 1.3 ASX issuer code MYX 1.4 The announcement is 1.5 Date of this announcement 29/10/2026 New announcement
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 3 / 6 Part 2 - Issue details 2.1 The +securities the subject of this notification are: 2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which: has an existing ASX security code ("existing class") +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 4 / 6 Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B Additional +securities in an existing class issued under an +employee incentive scheme ASX +security code and description MYXAN : PERFORMANCE RIGHTS Date the +securities the subject of this notification were issued 22/10/2026 Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Were any of the +securities issued to +key management personnel (KMP) or an +associate? Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms
- Rights are eligible for vesting on 1 September 2027, subject to continued employment by the relevant participant.
- The expiry date for the rights is 1 September 2029. If the Rights are not exercised before the expiry date they will automatically lapse.
- There are no voting rights or rights to dividends whilst the participant holds a Right. Any other information the entity wishes to provide about the +securities the subject of this notification Issue details Number of +securities 445,777 No Yes
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 5 / 6 Part 4 - +Securities on issue Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise: The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing. 4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX) ASX +security code and description Total number of +securities on issue MYX : ORDINARY FULLY PAID 81,890,887 4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX) ASX +security code and description Total number of +securities on issue MYXAA : CONVERTIBLE NOTES 27,950 MYXAN : PERFORMANCE RIGHTS 4,692,319
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 6 / 6 Part 5 - Other Listing Rule requirements 5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1? 5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1? 5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? 5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? 445777 5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? No Yes No No
Ask a question
100%
/ 6
1 / 6
Announcement PDF Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 1 / 6 Announcement Summary Entity name MAYNE PHARMA GROUP LIMITED Date of this announcement Thursday October 29, 2026 The +securities the subject of this notification are: Total number of +securities to be issued/transferred ASX +security code Security description Total number of +securities to be issued/transferred Issue date MYXAN PERFORMANCE RIGHTS 445,777 22/10/2026 Refer to next page for full details of the announcement +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 2 / 6 Part 1 - Entity and announcement details 1.1 Name of entity MAYNE PHARMA GROUP LIMITED We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities. 1.2 Registered number type ABN Registration number 76115832963 1.3 ASX issuer code MYX 1.4 The announcement is 1.5 Date of this announcement 29/10/2026 New announcement Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 3 / 6 Part 2 - Issue details 2.1 The +securities the subject of this notification are: 2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which: has an existing ASX security code ("existing class") +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 4 / 6 Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B Additional +securities in an existing class issued under an +employee incentive scheme ASX +security code and description MYXAN : PERFORMANCE RIGHTS Date the +securities the subject of this notification were issued 22/10/2026 Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Were any of the +securities issued to +key management personnel (KMP) or an +associate? Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms - Rights are eligible for vesting on 1 September 2027, subject to continued employment by the relevant participant. - The expiry date for the rights is 1 September 2029. If the Rights are not exercised before the expiry date they will automatically lapse. - There are no voting rights or rights to dividends whilst the participant holds a Right. Any other information the entity wishes to provide about the +securities the subject of this notification Issue details Number of +securities 445,777 No Yes Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 5 / 6 Part 4 - +Securities on issue Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise: The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing. 4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX) ASX +security code and description Total number of +securities on issue MYX : ORDINARY FULLY PAID 81,890,887 4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX) ASX +security code and description Total number of +securities on issue MYXAA : CONVERTIBLE NOTES 27,950 MYXAN : PERFORMANCE RIGHTS 4,692,319 Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities 6 / 6 Part 5 - Other Listing Rule requirements 5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1? 5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1? 5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? 5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? 445777 5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? No Yes No No
Open panelView summary and Q&As
Share your feedback
How likely is it that you would recommend Mayne Pharma Group Limited to another investor?
Likely
Neutral
Unlikely
0 responses
Questions (0)
Post question
Your question will be sent privately to Mayne Pharma Group Limited. The company may choose to make this question public.
Start the conversation
Ask Mayne Pharma Group Limited a question about this announcement.
Discover
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:03 AM](https://investors.maynepharma.com/announcements/RQVGgB-notification-regarding-unquoted-securities-myx)
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:02 AM](https://investors.maynepharma.com/announcements/46zl4q-notification-regarding-unquoted-securities-myx)
[![]()
Investor presentation
Released 25 Oct 2026 - 9:50 PM](https://investors.maynepharma.com/announcements/7bQw6o-investor-presentation)
Summary
Summary
Questions (0)
Provide feedback to Mayne Pharma Group Limited. Complete survey to view results.
How likely is it that you would recommend Mayne Pharma Group Limited to another investor?
Likely
Neutral
Unlikely
0 responses
Post question
Your question will be sent privately to Mayne Pharma Group Limited. The company may choose to make this question public.
Start the conversation
Ask Mayne Pharma Group Limited a question about this announcement.
Share your feedback
How likely is it that you would recommend Mayne Pharma Group Limited to another investor?
Likely
Neutral
Unlikely
0 responses
Discover
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:03 AM](https://investors.maynepharma.com/announcements/RQVGgB-notification-regarding-unquoted-securities-myx)
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:02 AM](https://investors.maynepharma.com/announcements/46zl4q-notification-regarding-unquoted-securities-myx)
[![]()
Investor presentation
Released 25 Oct 2026 - 9:50 PM](https://investors.maynepharma.com/announcements/7bQw6o-investor-presentation)
We value your privacy
We use cookies, including those from select third parties, to enhance your experience on our website and to help improve our services as specified in our Privacy Policy.
By clicking "Accept all", you consent to our use of cookies.
Our cookie notice lists every cookie we set, what it does and how long it lasts.
Closing this window accepts our default settings. You can change them at any time from cookie settings.
Accept allReject allCustomise settings
Mayne Pharma reports unaudited Q1 FY27 results
Released 25 Oct 2026 - 9:49 PM
Released 25 Oct 2026 - 9:49 PM
LikeFollowShare
ASX Announcement MAYNE PHARMA REPORTS UNAUDITED FIRST QUARTER FY27 RESULTS Key Points1 • Executing Women’s Health growth strategy with strong demand growth in 1Q FY27: total prescriptions (TRx)2 for BIJUVA® up 25% versus the pcp, IMVEXXY® up 13% and NEXTSTELLIS® demand cycles up 27%; • Multiple legal settlements executed: o IMVEXXY® Paragraph IV patent litigation settlements with Sun Pharma and Teva Pharmaceuticals USA (announced 30 Sep and 16 Oct) o Legacy generic drug pricing civil action resolved with State attorney generals for a one-time payment of US$0.65 million with no admission of liability, subject to court approval • Court of Appeal upheld Supreme Court judgment in Mayne Pharma’s favour in Cosette proceedings (with costs); damages claim continues (announced 15 Oct) • DistributeRx delivered 84k total prescriptions in 1Q FY27 (+120% versus pcp) from ~6,000 unique prescribers, with the automated Adelaide Apothecary facility in Lexington, Kentucky on track to commence operations in early 2027 • Exclusive five-year licence signed with Italfarmaco for BLISSEL® in Australia, extending the Company’s menopause portfolio alongside NEXTSTELLIS® in the International segment • 1Q FY27 revenue of $95.7 million with gross margin of 63%, reflecting solid growth in Women’s Health, offset by a decline in Dermatology branded sales from anticipated competitive erosion • 1Q FY27 underlying EBITDA3 of $5.3 million with total direct segment contribution of $23.3 million 26 October 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX), today announces an unaudited financial and operating update for the three months ended 30 September 2026 (1Q FY27). Group Financial Overview Three months ended 30 September 2026 (1Q FY27) $ million 1Q FY27 1Q FY26 Change vs 1Q FY26 % Change vs 1Q FY26 Revenue $95.7m $97.7m -$2.0m -2% Gross Profit $60.3m $65.3m -$5.0m -8% Direct Contribution $23.3m $30.5m -$7.2m -23% Underlying EBITDA $5.3m $11.0m -$5.7m -52% Mayne Pharma’s CEO, Mr Aaron Gray said “The first quarter of FY27 delivered continued strong prescription growth across our Women’s Health portfolio driven by our growth strategy and saw further momentum in DistributeRx. During the quarter we resolved IMVEXXY® Paragraph IV litigation, added BLISSEL® to our 1 All amounts are expressed in Australian Dollar Terms (A$/AUD) unless otherwise indicated and all figures are unaudited. Amounts include FX effects. 2 TRx data includes IQVIA data, plus prescription volume through non-reporting pharmacies (including Mayne Pharma’s own distribution channel). 3 Underlying EBITDA excludes earn-out reassessments, litigation and restructuring charges, derivative fair value adjustments, other.
ASX Announcement Page 2 Australian women’s health portfolio and strengthened our leadership team and Board. With a clearer legal backdrop and focused investment behind our growth opportunities, Mayne Pharma is well positioned for the remainder of FY27.” Financial and Operational Summary Mayne Pharma made solid commercial and strategic progress across all three segments in the September quarter. Women's Health continued to grow prescriptions, DistributeRx built further prescription and prescriber momentum ahead of the opening of its expanded Lexington facility and International strengthened its Australian women's health portfolio with NEXTSTELLIS® growth and the addition of BLISSEL®. The quarter reflects the Company’s ongoing portfolio transition from mature Dermatology brands towards growth opportunities in Women’s Health and DistributeRx, supported by focused investment in commercial capabilities and customer access. Revenue of $95.7 million was down 2% versus the pcp, with gross margin of 63%. Growth in Women’s Health and International was offset by lower Dermatology sales following the anticipated generic RHOFADE® entry and other competitive and payer-related pressures. Total direct contribution was $23.3 million (-23% versus pcp), reflecting lower Dermatology contribution and planned investment in Women’s Health and International. Adjusted operating cashflow from continuing operations was an outflow of $2.1 million, with a further $3.5 million in royalty payments and $4.5 million in legal costs. The adjusted operating cash outflow primarily reflects the timing of gross-to-net (GTN) cash payments, which can vary quarter to quarter. GTN rebates and chargebacks are accrued when product is sold but paid in cash one to two quarters later, so payments in 1Q FY27 reflect rebates on earlier sales. This timing difference was the main driver of the operating cash outflow and typically normalises out on a full year basis. Separately, the Company invested US$0.5 million in the Adelaide Apothecary Lexington facility and paid US$0.65 million in the United States’ Attorneys General settlement payment. Cashflow from discontinued operations was $0.2 million for the quarter. Cash and marketable securities were $67.3 million at 30 September 2026. Underlying EBITDA Underlying EBITDA for 1Q FY27 was $5.3 million (-52% versus pcp). The result reflected planned investment in Women’s Health commercial capabilities to support future growth across the menopause and contraception categories, together with the anticipated reduction in Dermatology contribution following generic RHOFADE® entry. Reported EBITDA was a loss of $1.6 million after $6.9 million of non-recurring items excluded from Underlying EBITDA. These items primarily comprised legal costs of $6.0 million (including $2.4 million related to Cosette litigation) and restructuring costs of $0.9 million. Women’s Health During the September quarter, Mayne Pharma’s Women’s Health segment continued to build momentum, with IMVEXXY® and NEXTSTELLIS® leading portfolio growth, supported by the expanded and realigned field force, refreshed campaigns and expanded payer coverage. ANNOVERA® net sales were impacted by the intentional reduction of channel inventory to address elevated product returns which
ASX Announcement Page 3 impacts net sales. The Company continues to evaluate channel alternatives with more favourable returns profiles. Excluding the impact of ANNOVERA® returns, net selling prices across the portfolio improved due to expanded coverage for NEXTSTELLIS® and optimisation of the channel strategy. The Company continues to invest in specialist field representatives across both menopause and contraception to capitalise on the solid market growth and low single digit category market share of the portfolio. The removal of the FDA black boxed warning for BIJUVA® continues to support solid healthcare practitioner confidence and prescribing, while the broader removal of boxed warnings from menopausal hormone therapy labelling continues to provide a structural tailwind for the category. Effective 1 August 2026, a large Pharmacy Benefit Manager (PBM) implemented coverage for prescription access to NEXTSTELLIS® where previously the coverage was restricted for participants. This increases the US commercial/Medicaid covered lives for NEXTSTELLIS® to approximately 128 million and aligns with the Affordable Care Act’s mandate for open, affordable contraceptive access for all women in the United States. On 20 August 2026, Mayne Pharma announced the presentation of real-world IMVEXXY® data at the International Society for Pharmacoepidemiology (ISPE) 2026 annual meeting in Milan, Italy. The analysis, one of the largest real-world studies of very-low-dose vaginal estrogen undertaken to date, drew on US data from more than nine million women and found no increased risk of endometrial cancer. Such data potentially supports its black box warning removal by the US FDA in the future. Mayne Pharma confirmed fulfilment of IMVEXXY® post-marketing study requirements on 9 October following FDA confirmation. BIJUVA® marketing campaigns were named a finalist in three categories at the 2026 PM360 Trailblazer Awards, a long-established US life-sciences marketing program. On 29 September 2026 BIJUVA® campaigns won two of the three categories: Relaunch/Revitalization of the Year (Products of the Year) and Sales Aid of the Year and was also a finalist for Professional Campaign of the Year. The awards recognise the commercial and marketing execution behind BIJUVA® as the Company continues to build momentum in its US Women’s Health portfolio. US policy support for menopause care strengthened during the quarter. On 16 September 2026, the Senate Committee on Aging held the first congressional hearing on menopause, and bipartisan Senators asked the Government Accountability Office to review the federal role in research and treatment access. This builds on the FDA's removal of black box warnings from certain menopausal treatments, including BIJUVA®. At state level, Illinois enacted three menopause laws in August 2026, including mandated insurance coverage of menopause treatment from 2028. Five states now require insurers to cover menopause treatment, and eight of 28 state menopause bills introduced in 2026 have been enacted. The Company will continue to monitor legislative changes beneficial for the menopause portfolio. Key 1Q FY27 financials include: • Revenue of US$34.4 million (+9% versus pcp) o BIJUVA® total prescriptions (TRx) +25% and net sales of US$4.5 million (+8%)
ASX Announcement Page 4 o IMVEXXY® TRx +13% and net sales of US$8.5 million (+39%) o NEXTSTELLIS® demand cycles4 +27% and net sales of US$14.7 million (+17%); o ANNOVERA® TRx -1% and net sales of US$5.9 million (-27%) • Gross profit of US$27.6 million (+8% versus pcp) and gross margin of 80% • Direct contribution of US$12.8 million (+4% versus pcp) Dermatology / DistributeRx Within the Mayne Pharma Dermatology portfolio, gACCUTANE® closed the quarter at approximately 69% category market share5 , which has continued to grow through a partnership with an online virtual dermatology platform. As flagged in the 4Q FY26 update, a generic RHOFADE® was launched into the US market in the third week of July 2026 and 1Q FY27 reflects the resulting loss of market share and volumes which negatively impacted sales and margin performance during the quarter. Mayne Pharma launched an authorised generic of RHOFADE® in July. The Company anticipates maintaining significant volume and profitability from RHOFADE® despite the loss of exclusivity. In addition, as previously indicated TWYNEO® lost some payer coverage resulting in lower sales. The pressure on traditional dermatology channels this quarter from competitive erosion and payer coverage loss supports the Company’s decision to build and launch DistributeRx in March 2026, which diversifies its revenues in the dermatology space. This disintermediated, patient-direct prescription channel combines the specialty field force; digital prescribing and access workflow along with transparent cash-pay fulfilment through Adelaide Apothecary. By creating this pathway, Mayne Pharma improves access and transparency for patients and healthcare practitioners. DistributeRx’s access solutions improve patient adherence directly and provides a scalable platform that positions the Company to grow independently of payer formulary decisions. Through expanding the number of products offered, DistributeRx lessens the impact of individual product sales profiles through competitive pressures that emerge. In addition, DistributeRx can retain dermatology scripts that would otherwise be lost to payer coverage gaps and generic substitution. DistributeRx DistributeRx completed its second full quarter of operations, with all Mayne Pharma dermatology sales representatives operating through the platform. DistributeRx helps to address the decline in Dermatology revenues by offering transparent cash-pay pricing through Adelaide Apothecary, which permits patients to continue filling prescriptions for TWYNEO® and supports volume for RHOFADE® and DORYX® as generic competition increases. Build out of Adelaide Apothecary’s new automated fulfilment facility in Lexington, Kentucky progressed during the quarter. The expansion will lift annual capacity over two phases to more than 2.5 million prescriptions (an approximate seven-fold increase), with up to US$2 million required to complete Phase 1 and operations expected to commence in early 2027. As at 30 September 2026, DistributeRx was in active discussions with multiple pharmaceutical companies seeking to onboard approximately 11 additional products into the DistributeRx channel. The exclusive US distribution agreement with Resilia Pharmaceuticals for RECEDO®, DistributeRx’s first third-party 4 Demand cycles calculated as IQVIA reported TRx (converted to units/cycles) plus non-reporting pharmacies (including Mayne Pharma’s own distribution channel). TRx converted to units by taking number of pills in the TRx divided by 28 (number of NEXTSTELLIS® pills included in 1 month of therapy). NEXTSTELLIS® prescriptions can be prescribed in 1-month and 3-month increments. On average 1 TRx equals 2.0 units/cycles. 5 Market share is based on current NRx (new prescription) volume from IQVIA measured against MYX defined set of competitors per brand.
ASX Announcement Page 5 commercial partnership was announced in June 2026 and has resulted in a 15-20% increase in monthly volumes for this product. In 1Q FY27, DistributeRx generated 84k total prescriptions, an increase of 35% versus 4Q FY26 and 120% versus the pcp. New prescriptions were 61k (+45% versus 4Q FY26 and +198% over the pcp) and targeted sales team initiatives drove a total of 6,059 unique prescribers during the quarter. Field representation of 18 territories (versus 34 targeted) provides meaningful coverage and volume opportunities in priority markets into FY27. The Company has made solid progress in 2Q FY27 so far with a further 4 positions now filled covering 22 territories. Key 1Q FY27 financials for Dermatology/DistributeRx include: • Revenue of US$18.9 million (-16% versus pcp) • Gross profit of US$10.7 million (-28% versus pcp) and gross margin of 57% (-14% versus pcp) • Direct contribution of US$3.1 million (-61% versus pcp) International In 1Q FY27 the International segment continued to benefit from NEXTSTELLIS® growth in Australia following PBS listing in October 2025, with demand cycles up 306% versus the pcp, and up 35% on 4Q FY26, alongside growth from KADIAN® in Canada under the expanded distribution agreement. On 15 September 2026, Mayne Pharma announced an exclusive five-year licence agreement with Italfarmaco S.A. for the Australian rights to BLISSEL® (estriol 50μg/g), an ultra-low-dose vaginal gel for the treatment of vaginal atrophy in postmenopausal women. BLISSEL® complements NEXTSTELLIS® in the Australian women's health portfolio, with launch targeted in FY28 through the existing commercial team. Mayne Pharma continues to invest in sales and marketing activities including education events to women’s health groups following NEXTSTELLIS® PBS approval, which has generated solid growth in prescription volumes as noted above. In addition, the Company continues to pursue global manufacturing partnerships following completion of the $18 million upgrade of the Salisbury facility. Key 1Q FY27 financials include: • Revenue of $20.2 million (+13% versus pcp) • Gross profit of $6.1 million (+3% versus pcp) and gross margin of 31% • Direct contribution of $1.4 million (-5% versus pcp) Corporate Leadership and Board Mr Griffin Buchanan commenced as Chief Financial Officer on 1 August 2026. Mr Buchanan brings extensive global healthcare finance experience, including senior finance roles at Establishment Labs and more than 19 years at Siemens Healthineers. Following the appointment of Ms Meghan Rivera as a Non- Executive Director in June 2026, Mr Jacob Ma-Weaver joined the Board as a Non-Executive Director on 14 August 2026, bringing extensive experience as an investor and analyst in the life sciences and healthcare sectors. Mr Ma-Weaver is the Managing Member of Cable Car Capital, LP (Cable Car), an investment adviser he founded in 2013. Cable Car is the General Partner of Funicular Funds, LP, a hedge fund, which holds 9.90% of the fully paid ordinary shares in the Company.
ASX Announcement Page 6 Legal On 14 October 2026, the NSW Court of Appeal upheld the October 2025 Supreme Court judgment in Mayne Pharma’s favour and awards costs to Mayne Pharma. The Court rejected Cosette’s claim that it was entitled to terminate the Scheme Implementation Deed and found no wrongdoing by Mayne Pharma and awarded costs to Mayne Pharma. The decision is a further successful outcome in the proceedings, following Mayne Pharma’s recovery of $14.4 million in legal costs from Cosette in June 2026. It will continue to pursue its damages claims against Cosette, Cosette Pharmaceuticals Holdings, Inc., Mr David Burgstahler and Avista Capital, on behalf of the Company and its shareholders. On 28 September 2026, Mayne Pharma announced that it had reached a settlement with the attorneys general of 49 US states and territories in relation to a civil complaint concerning alleged anticompetitive conduct in the US generic pharmaceutical sector. The settlement involves a one-time payment of US$0.65 million, with no admission of liability or wrongdoing, and is subject to court approval. On 30 September 2026 Mayne Pharma reached a settlement with Sun Pharma, resolving the Paragraph IV litigation over the IMVEXXY® FDA Orange Book listed patents, with Sun Pharma’s generic IMVEXXY® permitted to enter the market from 21 October 2032, or earlier under certain circumstances. Likewise on 16 October 2026 Mayne Pharma announced a settlement with Teva Pharmaceuticals USA for an agreed pathway for potential future entry of a Teva Pharmaceuticals USA generic product on 2 September 2032, or earlier under certain circumstances. These Paragraph IV settlements do not include any upfront monetary consideration between the parties. These two agreements resolve all outstanding Paragraph IV litigation relating to IMVEXXY®. The two settlements underscore the Company’s view on the strength of the IMVEXXY® patent portfolio. The Company will continue to defend its IP and invest in access and patient support initiatives to maximise the product's long-term contribution. IMVEXXY® delivered FY26 net sales of US$29.3 million (+8%). Mayne Pharma is progressing through FY27 with a lower legal cost base, and resolution of certain legal matters. Management focus remains directed to growing Women’s Health, DistributeRx and International. Annual General Meeting Mayne Pharma’s Annual General Meeting will be held on Friday 20 November 2026 at 10.00am (AEDT). Details of the venue and arrangements for participation are set out in the Notice of Meeting dispatched to shareholders on 19 October 2026. The AGM will be held at Minter Ellison, Level 20, Collins Arch, 447 Collins St, Melbourne, VIC 3000 or online at https://meetnow.global/MCUUA2J. Shareholders will consider the election of Non-Executive Directors Mr Jacob Ma-Weaver and Ms Meghan Rivera, the re-election of Chair Professor Bruce Robinson the adoption of the Remuneration Report and approval of the equity incentive plan, all of which the Board recommends shareholders support. Resolution 4 seeks the election of Dr Brett Wells, an external candidate not endorsed by the Board and having assessed his nomination against the Board's skills and composition requirements, the Board recommends shareholders vote against Resolution 4. The Chair intends to vote undirected proxies against this resolution.
ASX Announcement Page 7 FY27 Outlook Women’s Health: accelerate portfolio growth through a focused salesforce, refreshed marketing and improved prescriber access, underpinned by the macro tailwind from the removal of the HRT Black Box warning of the menopause category, in particular for BIJUVA®. Dermatology/DistributeRx: Strong opportunity to scale DistributeRx platform across additional products and therapeutic areas while leveraging Mayne Pharma’s established infrastructure. International: build on NEXTSTELLIS® growth following the PBS listing and leverage the Salisbury investment to deliver export growth and contract manufacturing revenues. Corporate: continue to evaluate capital-efficient, synergistic acquisitions that can leverage the Company’s existing Women’s Health and Dermatology/DistributeRx ecosystems, alongside disciplined capital management. Click here to view this announcement on Mayne Pharma’s Investor Hub.
- ENDS -
Investor presentation
Released 25 Oct 2026 - 9:50 PM
Released 25 Oct 2026 - 9:50 PM
LikeFollowShare
Mayne Pharma Group Limited Investor Presentation Aaron Gray (CEO) Griffin Buchanan (CFO) 26 October 2026
2 Disclaimer The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited Financial Statements and market disclosures. This material is not intended to be relied upon as advice to investors or potential investors. Non-IFRS information ● Other than as indicated, the financial information contained in this document is directly extracted or calculated from the audited Financial Statements. Throughout this document some non-IFRS financial information is stated, excluding certain specified income and expenses. Results excluding such items are considered by the Directors to provide a meaningful basis for comparison from period to period. ● Earnings before interest, tax, depreciation and amortisation (EBITDA) – a non-IFRS term – is considered by Directors to be a meaningful measure of the operating earnings and performance of the Group and this information may be useful for investors as it provides additional and relevant information that reflects the underlying performance of the business. ● The non-IFRS financial information has not been audited by the Group’s auditors. Forward looking statements ● This presentation contains forward-looking statements that involve subjective judgement and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to the Company. These forward looking statements use words such as ‘potential’, ‘expect’, ‘anticipate’, ‘intend’, ‘plan’ and ‘may’, and other words of similar meaning. No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including the Company). Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based. Given these uncertainties, readers are cautioned not to place undue reliance on such forward looking statements. Subject to the Company’s continuous disclosure obligations at law and under the listing rules of the Australian Securities Exchange, the Company disclaims any obligation to update or revise any forward looking statements. The factors that may affect the Company’s future performance include, among others: changes in economic conditions, changes in the legal and regulatory regimes in which the Company operates, litigation or government investigations, decisions by regulatory authorities, changes in behaviour of major customers, suppliers and competitors, interruptions to manufacturing or distribution, the success of research and development activities and research collaborations and the Company’s ability to protect its intellectual property. Other ● A glossary of industry terminology is contained in the Mayne Pharma Annual Report which can be accessed at https://investors.maynepharma.com/results-and-reports and product descriptions are detailed at maynepharma.com/us-products and maynepharma.com/au-products. ● DORYX®, FABIOR® and RHOFADE® are trademarks of Mayne Pharma. ACCUTANE®, ANNOVERA®, BIJUVA®, BLISSEL®, EPSOLAY®, IMVEXXY®, KADIAN®, NEXTSTELLIS®, RECEDO®, TWYNEO® and WYNZORA® and are trademarks of third parties.
3 International Dermatology A diversified portfolio of branded specialty and generic dermatology medicines including recently acquired products. Strategy to drive access and lower patient acquisition costs across rosacea, acne, psoriasis and atopic dermatitis. Strong focus on channel Disintermediation. Launch of DistributeRx in March 2026. Share price (ASX:MYX) $2.45 GICS Industry Group Code (Pharmaceuticals) 35202010 Shares on Issue 81.9 million Market Capitalisation $200.7 million FY26 Sales $383.7 million FY26 Underlying EBITDA $34.2 million Cash & Marketable Securities (30 June 2026) $80.0 million Top 20 Shareholders 60.4% Substantial Shareholders Funicular Funds LP (9.9%) Mr Bruce Mathieson (6.5%) Rubric Capital Management LP (5.4%) Trium Capital LLP (5.0%) Analyst Coverage Madeleine Williams: Canaccord Genuity Andrew Goodsall: MST Marquee Snapshot Corporate Summary1,2
- Share price data, Top 20 shareholders as at 23 Oct 2026
- Financial data per Mayne Pharma FY26 results • Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines • Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world Our Focus Segments Women’s Health A specialty branded portfolio with significant patent coverage focused on improving access and adherence in contraception and menopause care through targeted prescriber engagement and patient support. US Focus. Australian-based manufacturer (Salisbury, South Australia) with sales of branded and generic pharmaceutical products to customers and partners globally (ex-US) and the provision of contract development and manufacturing services to third party customers. Improving patient access to life-enhancing medications
4 Mayne Pharma in 2026 Branded Product Sales Now Represent a Significant Proportion (%) of Mayne Pharma’s Net Sales, Driving Margin Expansion
- Unaudited financial information FY24 FY25 FY26 68% Branded │ 32% Generic 56% Gross Margin 79% Branded │ 21% Generic 61% Gross Margin 83% Branded │ 17% Generic 65% Gross Margin500 bps 400 bps 68% 83% 79% 32% 21% 17%
5 FY26 Corporate Highlights Realignment of Women’s Health Sales Force • Refreshed sales and marketing materials • Dedicated menopause and contraception field representation driving deeper specialist engagement with high-value prescribers • Increased focus on menopause given structural tailwinds including regulatory changes, awareness and strong market growth Launch of DistributeRx • A landmark step in Mayne Pharma's disintermediation strategy; DistributeRx launched in March 2026, which is a healthcare solutions business that partners with manufacturers to streamline the prescription distribution process and expand patient access to medications • Significantly exceeded expectations in FY26 with new automated facility to deliver seven-fold increase in capacity over two phases Cosette Transaction • Cosette transaction process and subsequent legal matters placed considerable demands on management focus and organisational bandwidth, including general disruption to the Mayne Pharma business • The Company received $14.4 million from Cosette in full satisfaction of FY25 court-ordered legal costs and interest • Court of Appeal upheld ruling of October 20251 • Mayne Pharma damages claim against Cosette continues A year of resilience and focus against a backdrop of general operational distraction and disruption
- ASX announcement dated 14 October 2026
6 Global Headcount & Sales Force Global footprint Australia 243 18% Employees FY26 sales mix United States 227 82% Employees FY26 sales mix T O T A L H E A D C O U N T 1 470 Employees
- As at 30 June 2026 Salisbury, South Australia Lexington, KY | Raleigh, NC Current Women’s Health sales representation of ~90 persons Current DistributeRx sales representation of 22 persons Mayne Pharma International products manufactured from Salisbury are sold across international markets (ex-US) inc. Canada, Europe, Asia, Australia and NZ
7 FY26 Financial Highlights1
- All numbers are expressed in AUD/A$ terms unless otherwise stated.
- Underlying EBITDA is a non-IFRS measure and excludes earn-out reassessments, restructuring charges, class action settlement costs, derivative fair value adjustments and litigation expense.
- Excluding class action settlement and tax refund in FY25 and Scheme transaction and litigation costs in FY26. Margin expansion and resilient segment contribution through a year of disruption and reinvestment $383.7m Revenue down 6% FY25 64.7% Gross margin Up 4.1% from 60.6% FY25 $34.2m Underlying EBITDA2 down 27% from $47.0m FY25 $107.1m Total direct segment contribution down 2% from $109.7m FY25 $34.5m Adjusted operating cashflow from continuing operations3 down 24% from $45.4m FY25 $80.0m Cash and marketable securities at 30 June 2026 down from $100.4m FY25
8 A$174.3, 46%A$138.7, 36% A$70.7, 18% FY26 Snapshot – Segments $107.1m FY26 Total Direct Contribution A$57.9, 54% A$44.5, 42% A$4.6, 4% Women’s Health FY26 Segment Contribution (A$m, % of total) Dermatology/DistributeRx International FY26 Revenue Contribution (A$m, % of total)
1Q FY27 Review
10 1Q FY27 Financial Results1
- All numbers are expressed in AUD/A$ terms unless otherwise stated and are unaudited
- Underlying EBITDA is a non-IFRS measure and excludes earn-out reassessments, litigation and restructuring charges, derivative fair value adjustments, other
- Total net operating cashflow excluding outflows for discontinued operations and legal expenses (terminated scheme). Earnout payments recognised as financing cash outflows 1Q FY27 reflects solid momentum from Women’s Health, offset by a decline in higher margin branded Dermatology sales $95.7m Revenue down 2% from 1Q FY26 63% Gross margin down from 67% 1Q FY26 $5.3m Underlying EBITDA2 down 52% from 1Q FY26 $23.3m Total direct segment contribution down 23% from 1Q FY26 -$2.1m Adjusted operating cashflow from continuing operations 3, was +$6.6m in 1Q FY26 $67.3m Cash and marketable securities at 30 Sep 2026
11 1Q FY27 Unaudited EBITDA & Cash Flow1
- Main driver of the quarterly operating cash flow relates to the timing effect of certain GTN cash payments. EBITDA ($m) CASH FLOW ($m) -2.1 -4.5 -3.5 -0.2 -0.8 -0.5 -1.2 80.0 69.9 69.8 67.3 30 Jun 2026 Cash balance 30 Sep 2026 Cash balance Transaction & litigation costs Earn-outs (Royalties) Adjusted cash flow from continuing operations Discontinued operations Capital leases Capex (net) Other 6.0 0.9 -1.6 5.3 Reported EBITDA Underlying EBITDA Legal costs Restructuring & Other • Reported EBITDA of -$1.6 million: an improvement of 48% on the pcp • Underlying EBITDA of $5.3 million: down 52% on the pcp • 1Q of each FY period most US patients have met their annual co-pay and deductible obligations, which lowers patient out-of-pocket costs and Gross to Net (GTN) expense and supports net pricing and demand • -$2.1 million in adjusted cash flows from continuing operations • -$0.2 million for discontinued operations • Additional Capex for new DistributeRx facility to meet demand • Closing cash of $67.3 million
12 1Q FY27 Operating & Financial Highlights (Segments) Women’s Health Dermatology/DistributeRx • Policy tailwinds with first US congressional hearing on menopause held; Illinois mandates menopause treatment coverage • IMVEXXY® paragraph IV litigation concluded with settlement agreements • Large PBM added NEXTSTELLIS® coverage from 1 August 2026 (total ~128m covered lives); • BIJUVA® campaigns won two PM360 Trailblazer Awards • Revenue of US$34.4 million (+9% versus pcp) • NEXTSTELLIS® demand cycles1 up 27% and net sales of US$14.7 million (+17%); • BIJUVA® total prescriptions (TRx) up 25% and net sales of US$4.5 million (+8%); • IMVEXXY® TRx up 13% and net sales of US$8.5 million (+39%); and • ANNOVERA® TRx down 1% and net sales of US$5.9 million (-27%) • Gross profit of US$27.6 million (+8% versus pcp) and gross margin of 80% (net selling price holding) • Direct contribution of US$12.8 million (+4% versus pcp) • gACCUTANE® closed 1Q at ~69% category share; result reflects generic RHOFADE® entry in July 2026 and loss of coverage for TWYNEO® • DistributeRx Lexington, Kentucky facility on track for early 2027, lifting capacity ~seven-fold to >2.5m prescriptions p.a. • RECEDO® monthly volumes up 15–20% since onboarding • In discussions with 7 companies on 11 products to bring into DistributeRx channel • 84k total prescriptions (+35% versus 4Q FY26) | 6,059 unique prescribers | 18 of 34 target territories with field representation • Revenue of US$18.9 million (-16% versus pcp) • Gross profit of US$10.7 million (-28% versus pcp) and gross margin of 57% (-14% versus pcp) • Direct contribution of US$3.1 million (-61% versus pcp)
- Calculated as IQVIA reported TRx (converted to units/cycles) plus non-reporting pharmacies (including Mayne Pharma’s own distribution channel). TRx converted to units by taking number of pills in the TRx divided by 28 (number of NEXTSTELLIS® pills included in 1 month of therapy). NEXTSTELLIS® prescriptions can be prescribed in 1-month and 3-month increments. On average 1 TRx equals 2.0 units/cycles.
13 1Q FY27 Operating & Financial Highlights (Segments) International Corporate • Cash and marketable securities of $67.3 million at 30 September 2026 • Positive movement on legal matters in 1Q and early in 2Q: multiple settlements across a legacy action, paragraph IV litigation and winning the Cosette appeal • Griffin Buchanan commenced as CFO (1 August 2026) and Jacob Ma-Weaver joined the Board (14 August 2026) • Company retains financial flexibility to reinvest in its growth priorities and pursue capital-efficient business development opportunities • NEXTSTELLIS® demand cycles up 306% versus pcp, up 35% on 4Q FY261 • BLISSEL® Australian licence signed; launch targeted in FY28 • KADIAN® growth in Canada; Salisbury partnering underway • Revenue of $20.2 million (+13% versus pcp) • Gross profit of $6.1 million (+3% versus pcp) and gross margin of 31% • Direct contribution of $1.4 million (-5% versus pcp)
- iQVIA data. Adjusted from 1Q FY26 onwards due to transposition error on data set
Women’s Health
15 US Indication Deal Structure and Terms Women’s Health Global footprint Branded ProductsLast Patent Expiry1 2043 2039 20342 2032
- Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
- No further Paragraph IV challenges for IMVEXXY® (Sun Pharma settled in Sept 2026; Teva Pharma. USA settled in Oct 2026)
- Cumulative net sales of US$2.25 billion
- The 10% royalty is deducted from Net Sales of ANNOVERA® prior to the application of the 8% royalty payable to TXMD An Exclusively Licensed Portfolio for the US Market; manufacturing via third parties 8% Net Sales on all TXMD Licensed Products (ANNOVERA®, IMVEXXY®, BIJUVA®) Royalties 10% Net Sales to Population Council (ANNOVERA®)4 Pop. Council: US$40.0m (cumulative sales of US$400m: ANNOVERA®) Pop. Council: US$40.0m (cumulative sales of US$1.0bn: ANNOVERA®) TXMD: US$100m in net revenue (US$5m milestone payment) TXMD: US$200m in net revenue (US$10m milestone payment) TXMD: US$300m in net revenue (US$15m milestone payment) Variable COGS payment to Gedeon Richter (in gross margin) Dependent on forward sales of NEXTSTELLIS® (no guidance provided) Licensor: TherapeuticsMD (TXMD) • December 2022 • Cash consideration to TXMD of US$140m and a US$13.1m payment for acquired NWC Licensor: Mithra (Gedeon Richter) • October 2019 • US$11m cash + equity upfront + up to US$295m in contingent payments3 Milestones Royalties Milestones Menopause Menopause Contraception Contraception
16 The Rise of Menopause Global footprint Key Drivers 107 137 169 177 168 183 180 80 100 120 140 160 180 200 2HFY23 1HFY24 2HFY24 1HFY25 2HFY25 1HFY26 2HFY26 38 45 53 61 67 77 84
10 20 30 40 50 60 70 80 90 2HFY23 1HFY24 2HFY24 1HFY25 2HFY25 1HFY26 2HFY26 FY26 • Regulatory de-risking of the category: FDA announced black boxed-warning removal for certain hormone replacement therapies (HRTs) in Nov 2025 • Demographic tailwind: A large, sustained cohort is moving into peri- and post- menopause representing 75m women now in the United States (+1.3m annually) – significantly underpenetrated relative to other markets • Celebrity-led destigmatisation: converting awareness into clinical demand • Expanding payer coverage: lowering the affordability barrier with US States actively seeking to improve access • Large market growth: menopause market is expected to grow from ~US$10B– 15B market in 2026 to ~US$15B–25B in 20301 • Specialist menopause sales force in 2H FY26 given growth potential of category FY26 Penetration of Category1: ~1% FY26 Penetration of Category1: ~2% Total Prescriptions (TRx, ‘000) Total Prescriptions (TRx, ‘000) TRx +6% on pcp Net Sales +8%: US$29.3m TRx +26% on pcp Net Sales +20%: US$15.0m FY26
- PWC - Unlocking the menopause opportunity: A defining category in women’s health
17 Contraception Global footprint Key Drivers FY26 • Affordable Care Act benefits: payers showing more willingness to provide coverage for open, affordable contraceptive access for all women in the United States • Digital and direct-to-patient access: Increase adoption of telehealth prescribing, online pharmacies and delivery apps continue to broaden and streamline access • NEXTSTELLIS® new coverage: expanded access lowered net sales per unit due to incremental rebates, but the impact is more than offset by unlocking significant volume growth, as demonstrated in Q4 • ANNOVERA® returns: persistent challenges with returns driving net sales lower despite single digit TRx growth; focus on channel strategy optimisation towards channels with a more favourable returns profile and improved economic value FY26 Penetration of Category1: ~3% FY26 Penetration of Category1: ~2%
- iQVIA data as at 30 September 2026 45 58 71 89 106 118 125 138 146 152 155 168 171 176 175 194 28.9% 22.4% 25.4% 19.1% 11.3%5.9%10.4% 5.8% 4.1% 2.0% 8.4% 1.8% 2.9% -0.6% 10.6%11.7% -20.0% 0.0% 20.0% 40.0% 60.0% 80.0% 100.0% 0.0 20.0 40.0 60.0 80.0 100.0 120.0 140.0 160.0 180.0 200.0 216 12 12 14 14 14 14 14
2 4 6 8 10 12 14 2HFY23 1HFY24 2HFY24 1HFY25 2HFY25 1HFY26 2HFY26 TRx +2% on pcp Net Sales -13%: US$25.7m Total Prescriptions (TRx, ‘000) 7.1 7.1 13.8 16.3 22.4 20.1 23.4 21.8 -2.0 3.0 8.0 13.0 18.0 23.0 28.0 Net Sales (US$m) & Growth (%) FY26 Cycles +15% on pcp Net Sales +6%: US$45.2m Demand cycles (‘000) and Sequential Growth (%) 95% 123% 63% 9% 131% 23% 4% 567%
Dermatology and DistributeRx
19 Dermatology Products Global footprintA portfolio of branded and generics DermatologyLast Patent Expiry 20351 2030 2039 2034 2041 2041
- RHOFADE® generic launch in July 2026 Branded Portfolio 25 Generics, Authorised Generics Products 31 Total Mayne Pharma Dermatology Products 6 Branded Products
20 Mayne Pharma Disintermediation DistributeRx is Mayne Pharma's direct-to-patient distribution platform with Adelaide Apothecary serving as Mayne Pharma’s licensed pharmacy arm driving cash pay fulfilment of patient prescriptions as part of the Company’s overall disintermediation strategy. DistributeRx launched operations in March 2026. Total Investment at launch US$0.5m Disintermediation: Involves removing the intermediaries (wholesalers or others) between the manufacturer (Mayne Pharma) and the patient 60%Non-Wholesale volumes in FY261
- As a % percentage of total US Women’s Health and Dermatology product volumes Unfilled Prescriptions High copays and complex prior authorisations cause patients to abandon prescriptions at the pharmacy counter Lost Profit Margin Rebates, Direct and Indirect Remuneration (DIR) fees, and intermediary margins erode manufacturer profitability across the distribution chain Formulary Exclusions PBM restrictions limit formulary access, reducing branded product availability and patient choice Expanding Cash Market Patients increasingly bypass insurance, seeking lower-cost alternatives outside traditional channels Pharmacy Losses DIR clawbacks and below-cost reimbursement drive negative margins on branded dispensing The complexity of the US pharmacy distribution system creates barriers that impact manufacturers, pharmacies, and patients Cycle of inefficiency and waste
21 DistributeRx partners with manufacturers, providers, and pharmacies to improve patient access and offer predictable prices P R E S C R I P T I O N A C C E S S M A D E S I M P L E
- Precedence Research • ePharmacy size ~US$252 billion by 2030 (CAGR 17%)1 driven by rising consumer adoption of digital pharmacy and home delivery • DistributeRx has delivered very strong growth since launch in March 2026 • Early 2Q FY27 Field representation of 22 territories versus 34 targeted provides meaningful coverage and vol. opportunities in priority markets through FY27. • Strong demand profile: May 2026 announced major expansion of Adelaide Apothecary (MYX cash pay pharmacy) in Lexington, KY • Up to 2.5m Rx per annum capacity, US$4m CAPEX across two phases for equipment and automation capability +120% | +35% 1Q FY27 Total Rx growth versus the pcp | 4Q FY26 ~84,000 Total Rx 1Q FY27 6,059 New prescribers added since launch
22 Global footprint100% Mayne Pharma owned subsidiary with a portfolio of branded and generics, both Mayne Pharma owned and Via Third Parties
- As at 30 September 2026. Source: https://www.distributerx.com/price-list
- Formal contracts with third party manufacturers in negotiation or signed (Resilia Pharma per ASX release 1 June 2026) as at 30 September 2026 211 Other Non-Mayne Products sold via DistributeRx Channel1 31 12
Additional Pipeline Products2 1 Contracted (1 Manufacturer) plus 11 in Pipeline (7 New Manufacturers) 239 Total Products Mayne Pharma Dermatology Products1
23 Global footprint Legal Overhang Materially Reduced 28 Sep 2026 US State Attorneys General – generics SETTLED Resolved for US$0.65m with no admission of liability. Closes a legacy matter linked to the 2016 US generic pharma industry-wide investigation1 30 Sep 2026 IMVEXXY® Paragraph IV – Sun Pharma SETTLED Agreed generic entry date of 21 October 2032¹. No upfront payment or monetary consideration between the parties 14 Oct 2026 Cosette – NSW Court of Appeal WON Appeal dismissed in full and Supreme Court judgment upheld. Cosette ordered to pay Mayne Pharma's appeal costs 16 Oct 2026 IMVEXXY® Paragraph IV – Teva Pharma. USA SETTLED Agreed generic entry date of 2 September 20322. No upfront payment or monetary consideration between the parties. No further IMVEXXY® Paragraph IV litigation Lower costs Ongoing legal spend Certain legacy US antitrust and all IMVEXXY® patent litigation resolved, with no payments in either IMVEXXY® settlement. 2032 IMVEXXY® IP protected No generic entry before September 20321. FY26 net sales of US$29.3m (+8%). Last Orange Book patent expires February 2034. $14.4m Cosette costs recovered to date, damages claim continues Appeal costs to follow. Damages claim against Cosette, Avista and controllers continues.³
- Subject to final court approval; includes a two-year antitrust compliance undertaking. 2. Or earlier under certain circumstances; subject to court approval. 3. Cosette Pharmaceuticals, Inc., Cosette Pharmaceuticals Holdings, Inc., Avista Capital and Mr David Burgstahler. Cosette has until 11 November 2026 to seek special leave to appeal to the High Court. Source: Mayne Pharma ASX announcements. Legal Matters - Summary Positive Impacts Legacy legal matter closed, IMVEXXY® IP secured, Cosette appeal dismissed
24 FY27 focus and outlook • Women’s Health: accelerate portfolio growth through a focused salesforce, refreshed marketing and improved prescriber access, underpinned by the macro tailwind from the removal of the HRT Black Box warning of the menopause category, in particular for BIJUVA® • Dermatology/DistributeRx: Strong opportunity to scale DistributeRx platform across additional products and therapeutic areas while leveraging Mayne Pharma’s established infrastructure • International: build on NEXTSTELLIS® growth following PBS listing, and leverage the Salisbury investment to deliver export growth and contract manufacturing revenues • Corporate: continue to evaluate capital-efficient, synergistic acquisitions that can leverage our existing Women’s Health and Dermatology/DistributeRx ecosystems, alongside disciplined capital management
25 You deserve tomorrow. Q&A
2026 Notice of Annual General Meeting and shareholder pack
Released 18 Oct 2026 - 10:15 PM
Released 18 Oct 2026 - 10:15 PM
LikeFollowShare
19 October 2026 Manager, Company Announcements ASX Limited Level 27 39 Martin Place SYDNEY NSW 2000 Via E-Lodgement 2026 Annual General Meeting Attached is the Mayne Pharma Group Limited 2026 Notice of Annual General Meeting and a related proxy form. A letter to shareholders from the Chair is also attached. The 2026 Annual General Meeting will be held at 10:00am on Friday, 20 November 2026 (AEDT). The Notice of Meeting contains instructions for shareholders explaining how to participate in the AGM, including how to attend or watch the proceedings, vote and ask questions. This announcement is authorised by the Chair. Yours faithfully, Mayne Pharma Group Limited Laura Loftus Company Secretary
SRN/HIN: I9999999999328946_01_V3 Control Number: 189278 19 October 2026 2026 Mayne Pharma Group Limited Annual General Meeting Dear Fellow Shareholder On behalf of the Board, I am pleased to invite you to the 2026 Mayne Pharma Group Limited Annual General Meeting (AGM) which will be held at 10:00am (Melbourne time) on Friday, 20 November 2026 at Minter Ellison Offices, Level 20, Collins Arch, 447 Collins St, Melbourne and online at https://meetnow.global/MCUUA2J. The AGM is an important annual event for Mayne Pharma giving shareholders the opportunity to hear from your Chair and your Chief Executive Officer, ask questions about the management and operations of your Company and vote on the items of business. The Notice of Meeting for the 2026 AGM is available at maynepharma.com/investor-relations/annual- general-meeting/. Shareholders, proxyholders and interested parties can participate in the AGM by attending in person or via the webcast live at https://meetnow.global/MCUUA2J. Any shareholders wishing to lodge a proxy vote or lodge questions ahead of the meeting can do this by logging onto https://www.investorvote.com.au and entering the Control Number and your holder number (SRN/HIN) located at the top of this letter. Lodging questions or casting your proxy vote ahead of the meeting will not prevent you from attending online or in person. You can also submit questions to [email protected]. The business of the meeting set out in the Notice of 2026 Annual General Meeting is as follows:
- Consider the statutory reports for the financial year ended 30 June 2026;
- Election and re-election of Board endorsed Directors (Resolutions 1-3);
- Election of external non-Board endorsed candidate (Resolution 4);
- Adopt the 2026 Remuneration Report (Resolution 5); and
- Approve the Omnibus Equity Incentive Plan (Resolution 6). MYX MR SAM SAMPLE FLAT 123 123 SAMPLE STREET THE SAMPLE HILL SAMPLE ESTATE SAMPLEVILLE VIC 3030 Samples/000001/000002/i12 M00000112Q02
328946_01_V3 Each Director (where permitted to do so) recommends that shareholders vote in favour of Resolutions 1, 2, 3, 5 and 6 and against resolution 4. The Board does not believe that the election of Dr Wells is in the best interests of Mayne Pharma. The Board has carefully considered Dr Wells’ nomination against the current Board composition and the skills and experience required to deliver Mayne Pharma’s purpose and strategy. Following that review, the Board has concluded that the size and composition of your Board is optimal at the present time, therefore the addition of Dr Wells would not add value to your Board. Thank you for your continued support of Mayne Pharma. I hope you can join us for the AGM this year. Yours sincerely Professor Bruce Robinson Chair
Notice of 2026 Annual General Meeting Notice is given that the 2026 Annual General Meeting of Mayne Pharma Group Limited will be held on Friday, 20 November 2026 at 10:00am (Melbourne time)
Mayne Pharma Notice of Annual General Meeting 2026 2 NOTICE OF ANNUAL GENERAL MEETING Mayne Pharma Group Limited ACN 115 832 963 The annual general meeting of shareholders (Shareholders) of Mayne Pharma Group Limited (Company or Mayne Pharma) will be held at 10:00am (Melbourne time) on Friday, 20 November 2026 as a hybrid meeting (AGM). Shareholders, proxyholders and interested parties can participate in the AGM by attending in person at MinterEllison, Level 20, Collins Arch, 447 Collins St, Melbourne, VIC 3000 or online at https://meetnow.global/MCUUA2J. Further information on how to participate in the AGM is provided in this Notice of AGM and in the AGM Meeting Guide which you can access at maynepharma.com/investor-relations/annual-general-meeting/. If you cannot attend the AGM in person or online at the scheduled time, you can participate in the AGM by appointing a proxy to attend and vote on your behalf. Details on how to appoint a proxy are contained in this Notice of AGM. This Notice of AGM is being distributed electronically and is available to view and download at maynepharma.com/investor-relations/annual-general-meeting/. Copies of the Chair’s address will be available on both the ASX website at asx.com.au and Mayne Pharma’s website maynepharma.com. PARTICIPATION AT THE AGM Attend in person or watch and participate live online Shareholders are invited to watch and participate in the AGM by either: • participating in person at MinterEllison, Level 20, Collins Arch, 447 Collins St, Melbourne, VIC 3000; or • participating virtually by entering the following URL in your browser: https://meetnow.global/MCUUA2J. To do this you will need a computer or mobile/tablet device with internet access. Participation in the meeting in person and online enables Shareholders to view the AGM live, ask questions and cast votes during the meeting. All Shareholders will have an equal opportunity to participate in the online meeting regardless of their physical location. Shareholders, once verified, will be taken to be present at the AGM for all purposes, until either the meeting ends or (for those participating online) the Shareholder exits the online platform. It is important that Shareholders participating online are connected to the internet at all times during the AGM in order to vote. Voting options
3 Mayne Pharma Notice of Annual General Meeting 2026 BUSINESS
- Financial statements and reports To receive and consider the Directors' Report, Financial Statements and the Independent Auditor’s Report for the year ended 30 June 2026. Note: There is no vote on this item.
- Election and Re-election of Board endorsed Directors This year there are two Board endorsed Directors standing for election: Mr Jacob Ma-Weaver and Ms Meghan Rivera, and one Board endorsed Director standing for re-election: Professor Bruce Robinson. Resolution 1 – Election of Jacob Ma-Weaver To consider and, if thought fit, to pass the following ordinary resolution: 'That Mr Jacob Ma-Weaver, who was appointed to the Board since the last Annual General Meeting and who retires in accordance with the Company’s constitution and, being eligible and having signified his candidature for office, be elected as a Director.' Resolution 2 – Election of Meghan Rivera To consider and, if thought fit, to pass the following ordinary resolution: 'That Ms Meghan Rivera, who was appointed to the Board since the last Annual General Meeting and who retires in accordance with the Company’s constitution and, being eligible and having signified her candidature for office, be elected as a Director.' Resolution 3 – Re-election of Bruce Robinson To consider and, if thought fit, to pass the following ordinary resolution: 'That Professor Bruce Robinson, who retires by rotation in accordance with the Constitution and, being eligible and having signified his candidature for office, be re-elected as a Director.'
- Election of external non-Board endorsed candidate Resolution 4 –Election of Brett Wells To consider and, if thought fit, to pass the following ordinary resolution: 'That Dr Brett Wells, an external candidate nominated for election in accordance with the Company's constitution and, being eligible and having signified his candidature for office, be elected as a Director.' The Board recommends shareholders vote against Resolution 4.
Mayne Pharma Notice of Annual General Meeting 2026 4 4. Remuneration report Resolution 5 – Adoption of Remuneration Report To consider and, if thought fit, pass the following ordinary resolution: 'That, for the purposes of section 250R(2) of the Corporations Act, the Remuneration Report that forms part of the Directors' Report of the Company for the financial year ended 30 June 2026 be adopted.' Note: In accordance with section 250R(3) of the Corporations Act, the vote on this Resolution is advisory only and does not bind the Directors. 5. Omnibus Equity Incentive Plan Resolution 6 – Approval of Omnibus Equity Incentive Plan To consider and, if thought fit, pass the following ordinary resolution: 'That, for the purposes of ASX Listing Rule 7.2 (Exception 13) and for all other purposes, Shareholders approve the issue and grant of securities by the Board in its discretion in accordance with the Omnibus Equity Incentive Plan (a summary of which is set out in the Explanatory Information) as an exception to ASX Listing Rule 7.1.'
5 Mayne Pharma Notice of Annual General Meeting 2026 VOTING RESTRICTIONS Voting exclusion for Resolution 5 The Company will disregard any votes cast on Resolution 5: • by or on behalf of a member of the Company’s key management personnel (KMP) named in the Remuneration Report for the year ended 30 June 2026 or their Closely Related Parties (regardless of the capacity in which the vote is cast); or • as a proxy by a person who, at the date of the Meeting, is a member of the Company’s KMP or their Closely Related Parties, unless the vote is cast as proxy for a person entitled to vote on Resolution 5: • in accordance with a direction on the proxy form; or • by the Chair of the Meeting pursuant to an express authorisation in the proxy form to exercise the proxy as the Chair sees fit, even though Resolution 5 is connected with the remuneration of members of the KMP. Voting exclusion for Resolution 6 The Company will disregard any votes cast in favour of Resolution 6 by or on behalf of: • a person who is eligible to participate in the Omnibus Equity Incentive Plan; or • an Associate of that person (or those persons). However, this does not apply to a vote cast in favour of the resolution by: • a person as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with the directions given to the proxy or attorney to vote on the resolution in that way; • the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the Item, in accordance with a direction given to the Chair to vote on the resolution as the Chair decides; or • a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary, provided the following conditions are met: o the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the resolution; and o the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way. In addition, a vote must not be cast on Resolution 6 by a member of the KMP of the Company or their Closely Related Party, acting as proxy for a person entitled to vote, if their appointment does not specify the way the proxy is to vote on Resolution 6. This restriction on voting undirected proxies does not apply to the Chair of the Meeting acting as a proxy for a person entitled to vote on the resolution because the Company’s proxy appointment expressly authorises the Chair of the Meeting to exercise undirected proxies even though the resolution is connected directly or indirectly with the remuneration of a member of the KMP of the Company.
Mayne Pharma Notice of Annual General Meeting 2026 6 PROXIES AND SHAREHOLDER INFORMATION IMPORTANT: Shareholders are urged to direct their proxy on how to vote by clearly marking the relevant box for each Resolution on the proxy form. Proxies
- A Shareholder entitled to attend and vote at the Meeting has the right to appoint a person (who does not need to be a Shareholder) as the Shareholder’s proxy to attend and vote at the Meeting.
- If a Shareholder is entitled to cast two or more votes they may appoint two proxies (but no more) provided that an appointment of two proxies will have no effect unless each proxy is appointed to represent a specified proportion of the Shareholder’s voting rights aggregating to no more than 100% of that Shareholder’s voting rights. If the Shareholder appoints two proxies, neither proxy may vote on a show of hands.
- The proxy form must be signed by the Shareholder or their attorney. Proxies given by corporations must be signed by a director and company secretary or two directors or a sole director/secretary or a sole director or its duly authorised attorney.
- If the proxy form is signed but is blank in all other material respects, it will be taken to mean that it is in favour of the Chair of the Meeting for full voting rights and the Chair will vote in favour of Resolutions 1-3, 5 and 6 on a poll (subject to the voting exclusions set out in this Notice). The Chair will vote against Resolution 4.
- A proxy may decide whether to vote on any motion, except where the proxy is required by law, the ASX Listing Rules or the Constitution to vote, or abstain from voting, in their capacity as proxy. If a proxy is directed to vote on an item of business, the proxy may vote on that item only in accordance with the direction. If a proxy is not directed how to vote on an item of business, the proxy may vote as they think fit.
- If proxy holders vote, they must cast all directed proxies as directed. Any directed proxies which are not voted will automatically default to the Chair of the Meeting, who must vote the proxies as directed.
- The proxy form accompanying this Notice contains detailed instructions regarding how to complete the proxy form if a Shareholder wishes to appoint the Chair as his or her proxy. You should read those instructions carefully.
- Except where paragraph 9 immediately below applies, in relation to Resolution 5 and Resolution 6, a proxy must not vote if: (a) they are a KMP or a Closely Related Party of a KMP; and (b) their appointment as proxy does not specify the way they are to vote on the Resolution.
- By appointing the Chair of the meeting as your proxy in relation to Resolution 5 and/ or Resolution 6, you expressly authorise the Chair to vote in favour of that Resolution unless: (a) you direct the Chair to vote against or to abstain from voting on that Resolution; or (b) you are a member of the KMP, or a Closely Related Party of a KMP.
- Subject to any voting exclusions, the Chair of the Meeting intends to exercise all open proxies by voting in favour of Resolutions 1, 2, 3, 5 and 6, and against Resolution 4.
- Proxies may be lodged in the following way: Mail Computershare Investor Services Pty Limited GPO Box 242 Melbourne VIC 3001
7 Mayne Pharma Notice of Annual General Meeting 2026 Facsimile: (within Australia) 1800 783 447 (outside Australia) +61 3 9473 2555 Online: www.investorvote.com.au (by following the instructions set out on the website) Custodian voting – For Intermediary Online subscribers only please visit www.intermediaryonline.com to submit your voting intentions 12. Enquiries can be made at 1300 850 505 (within Australia) or +61 3 9415 4000 (outside Australia) between 8.30am and 5.30pm (Melbourne time), Monday to Friday. 13. Proxy forms must be received at least 48 hours before the Meeting, being by no later than 10:00 am (Melbourne time) on Wednesday, 18 November 2026. Entitlement to vote 14. The Company has determined that the persons entitled to attend and vote at the Annual General Meeting will be those persons set out in the register of Shareholders as at 7:00 pm (Melbourne time) on Wednesday, 18 November 2026. Voting by attorney 15. A Shareholder may appoint an attorney to vote on their behalf. For an appointment to be effective for the AGM, the instrument effecting the appointment (or a certified copy of it) must be received at the address listed above for the receipt of proxy appointments at least 48 hours before the commencement of the AGM, being by no later than 10:00 am (Melbourne time) on Wednesday, 18 November 2026. Voting by corporate representative 16. A body corporate which is a Shareholder, or which has been appointed as a proxy, may appoint an individual to act as its representative at the AGM. The appointment must comply with the requirements of section 250D of the Corporations Act. The representative should ensure that a copy of their appointment, including any authority under which it is signed, has been provided to Computershare before the AGM.
Mayne Pharma Notice of Annual General Meeting 2026 8 EXPLANATORY INFORMATION
- Financial statements and reports At the AGM, Shareholders will be given an opportunity to ask questions and comment on the Directors' Report, Financial Statements and Independent Auditor's Report for the financial year ended 30 June 2026. Shareholders can view or download a copy of the 2026 Annual Report from the Company's website at maynepharma.com. The Company's auditor will be available to answer questions as to the conduct of the audit and the Independent Auditor's Report. Shareholders should note that the sole purpose of tabling the Directors' Report, Financial Statements and Independent Auditor's Report of the Company at the Annual General Meeting is to provide Shareholders with the opportunity to ask questions or discuss matters arising from them. It is not the purpose of the Meeting that the Directors' Report, Financial Statements and Independent Auditor's Report be accepted, rejected or modified in any way. Further, as it is not required by the Corporations Act, no resolution to adopt, receive or consider the Company's Directors' Report, Financial Statements and Independent Auditor's Report will be put to Shareholders at the Meeting.
- Election and Re-election of Board endorsed Directors Under rule 3.3 of the Constitution, any Director appointed by the Board since the last annual general meeting automatically retires at the next annual general meeting and is eligible for election at that general meeting. Appropriate background checks were completed before Mr Jacob Ma-Weaver and Ms Meghan Rivera were appointed to the Board. Under rule 3.6 of the Constitution, at each annual general meeting one third (or if that is not a whole number, the whole number nearest to one third) of the Company's Directors (excluding any Directors appointed since the last Annual General Meeting) must retire from office and are eligible for re-election. Resolution 1 –
9 Mayne Pharma Notice of Annual General Meeting 2026 Resolution 2 – Election of Ms Meghan Rivera (BScBusAdmin) Resolution 2 seeks approval for the election of Ms Meghan Rivera as a Director with effect from the end of the Annual General Meeting. Ms Rivera was appointed to the Board on 26 June 2026. Ms Rivera, a US resident, brings more than 25 years of experience in the US pharmaceutical industry across multiple therapeutic areas including women’s health. Ms Rivera’s experience includes building, scaling and transforming businesses across biopharma and she has played a key role in launching branded products in the US. She currently serves as Vice President and Global Commercial Lead for ViiV Healthcare, a leading biopharmaceutical organisation focused on the prevention, treatment and cure of HIV. Prior roles include US Market President at Organon & Co (NYSE: OGN), Chief Marketing Officer and Head of Commercial at Akili Interactive, and Senior Vice President of Women's Health at AMAG Pharmaceuticals. Prior to her appointment, Mayne Pharma undertook appropriate background and experience checks on Ms Rivera. Ms Rivera is a member of the Remuneration and People Committee and the Nomination Committee. The Board has determined that Ms Rivera is an independent Director. The Board (with Ms Rivera abstaining) recommends that Shareholders vote in favour of Resolution 2.
Mayne Pharma Notice of Annual General Meeting 2026 10 3. Election of non-Board endorsed candidate Resolution 4 – Election of Dr Brett Wells (BEng (Aerospace) (Hons), PhD (Astronomy & Astrophysics) (ANU), MBBS (Hons) (Syd), FANZCA) Dr Wells has been nominated for election as a Director in accordance with rule 3.5(c) of the Constitution. Dr Wells was nominated by his wife, Dr Kenney Wan, a Shareholder. Dr Wells’ nomination is not endorsed by the Board. The Board is in the process of undertaking appropriate checks into Dr Wells’ background and experience, in accordance with the ASX Corporate Governance Principles and Recommendations and Mayne Pharma’s standard practice. If those checks reveal anything of concern, the Company will provide an update to shareholders. Dr Wells provided the following information for inclusion in this Notice of Meeting. The information has not been verified nor is it endorsed by Mayne Pharma. Dr Brett Wells is an astrophysicist, a specialist anaesthetist, an aerospace engineer and a financial analyst who runs his family office. His family own just under 2% of Mayne Pharma’s issued shares. He is seeking election to bring that combination of expertise, substantial personal investment and demonstrated shareholder engagement to the Board. His family carries a significant unrealised loss on its investment while continuing to have substantial personal capital exposed to the Company’s future performance. Dr Wells trained in aerospace engineering before completing his PhD in Astronomy and Astrophysics at the Australian National University’s Mount Stromlo Observatory. His research included work at Caltech’s Infrared Processing and Analysis Center and the Australia Telescope National Facility, followed by a postdoctoral fellowship at the Institut d’Astrophysique Spatiale, Université Paris-Sud. He graduated from the University of Sydney’s medical program in 2001 with the highest level of honours and the K.C.T. Rawle Surgical Prize. During his medical studies, he undertook visiting study in space medicine at the University of Texas Medical Branch and at the University of Oxford.
11 Mayne Pharma Notice of Annual General Meeting 2026 Dr Wells would combine financial alignment with shareholders, clinical insight, quantitative research skills and demonstrated commitment to understanding Mayne Pharma’s challenges. His priorities would be effective oversight, rigorous assessment of strategic alternatives, disciplined investment, measurable performance and timely disclosure. He would work constructively with fellow directors and management while exercising independent judgement and scrutinising strategy and execution. He recognises that his responsibilities would be to the Company as a whole and would consider the interests of all shareholders. The Board’s recommendation The Board does not believe that the election of Dr Wells is in the best interests of Mayne Pharma. The Board has carefully considered Dr Wells’ nomination against the current Board composition and the skills and experience required to deliver Mayne Pharma’s purpose and strategy. Following that review, the Board has concluded that the size and composition of your Board is optimal at the present time, therefore the addition of Dr Wells would not add value to your Board. The Board recommends Shareholders vote against Resolution 4. The Chair of the AGM intends to vote undirected proxies against Resolution 4. 4. Resolution 5 – Adoption of Remuneration Report The Annual Report for the financial year ended 30 June 2026 contains a Remuneration Report, which forms part of the Director’s Report and sets out the remuneration policy for the consolidated entity comprising the Company and its controlled entities and reports on the remuneration arrangements in place for its KMP.
Mayne Pharma Notice of Annual General Meeting 2026 12 5. Resolution 6 – Approval of Omnibus Equity Incentive Plan Background The Board has established an omnibus equity incentive plan (Omnibus Equity Incentive Plan or Plan) to foster strong alignment between the interests of employees and shareholders in the creation of long term sustainable shareholder value. In establishing the Plan, the Board has considered the following: • Incentivising Performance: Aligning the interests of key employees with Shareholders by rewarding the creation of shareholder value; • Attracting and Retaining Talent: A competitive options / rights scheme is essential to attract and retain high-calibre talent in a competitive market; and • Company Growth: The Board believes that linking rewards to the long-term performance of the Company will drive sustainable growth. Shareholder approval ASX Listing Rule 7.2 (Exception 13) provides that any Equity Securities issued under an employee incentive scheme that has been approved by shareholders within the last three years are not counted when calculating the maximum number of Equity Securities that a company may issue (or agree to issue) without shareholder approval under the 15% limit in ASX Listing Rule 7.1. The Omnibus Equity Incentive Plan is a new employee incentive scheme that has not previously been approved by Shareholders. As a result, the Omnibus Equity Incentive Plan is being put to Shareholders for approval at this AGM for the purposes of ASX Listing Rule 7.2 (Exception 13). Summary of the terms of the Omnibus Equity Incentive Plan
13 Mayne Pharma Notice of Annual General Meeting 2026 Term Summary • the total number of Shares issued, or rights or options outstanding under any other Company employee share plan granted, within three years preceding the proposed application; but excluding the total number of Shares granted pursuant to the Plan, Awards granted or any securities granted under another Company employee share plan, that have been subsequently forfeited or that were issued more than 3 years before the invitation. Ranking of Shares issued under the Plan Any Shares issued pursuant to an Award will rank equally with all other Shares of the same class for the time being on issue by the Company, except as regards to any rights attaching to Shares by reference to a record date prior to the date of their issue. Participation in new issues of Shares A holder of Awards cannot, in their capacity as a holder of Awards, participate in new issues of securities to existing Shareholders without exercising the Awards and becoming a Shareholder by the relevant record date. Vesting conditions, expiry dates, exercise price and share acquisition price Rights are issued to eligible participants with each Right entitling the holder to be allotted or transferred one Share in the Company on exercise. The Conditions (i.e. 'Vesting Conditions'), if any, Term (if applicable), acquisition price (if any) and exercise price (if any) are determined by the Board in its discretion.
Mayne Pharma Notice of Annual General Meeting 2026 14 Term Summary retirement, severe illness, total and permanent disablement, redundancy (where the Board so determines) or death, voluntary resignation (in certain circumstances) or any other circumstances determined by the Board at any time. Cessation of employment as an Ineligible Leaver Where a participant is an Ineligible Leaver, all unvested Awards will lapse immediately (unless otherwise determined by the Board). Vested Awards will remain exercisable for up to 6 months after cessation of employment (or such later period as permitted where exercise is restricted by the ASX Listing Rules), after which any unexercised Awards will lapse and be forfeited. An 'Ineligible Leaver' is a participant who ceases to be Engaged by a Group Entity and is not a Good Leaver. Change of control Unless otherwise specified in the invitation letter, all Awards will vest if a change of control event occurs, unless the Board determines otherwise. The Board may determine prior to the change of control event that unvested Awards should remain unvested and lapse, waive vesting or exercise conditions, buy-back or cash settle Awards or specify some other treatment. Trading restrictions Awards are not able to be sold or transferred until they vest, all Vesting Conditions and exercise conditions have been met and they are not subject to dealing restrictions. Awards do not give the holder any rights to a Share unless and until the Vesting Conditions for the Awards are met and Shares are allocated on exercise. Disposal of Shares allocated on exercise of Awards are subject to the Company’s Security Trading Policy.
15 Mayne Pharma Notice of Annual General Meeting 2026 Term Summary Amendments and administration The Plan is administered by the Board. Subject to the Plan rules and applicable law, the Board has broad powers to: • delegate administration of the Plan; • determine appropriate administrative procedures; • resolve questions of fact or interpretation; • correct defects, omissions or inconsistencies; • impose conditions on decisions or permissions; and • make other determinations necessary or desirable to administer the Plan. Board decisions concerning the interpretation, effect or application of the Plan are final and binding on participants. The Board may amend the Plan by written instrument. An amendment that materially reduces participants’ existing rights or increases their obligations generally requires the prior written consent of at least 75%
Mayne Pharma Notice of Annual General Meeting 2026 16 GLOSSARY In this Notice: Annual General Meeting or Meeting or AGM means the annual general meeting of the Company to be held on Friday, 20 November 2026 at 10:00am (Melbourne time). Annual Report means the annual report of the Company in respect of the financial year ended 30 June 2026. ASIC means Australian Securities & Investments Commission. ASX means ASX Limited or the financial market operated by it, as the context requires. ASX Listing Rules means the listing rules of the ASX. Award means one of the following instruments issued and defined under the Omnibus Equity Incentive Plan: (a) an Option; (b) a Right (including RSU); (c)
SRN/HIN: For your proxy appointment to be effective it must be received by 10:00am (Melbourne time) on Wednesday, 18 November 2026. All your securities will be voted in accordance with your directions. YOUR VOTE IS IMPORTANT Phone: 1300 850 505 (within Australia) +61 3 9415 4000 (outside Australia) Online: www.investorcentre.com/contact Need assistance? Proxy Form Lodge your Proxy Form:How to Vote on Items of Business Online: Lodge your vote online at www.investorvote.com.au using your secure access information or use your mobile device to scan the personalised QR code. Corporate Representative If a representative of a corporate securityholder or proxy is to participate in the meeting you will need to provide the appropriate “Appointment of Corporate Representative”. A form may be obtained from Computershare or online at www.investorcentre.com/au and select "Printable Forms". PARTICIPATING IN THE MEETING SIGNING INSTRUCTIONS FOR POSTAL FORMS For Intermediary Online subscribers (custodians) go to www.intermediaryonline.com By Mail: Computershare Investor Services Pty Limited GPO Box 242 Melbourne VIC 3001 Australia 1800 783 447 within Australia or +61 3 9473 2555 outside Australia By Fax: Your secure access information is APPOINTMENT OF PROXY PLEASE NOTE: For security reasons it is important that you keep your SRN/HIN confidential. Control Number: 189278 Individual: Where the holding is in one name, the securityholder must sign. Joint Holding: Where the holding is in more than one name, all of the securityholders should sign. Power of Attorney: If you have not already lodged the Power of Attorney with the registry, please attach a certified photocopy of the Power of Attorney to this form when you return it. Companies: Where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. If the company (pursuant to section 204A of the Corporations Act 2001) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director or a Company Secretary. Please sign in the appropriate place to indicate the office
or failing the individual or body corporate named, or if no individual or body corporate is named, the Chair of the Meeting, as my/our proxy to act generally at the meeting on my/our behalf and to vote in accordance with the following directions (or if no directions have been given, and to the extent permitted by law, as the proxy sees fit) at the Annual General Meeting of Mayne Pharma Group Limited to be held at MinterEllison, Level 20, Collins Arch, 447 Collins St, Melbourne, VIC 3000 and as a virtual meeting on Friday, 20 November 2026 at 10:00am (Melbourne time) and at any adjournment or postponement of that meeting. Chair authorised to exercise undirected proxies on remuneration related resolutions: Where I/we have appointed the Chair of the Meeting as my/our proxy (or the Chair becomes my/our proxy by default), I/we expressly authorise the Chair to exercise my/our proxy on Resolutions 5 and 6 (except where I/we have indicated a different voting intention in step 2) even though Resolutions 5 and 6 are connected directly or indirectly with the remuneration of a member of key management personnel, which includes the Chair. Important Note: If the Chair of the Meeting is (or becomes) your proxy you can direct the Chair to vote for or against or abstain from voting on Resolutions 5 and 6 by marking the appropriate box in step 2. The Chair of the Meeting intends to vote undirected proxies in favour of each item of business except against resolution 4. In exceptional circumstances, the Chair of the Meeting may change his/her voting intention on any resolution, in which case an ASX announcement will be made. Appoint a Proxy to Vote on Your Behalf Change of address. If incorrect, mark this box and make the correction in the space to the left. Securityholders sponsored by a broker (reference number commences with ‘X’) should advise your broker of any changes. Proxy Form Please mark to indicate your directions I/We being a member/s of Mayne Pharma Group Limited hereby appoint the Chair of the Meeting OR PLEASE NOTE: Leave this box blank if you have selected the Chair of the Meeting. Do not insert your own name(s).Step 1 Items of Business PLEASE NOTE: If you mark the Abstain box for an item, you are directing your proxy not to vote on your behalf on a show of hands or a poll and your votes will not be counted in computing the required majority.Step 2 This section must be completed. Individual or Securityholder 1 Securityholder 2 Securityholder 3 Sole Director & Sole Company Secretary Director Director/Company Secretary Update your communication details By providing your email address, you consent to receive future Notice of Meeting & Proxy communications electronicallyMobile Number Email Address (Optional) Signature of Securityholder(s)Step 3
Ask a question
100%
/ 21
1 / 21
Announcement PDF 19 October 2026 Manager, Company Announcements ASX Limited Level 27 39 Martin Place SYDNEY NSW 2000 Via E-Lodgement 2026 Annual General Meeting Attached is the Mayne Pharma Group Limited 2026 Notice of Annual General Meeting and a related proxy form. A letter to shareholders from the Chair is also attached. The 2026 Annual General Meeting will be held at 10:00am on Friday, 20 November 2026 (AEDT). The Notice of Meeting contains instructions for shareholders explaining how to participate in the AGM, including how to attend or watch the proceedings, vote and ask questions. This announcement is authorised by the Chair. Yours faithfully, Mayne Pharma Group Limited Laura Loftus Company Secretary SRN/HIN: I9999999999 328946_01_V3 Control Number: 189278 19 October 2026 2026 Mayne Pharma Group Limited Annual General Meeting Dear Fellow Shareholder On behalf of the Board, I am pleased to invite you to the 2026 Mayne Pharma Group Limited Annual General Meeting (AGM) which will be held at 10:00am (Melbourne time) on Friday, 20 November 2026 at Minter Ellison Offices, Level 20, Collins Arch, 447 Collins St, Melbourne and online at https://meetnow.global/MCUUA2J. The AGM is an important annual event for Mayne Pharma giving shareholders the opportunity to hear from your Chair and your Chief Executive Officer, ask questions about the management and operations of your Company and vote on the items of business. The Notice of Meeting for the 2026 AGM is available at maynepharma.com/investor-relations/annual- general-meeting/. Shareholders, proxyholders and interested parties can participate in the AGM by attending in person or via the webcast live at https://meetnow.global/MCUUA2J. Any shareholders wishing to lodge a proxy vote or lodge questions ahead of the meeting can do this by logging onto https://www.investorvote.com.au and entering the Control Number and your holder number (SRN/HIN) located at the top of this letter. Lodging questions or casting your proxy vote ahead of the meeting will not prevent you from attending online or in person. You can also submit questions to [email protected]. The business of the meeting set out in the Notice of 2026 Annual General Meeting is as follows: 1. Consider the statutory reports for the financial year ended 30 June 2026; 2. Election and re-election of Board endorsed Directors (Resolutions 1-3); 3. Election of external non-Board endorsed candidate (Resolution 4); 4. Adopt the 2026 Remuneration Report (Resolution 5); and 5. Approve the Omnibus Equity Incentive Plan (Resolution 6). MYX MR SAM SAMPLE FLAT 123 123 SAMPLE STREET THE SAMPLE HILL SAMPLE ESTATE SAMPLEVILLE VIC 3030 Samples/000001/000002/i12 M00000112Q02 328946_01_V3 Each Director (where permitted to do so) recommends that shareholders vote in favour of Resolutions 1, 2, 3, 5 and 6 and against resolution 4. The Board does not believe that the election of Dr Wells is in the best interests of Mayne Pharma. The Board has carefully considered Dr Wells’ nomination against the current Board composition and the skills and experience required to deliver Mayne Pharma’s purpose and strategy. Following that review, the Board has concluded that the size and composition of your Board is optimal at the present time, therefore the addition of Dr Wells would not add value to your Board. Thank you for your continued support of Mayne Pharma. I hope you can join us for the AGM this year. Yours sincerely Professor Bruce Robinson Chair Notice of 2026 Annual General Meeting Notice is given that the 2026 Annual General Meeting of Mayne Pharma Group Limited will be held on Friday, 20 November 2026 at 10:00am (Melbourne time) Mayne Pharma Notice of Annual General Meeting 2026 2 NOTICE OF ANNUAL GENERAL MEETING Mayne Pharma Group Limited ACN 115 832 963 The annual general meeting of shareholders (Shareholders) of Mayne Pharma Group Limited (Company or Mayne Pharma) will be held at 10:00am (Melbourne time) on Friday, 20 November 2026 as a hybrid meeting (AGM). Shareholders, proxyholders and interested parties can participate in the AGM by attending in person at MinterEllison, Level 20, Collins Arch, 447 Collins St, Melbourne, VIC 3000 or online at https://meetnow.global/MCUUA2J. Further information on how to participate in the AGM is provided in this Notice of AGM and in the AGM Meeting Guide which you can access at maynepharma.com/investor-relations/annual-general-meeting/. If you cannot attend the AGM in person or online at the scheduled time, you can participate in the AGM by appointing a proxy to attend and vote on your behalf. Details on how to appoint a proxy are contained in this Notice of AGM. This Notice of AGM is being distributed electronically and is available to view and download at maynepharma.com/investor-relations/annual-general-meeting/. Copies of the Chair’s address will be available on both the ASX website at asx.com.au and Mayne Pharma’s website maynepharma.com. PARTICIPATION AT THE AGM Attend in person or watch and participate live online Shareholders are invited to watch and participate in the AGM by either: • participating in person at MinterEllison, Level 20, Collins Arch, 447 Collins St, Melbourne, VIC 3000; or • participating virtually by entering the following URL in your browser: https://meetnow.global/MCUUA2J. To do this you will need a computer or mobile/tablet device with internet access. Participation in the meeting in person and online enables Shareholders to view the AGM live, ask questions and cast votes during the meeting. All Shareholders will have an equal opportunity to participate in the online meeting regardless of their physical location. Shareholders, once verified, will be taken to be present at the AGM for all purposes, until either the meeting ends or (for those participating online) the Shareholder exits the online platform. It is important that Shareholders participating online are connected to the internet at all times during the AGM in order to vote. Voting options Voting on all Resolutions will be conducted by a poll. Shareholders who are attending in person can cast votes during the meeting. Shareholders who are attending online can watch the AGM and cast votes using the Computershare online platform. Non-Shareholders will be able to attend the AGM in person or watch the AGM via the Computershare online platform by registering as a guest but will not be able to vote or ask questions. Questions Shareholders who are attending in person can ask questions during the meeting. Shareholders are encouraged to lodge questions prior to the AGM by submitting questions to [email protected]. Shareholders participating via the Computershare online platform will be able to ask questions by following the prompts in the online platform. It may not be possible to respond to all questions. However, Shareholders as a whole will have a reasonable opportunity to ask questions about or make comments on the management of the Company. 3 Mayne Pharma Notice of Annual General Meeting 2026 BUSINESS 1. Financial statements and reports To receive and consider the Directors' Report, Financial Statements and the Independent Auditor’s Report for the year ended 30 June 2026. Note: There is no vote on this item. 2. Election and Re-election of Board endorsed Directors This year there are two Board endorsed Directors standing for election: Mr Jacob Ma-Weaver and Ms Meghan Rivera, and one Board endorsed Director standing for re-election: Professor Bruce Robinson. Resolution 1 – Election of Jacob Ma-Weaver To consider and, if thought fit, to pass the following ordinary resolution: 'That Mr Jacob Ma-Weaver, who was appointed to the Board since the last Annual General Meeting and who retires in accordance with the Company’s constitution and, being eligible and having signified his candidature for office, be elected as a Director.' Resolution 2 – Election of Meghan Rivera To consider and, if thought fit, to pass the following ordinary resolution: 'That Ms Meghan Rivera, who was appointed to the Board since the last Annual General Meeting and who retires in accordance with the Company’s constitution and, being eligible and having signified her candidature for office, be elected as a Director.' Resolution 3 – Re-election of Bruce Robinson To consider and, if thought fit, to pass the following ordinary resolution: 'That Professor Bruce Robinson, who retires by rotation in accordance with the Constitution and, being eligible and having signified his candidature for office, be re-elected as a Director.' 3. Election of external non-Board endorsed candidate Resolution 4 –Election of Brett Wells To consider and, if thought fit, to pass the following ordinary resolution: 'That Dr Brett Wells, an external candidate nominated for election in accordance with the Company's constitution and, being eligible and having signified his candidature for office, be elected as a Director.' The Board recommends shareholders vote against Resolution 4. Mayne Pharma Notice of Annual General Meeting 2026 4 4. Remuneration report Resolution 5 – Adoption of Remuneration Report To consider and, if thought fit, pass the following ordinary resolution: 'That, for the purposes of section 250R(2) of the Corporations Act, the Remuneration Report that forms part of the Directors' Report of the Company for the financial year ended 30 June 2026 be adopted.' Note: In accordance with section 250R(3) of the Corporations Act, the vote on this Resolution is advisory only and does not bind the Directors. 5. Omnibus Equity Incentive Plan Resolution 6 – Approval of Omnibus Equity Incentive Plan To consider and, if thought fit, pass the following ordinary resolution: 'That, for the purposes of ASX Listing Rule 7.2 (Exception 13) and for all other purposes, Shareholders approve the issue and grant of securities by the Board in its discretion in accordance with the Omnibus Equity Incentive Plan (a summary of which is set out in the Explanatory Information) as an exception to ASX Listing Rule 7.1.' 5 Mayne Pharma Notice of Annual General Meeting 2026 VOTING RESTRICTIONS Voting exclusion for Resolution 5 The Company will disregard any votes cast on Resolution 5: • by or on behalf of a member of the Company’s key management personnel (KMP) named in the Remuneration Report for the year ended 30 June 2026 or their Closely Related Parties (regardless of the capacity in which the vote is cast); or • as a proxy by a person who, at the date of the Meeting, is a member of the Company’s KMP or their Closely Related Parties, unless the vote is cast as proxy for a person entitled to vote on Resolution 5: • in accordance with a direction on the proxy form; or • by the Chair of the Meeting pursuant to an express authorisation in the proxy form to exercise the proxy as the Chair sees fit, even though Resolution 5 is connected with the remuneration of members of the KMP. Voting exclusion for Resolution 6 The Company will disregard any votes cast in favour of Resolution 6 by or on behalf of: • a person who is eligible to participate in the Omnibus Equity Incentive Plan; or • an Associate of that person (or those persons). However, this does not apply to a vote cast in favour of the resolution by: • a person as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with the directions given to the proxy or attorney to vote on the resolution in that way; • the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the Item, in accordance with a direction given to the Chair to vote on the resolution as the Chair decides; or • a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary, provided the following conditions are met: o the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the resolution; and o the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way. In addition, a vote must not be cast on Resolution 6 by a member of the KMP of the Company or their Closely Related Party, acting as proxy for a person entitled to vote, if their appointment does not specify the way the proxy is to vote on Resolution 6. This restriction on voting undirected proxies does not apply to the Chair of the Meeting acting as a proxy for a person entitled to vote on the resolution because the Company’s proxy appointment expressly authorises the Chair of the Meeting to exercise undirected proxies even though the resolution is connected directly or indirectly with the remuneration of a member of the KMP of the Company. Mayne Pharma Notice of Annual General Meeting 2026 6 PROXIES AND SHAREHOLDER INFORMATION IMPORTANT: Shareholders are urged to direct their proxy on how to vote by clearly marking the relevant box for each Resolution on the proxy form. Proxies 1. A Shareholder entitled to attend and vote at the Meeting has the right to appoint a person (who does not need to be a Shareholder) as the Shareholder’s proxy to attend and vote at the Meeting. 2. If a Shareholder is entitled to cast two or more votes they may appoint two proxies (but no more) provided that an appointment of two proxies will have no effect unless each proxy is appointed to represent a specified proportion of the Shareholder’s voting rights aggregating to no more than 100% of that Shareholder’s voting rights. If the Shareholder appoints two proxies, neither proxy may vote on a show of hands. 3. The proxy form must be signed by the Shareholder or their attorney. Proxies given by corporations must be signed by a director and company secretary or two directors or a sole director/secretary or a sole director or its duly authorised attorney. 4. If the proxy form is signed but is blank in all other material respects, it will be taken to mean that it is in favour of the Chair of the Meeting for full voting rights and the Chair will vote in favour of Resolutions 1-3, 5 and 6 on a poll (subject to the voting exclusions set out in this Notice). The Chair will vote against Resolution 4. 5. A proxy may decide whether to vote on any motion, except where the proxy is required by law, the ASX Listing Rules or the Constitution to vote, or abstain from voting, in their capacity as proxy. If a proxy is directed to vote on an item of business, the proxy may vote on that item only in accordance with the direction. If a proxy is not directed how to vote on an item of business, the proxy may vote as they think fit. 6. If proxy holders vote, they must cast all directed proxies as directed. Any directed proxies which are not voted will automatically default to the Chair of the Meeting, who must vote the proxies as directed. 7. The proxy form accompanying this Notice contains detailed instructions regarding how to complete the proxy form if a Shareholder wishes to appoint the Chair as his or her proxy. You should read those instructions carefully. 8. Except where paragraph 9 immediately below applies, in relation to Resolution 5 and Resolution 6, a proxy must not vote if: (a) they are a KMP or a Closely Related Party of a KMP; and (b) their appointment as proxy does not specify the way they are to vote on the Resolution. 9. By appointing the Chair of the meeting as your proxy in relation to Resolution 5 and/ or Resolution 6, you expressly authorise the Chair to vote in favour of that Resolution unless: (a) you direct the Chair to vote against or to abstain from voting on that Resolution; or (b) you are a member of the KMP, or a Closely Related Party of a KMP. 10. Subject to any voting exclusions, the Chair of the Meeting intends to exercise all open proxies by voting in favour of Resolutions 1, 2, 3, 5 and 6, and against Resolution 4. 11. Proxies may be lodged in the following way: Mail Computershare Investor Services Pty Limited GPO Box 242 Melbourne VIC 3001 7 Mayne Pharma Notice of Annual General Meeting 2026 Facsimile: (within Australia) 1800 783 447 (outside Australia) +61 3 9473 2555 Online: www.investorvote.com.au (by following the instructions set out on the website) Custodian voting – For Intermediary Online subscribers only please visit www.intermediaryonline.com to submit your voting intentions 12. Enquiries can be made at 1300 850 505 (within Australia) or +61 3 9415 4000 (outside Australia) between 8.30am and 5.30pm (Melbourne time), Monday to Friday. 13. Proxy forms must be received at least 48 hours before the Meeting, being by no later than 10:00 am (Melbourne time) on Wednesday, 18 November 2026. Entitlement to vote 14. The Company has determined that the persons entitled to attend and vote at the Annual General Meeting will be those persons set out in the register of Shareholders as at 7:00 pm (Melbourne time) on Wednesday, 18 November 2026. Voting by attorney 15. A Shareholder may appoint an attorney to vote on their behalf. For an appointment to be effective for the AGM, the instrument effecting the appointment (or a certified copy of it) must be received at the address listed above for the receipt of proxy appointments at least 48 hours before the commencement of the AGM, being by no later than 10:00 am (Melbourne time) on Wednesday, 18 November 2026. Voting by corporate representative 16. A body corporate which is a Shareholder, or which has been appointed as a proxy, may appoint an individual to act as its representative at the AGM. The appointment must comply with the requirements of section 250D of the Corporations Act. The representative should ensure that a copy of their appointment, including any authority under which it is signed, has been provided to Computershare before the AGM. Mayne Pharma Notice of Annual General Meeting 2026 8 EXPLANATORY INFORMATION 1. Financial statements and reports At the AGM, Shareholders will be given an opportunity to ask questions and comment on the Directors' Report, Financial Statements and Independent Auditor's Report for the financial year ended 30 June 2026. Shareholders can view or download a copy of the 2026 Annual Report from the Company's website at maynepharma.com. The Company's auditor will be available to answer questions as to the conduct of the audit and the Independent Auditor's Report. Shareholders should note that the sole purpose of tabling the Directors' Report, Financial Statements and Independent Auditor's Report of the Company at the Annual General Meeting is to provide Shareholders with the opportunity to ask questions or discuss matters arising from them. It is not the purpose of the Meeting that the Directors' Report, Financial Statements and Independent Auditor's Report be accepted, rejected or modified in any way. Further, as it is not required by the Corporations Act, no resolution to adopt, receive or consider the Company's Directors' Report, Financial Statements and Independent Auditor's Report will be put to Shareholders at the Meeting. 2. Election and Re-election of Board endorsed Directors Under rule 3.3 of the Constitution, any Director appointed by the Board since the last annual general meeting automatically retires at the next annual general meeting and is eligible for election at that general meeting. Appropriate background checks were completed before Mr Jacob Ma-Weaver and Ms Meghan Rivera were appointed to the Board. Under rule 3.6 of the Constitution, at each annual general meeting one third (or if that is not a whole number, the whole number nearest to one third) of the Company's Directors (excluding any Directors appointed since the last Annual General Meeting) must retire from office and are eligible for re-election. Resolution 1 – Election of Mr Jacob Ma-Weaver (BA, MA, CFA) Resolution 1 seeks approval for the election of Mr Jacob Ma-Weaver as a Director with effect from the end of the Annual General Meeting. Mr Ma-Weaver was appointed to the Board on 14 August 2026. Mr Ma-Weaver, a US resident, is the Managing Member of Cable Car Capital, LP (Cable Car), an investment adviser he founded in 2013. Cable Car is the General Partner of Funicular Funds, LP, a hedge fund. Funicular Funds, LP, holds 9.90% of the Shares. Mr Ma-Weaver served on the Board of ARCA biopharma, Inc. from 2022 until its business combination with Oruka Therapeutics in 2024. Prior to his role at Cable Car, Mr Ma-Weaver was an investment analyst at Amici Capital LLC, where he focused on healthcare. He previously worked as an equity research associate at Dodge & Cox and a corporate finance business analyst at McKinsey & Company. Prior to his appointment, Mayne Pharma undertook appropriate background and experience checks on Mr Ma- Weaver. The Board has determined that Mr Ma-Weaver is not an independent Director. The Board (with Mr Ma-Weaver abstaining) recommends that Shareholders vote in favour of Resolution 1. 9 Mayne Pharma Notice of Annual General Meeting 2026 Resolution 2 – Election of Ms Meghan Rivera (BScBusAdmin) Resolution 2 seeks approval for the election of Ms Meghan Rivera as a Director with effect from the end of the Annual General Meeting. Ms Rivera was appointed to the Board on 26 June 2026. Ms Rivera, a US resident, brings more than 25 years of experience in the US pharmaceutical industry across multiple therapeutic areas including women’s health. Ms Rivera’s experience includes building, scaling and transforming businesses across biopharma and she has played a key role in launching branded products in the US. She currently serves as Vice President and Global Commercial Lead for ViiV Healthcare, a leading biopharmaceutical organisation focused on the prevention, treatment and cure of HIV. Prior roles include US Market President at Organon & Co (NYSE: OGN), Chief Marketing Officer and Head of Commercial at Akili Interactive, and Senior Vice President of Women's Health at AMAG Pharmaceuticals. Prior to her appointment, Mayne Pharma undertook appropriate background and experience checks on Ms Rivera. Ms Rivera is a member of the Remuneration and People Committee and the Nomination Committee. The Board has determined that Ms Rivera is an independent Director. The Board (with Ms Rivera abstaining) recommends that Shareholders vote in favour of Resolution 2. Resolution 3 – Re-election of Professor Bruce Robinson (AC, MD, MSC, FRACP, FAAHMS, FAICD) Resolution 3 seeks approval for the re-election of Bruce Robinson as a Director with effect from the end of the Annual General Meeting. The Board appointed Professor Robinson as a Director of the Company on 26 August 2014, and he was appointed Chair effective 14 January 2026. Professor Robinson, a practising Endocrinologist at Sydney’s Royal North Shore Hospital, is Former Dean of University of Sydney’s Sydney Medical School. Professor Robinson has been the head of the Cancer Genetics Unit at the Kolling Institute of Medical Research, Royal North Shore Hospital since 1989. Since 2001, Professor Robinson has been Chairman of Hoc Mai Foundation, a major program in medical and health education and exchange with Vietnam. He is a Non-Executive Director of Cochlear Limited, Lorica and QBiotics Group Limited. He is a Board Member of the Woolcock Institute, is Chair of National Health and Medical Research Council and Chair of the Medical Benefits Review Taskforce. Professor Robinson is a member of the Audit and Risk Committee and Chair of the Nomination Committee. The Board has determined that Professor Robinson is an independent Director. The Board (with Professor Robinson abstaining) recommends that Shareholders vote in favour of Resolution 3. Mayne Pharma Notice of Annual General Meeting 2026 10 3. Election of non-Board endorsed candidate Resolution 4 – Election of Dr Brett Wells (BEng (Aerospace) (Hons), PhD (Astronomy & Astrophysics) (ANU), MBBS (Hons) (Syd), FANZCA) Dr Wells has been nominated for election as a Director in accordance with rule 3.5(c) of the Constitution. Dr Wells was nominated by his wife, Dr Kenney Wan, a Shareholder. Dr Wells’ nomination is not endorsed by the Board. The Board is in the process of undertaking appropriate checks into Dr Wells’ background and experience, in accordance with the ASX Corporate Governance Principles and Recommendations and Mayne Pharma’s standard practice. If those checks reveal anything of concern, the Company will provide an update to shareholders. Dr Wells provided the following information for inclusion in this Notice of Meeting. The information has not been verified nor is it endorsed by Mayne Pharma. Dr Brett Wells is an astrophysicist, a specialist anaesthetist, an aerospace engineer and a financial analyst who runs his family office. His family own just under 2% of Mayne Pharma’s issued shares. He is seeking election to bring that combination of expertise, substantial personal investment and demonstrated shareholder engagement to the Board. His family carries a significant unrealised loss on its investment while continuing to have substantial personal capital exposed to the Company’s future performance. Dr Wells trained in aerospace engineering before completing his PhD in Astronomy and Astrophysics at the Australian National University’s Mount Stromlo Observatory. His research included work at Caltech’s Infrared Processing and Analysis Center and the Australia Telescope National Facility, followed by a postdoctoral fellowship at the Institut d’Astrophysique Spatiale, Université Paris-Sud. He graduated from the University of Sydney’s medical program in 2001 with the highest level of honours and the K.C.T. Rawle Surgical Prize. During his medical studies, he undertook visiting study in space medicine at the University of Texas Medical Branch and at the University of Oxford. After working at Royal North Shore Hospital, he completed five years of specialist anaesthetic training through St George Public Hospital. He is a Fellow of the Australian and New Zealand College of Anaesthetists and now practises in Sydney’s private hospitals, principally supporting ophthalmic and urological surgery. He is also developing a large-scale cancer research database and a Python-based analytical framework using existing large language models to organise and interrogate evidence and investigate potential treatment approaches, particularly in prostate cancer. His broader commercial interests include modular construction, which he is exploring through preliminary discussions with Wild Modular. Dr Wells manages his family’s investment office. His investment experience includes equity research, company valuation, financial analysis and scenario modelling. He has undertaken extensive modelling of alternative outcomes for Mayne Pharma, examining the financial viability of different strategic pathways, their capital requirements, potential returns and downside risks. This includes evaluating appropriate investment in DistributeRx and how different strategic choices could affect the Company’s value and financial position. His work uses large- scale existing AI models to assist with research, valuation and scenario analysis. His investment education is self-directed and includes reading all 18 volumes of the 2022 CFA curriculum and hundreds of investment books. He has not taken the CFA examinations and does not hold the CFA designation, as the qualification was not necessary for his family office work. Through his X account, @toy59496, he publishes equity analysis and commentary on corporate governance to a significant following that includes retail investors and fund managers. 11 Mayne Pharma Notice of Annual General Meeting 2026 Dr Wells would combine financial alignment with shareholders, clinical insight, quantitative research skills and demonstrated commitment to understanding Mayne Pharma’s challenges. His priorities would be effective oversight, rigorous assessment of strategic alternatives, disciplined investment, measurable performance and timely disclosure. He would work constructively with fellow directors and management while exercising independent judgement and scrutinising strategy and execution. He recognises that his responsibilities would be to the Company as a whole and would consider the interests of all shareholders. The Board’s recommendation The Board does not believe that the election of Dr Wells is in the best interests of Mayne Pharma. The Board has carefully considered Dr Wells’ nomination against the current Board composition and the skills and experience required to deliver Mayne Pharma’s purpose and strategy. Following that review, the Board has concluded that the size and composition of your Board is optimal at the present time, therefore the addition of Dr Wells would not add value to your Board. The Board recommends Shareholders vote against Resolution 4. The Chair of the AGM intends to vote undirected proxies against Resolution 4. 4. Resolution 5 – Adoption of Remuneration Report The Annual Report for the financial year ended 30 June 2026 contains a Remuneration Report, which forms part of the Director’s Report and sets out the remuneration policy for the consolidated entity comprising the Company and its controlled entities and reports on the remuneration arrangements in place for its KMP. Mayne Pharma’s executive remuneration framework is focused on aligning Shareholder and management interests by adopting a remuneration policy with a significant weighting to at-risk remuneration including equity- based incentives. The Remuneration Report includes further details on the elements of remuneration that are performance based, the performance conditions that apply and the methodology used to assess satisfaction of those performance conditions. The vote on Resolution 5 to adopt the Remuneration Report relates to the Company’s remuneration policy and outcomes for the 2026 financial year (FY26). During consideration of this item, there will be an opportunity for Shareholders at the Meeting to comment on and ask questio
Open panelView summary and Q&As
Share your feedback
How likely is it that you would recommend Mayne Pharma Group Limited to another investor?
Likely
Neutral
Unlikely
0 responses
Questions (0)
Post question
Your question will be sent privately to Mayne Pharma Group Limited. The company may choose to make this question public.
Start the conversation
Ask Mayne Pharma Group Limited a question about this announcement.
Discover
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:04 AM](https://investors.maynepharma.com/announcements/69glBo-notification-regarding-unquoted-securities-myx)
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:03 AM](https://investors.maynepharma.com/announcements/RQVGgB-notification-regarding-unquoted-securities-myx)
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:02 AM](https://investors.maynepharma.com/announcements/46zl4q-notification-regarding-unquoted-securities-myx)
Summary
Summary
Questions (0)
Provide feedback to Mayne Pharma Group Limited. Complete survey to view results.
How likely is it that you would recommend Mayne Pharma Group Limited to another investor?
Likely
Neutral
Unlikely
0 responses
Post question
Your question will be sent privately to Mayne Pharma Group Limited. The company may choose to make this question public.
Start the conversation
Ask Mayne Pharma Group Limited a question about this announcement.
Share your feedback
How likely is it that you would recommend Mayne Pharma Group Limited to another investor?
Likely
Neutral
Unlikely
0 responses
Discover
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:04 AM](https://investors.maynepharma.com/announcements/69glBo-notification-regarding-unquoted-securities-myx)
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:03 AM](https://investors.maynepharma.com/announcements/RQVGgB-notification-regarding-unquoted-securities-myx)
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:02 AM](https://investors.maynepharma.com/announcements/46zl4q-notification-regarding-unquoted-securities-myx)
We value your privacy
We use cookies, including those from select third parties, to enhance your experience on our website and to help improve our services as specified in our Privacy Policy.
By clicking "Accept all", you consent to our use of cookies.
Our cookie notice lists every cookie we set, what it does and how long it lasts.
Closing this window accepts our default settings. You can change them at any time from cookie settings.
Accept allReject allCustomise settings
MYX settles US patent litigation re Imvexxy with Teva USA
Released 15 Oct 2026 - 10:43 PM
Released 15 Oct 2026 - 10:43 PM
LikeFollowShare
ASX Announcement MAYNE PHARMA SETTLES US PATENT LITIGATION RELATING TO IMVEXXY® WITH TEVA PHARMACEUTICALS USA Key Points: • Settlement reached with Teva Pharmaceuticals USA resolving Paragraph IV litigation concerning IMVEXXY® FDA Orange Book patents • Settlement includes an agreed market entry date of generic IMVEXXY® of 2 September 2032 • The settlement highlights the validity and enforceability of the IMVEXXY® patent portfolio • Mayne Pharma continues to support IMVEXXY® and defence of its IP portfolio with the last expiring patent in February 2034 16 October 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX), today announces that Teva Pharmaceuticals USA Inc. (Teva Pharmaceuticals USA) has agreed to resolve the US Paragraph IV litigation relating to IMVEXXY® (estradiol vaginal inserts) and the associated FDA Orange Book-listed patents, brought by Mayne Pharma and TherapeuticsMD. The settlement resolves ongoing patent litigation with Teva Pharmaceuticals USA (commenced in April 2020) and provides an agreed pathway for potential future entry of a Teva Pharmaceuticals USA generic product on 2 September 2032, or earlier under certain circumstances, subject to court approval of the settlement terms. The settlement does not include any financial payment or upfront monetary consideration between the parties. Mr Aaron Gray, CEO of Mayne Pharma said “Following our settlement with Sun Pharma announced on 30 September, today’s agreement with Teva Pharmaceuticals USA resolves all outstanding Paragraph IV litigation relating to IMVEXXY®. Together, these settlements give us clarity on the generic entry landscape and remove the cost and uncertainty of ongoing litigation. This provides a firm foundation for our longer-term planning for IMVEXXY® within our menopause portfolio and broader Women’s Health business. We will continue to defend our IP estate and invest in access, adherence and prescriber engagement to maximise the product’s long-term contribution.” IMVEXXY® is a locally administered estradiol vaginal insert used in the treatment of moderate to severe dyspareunia due to menopause. The product sits within Mayne Pharma’s Women’s Health franchise and is supported by ongoing commercial execution initiatives focused on access, adherence and prescriber engagement. In the 12 months to 30 June 2026, IMVEXXY® total prescriptions grew 6% over the prior corresponding period and net sales were up 8% to US$29.3 million. After the settlement announced today, the Company has no further ongoing Paragraph IV litigation matters for IMVEXXY®. Click here to view the announcement on Investor Hub.
- ENDS -
ASX Announcement Page 2
Supreme Court Decision in Cosette Proceedings
Released 14 Oct 2026 - 2:29 AM
Released 14 Oct 2026 - 2:29 AM
1FollowShare
ASX Announcement SUPREME COURT DECISION IN COSETTE PROCEEDINGS 14 October 2026, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) (Mayne Pharma) refers to its announcement on 15 January 2026 relating to the notice of appeal filed by Cosette with the Supreme Court of New South Wales, Court of Appeal in relation to the proposed transaction between Mayne Pharma and Cosette the subject of the decision of the Supreme Court of New South Wales delivered on 15 October 2025. Cosette is ultimately owned by Hamilton Lane and Avista Capital. The Supreme Court of New South Wales, Court of Appeal today delivered its judgment dismissing the appeal brought by Cosette on all grounds and awarded Mayne Pharma its costs of the appeal. Cosette’s appeal sought to overturn parts of the first instance decision, including the decision that no Mayne Material Adverse Change had occurred and that Mayne Pharma did not engage in misleading and deceptive conduct regarding its FY25 EBITDA financial performance. The Court of Appeal rejected every argument advanced by Cosette in support of its appeal, affirming the findings made by Justice Black. The Court of Appeal also held that by Cosette’s conduct at the first Court hearing in connection with the proposed Scheme, Cosette elected to affirm the scheme implementation deed thereby foregoing any alleged right to terminate. As disclosed on 22 May 2026, Cosette paid approximately $14.4 million to Mayne Pharma in connection with its costs of the proceeding below. This decision has no effect on the payment of those costs. In addition, the Court of Appeal has awarded Mayne Pharma its costs of the appeal, which costs remains to be determined. Mayne Pharma Board Chair, Professor Bruce Robinson said: “We are delighted that the Court of Appeal has upheld the decision of the Supreme Court at first instance and rejected Cosette’s attempts to assert it had any right to terminate the deal. The Court also rejected that there had been any wrongdoing on the part of Mayne Pharma. Mayne Pharma remains committed to continuing to maximise shareholder value and remains focussed on continuing to strengthen the business. Mayne Pharma will continue to pursue its claims against Cosette, Cosette Pharmaceuticals Holdings, Inc, and its controllers, Mr David Burghstahler and Avista Capital for damages on behalf of itself and Mayne Pharma shareholders.” Cosette has until 11 November 2026 to consider whether it will seek special leave to appeal the decision to the High Court. A copy of the judgement is available here. Click here to view this announcement on Mayne Pharma’s Investor Hub.
ASX Announcement Page 2
Trading Halt
Released 13 Oct 2026 - 9:20 PM
Released 13 Oct 2026 - 9:20 PM
LikeFollowShare
Market Announcement 14 October 2026 14 October 2026 Market Announcement 1/1 ASX Limited ASX Customer Service Centre 131 279 | asx.com.au Mayne Pharma Group Limited (ASX: MYX) – Trading Halt Trading in the securities of Mayne Pharma Group Limited (‘MYX’) will be halted at the request of MYX, pending the release of an announcement by MYX. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of: • the commencement of normal trading on Friday, 16 October 2026; or • the release of the announcement to the market. MYX’s request for a trading halt is attached below for the information of the market. Issued by ASX Supervision
Wednesday, 14 October 2026 Manager, Company Announcements ASX Limited Level 27 39 Martin Place SYDNEY NSW 2000 Dear Sir/Madam, Mayne Pharma Group Limited – Request for Trading Halt Mayne Pharma Group Limited (ASX: MYX) (Mayne Pharma) requests a trading halt in its securities with immediate effect in accordance with Listing Rule 17.1 pending the release of an announcement in relation to the decision of the Supreme Court of New South Wales, Court of Appeal related to Cosette’s appeal of the judgement of the Supreme Court of New South Wales delivered on 15 October 2025. The Court of Appeal’s decision is scheduled to be handed down after market open on 14 October 2026. Mayne Pharma requests the trading halt remain in place until the earlier of the commencement of normal trading on 16 October 2026, or when the above announcement is released to the market. Mayne Pharma is not aware of any reason why the trading halt should not be granted and is not aware of any other information that is necessary to inform the market about the trading halt. This ASX announcement is authorised for release by the Chair of the Board of Mayne Pharma. Yours faithfully, Laura Loftus Company Secretary
Fulfilment of Imvexxy post-marketing study requirements
Released 8 Oct 2026 - 10:41 PM
Released 8 Oct 2026 - 10:41 PM
LikeFollowShare
ASX Announcement FDA CONFIRMS FULFILMENT OF IMVEXXY® POST- MARKETING STUDY REQUIREMENTS Key Points • The US Food and Drug Administration (FDA) has confirmed the Company has fulfilled its post- approval obligations by completing the post-marketing requirement (PMR) safety study for IMVEXXY® (estradiol vaginal inserts) • The study was one of the largest real-world analyses of very-low-dose vaginal estrogen (VLDVE) undertaken to date, covering more than 9.5 million US postmenopausal women • The study demonstrated no association between very-low-dose vaginal estrogen use as prescribed and endometrial cancer risk (pooled hazard ratio 1.00; 95% CI 0.69–1.45)1 • Completion of the PMR closes all outstanding FDA post-marketing regulatory requirements for IMVEXXY® and reinforces the favourable benefit–risk profile of IMVEXXY® and other VLDVE therapy • New real-world evidence published in 2026 and joint US urology and urogynaecology guidelines further support the role of local low-dose vaginal estrogen in genitourinary syndrome of menopause (GSM), including reducing the risk of recurrent urinary tract infections (rUTIs) • IMVEXXY® delivered FY26 net sales of US$29.3 million (+8%), total prescription growth of 6% and is well positioned to capture structural growth in the US menopause market 9 October 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX) today announces that it has received a letter from the US Food and Drug Administration (FDA) confirming that the Company has fulfilled its post-marketing requirement (PMR) for IMVEXXY® (estradiol vaginal inserts). IMVEXXY® is FDA-approved for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA) due to menopause. The PMR study was an observational study with a primary endpoint designed to evaluate the risk of endometrial cancer in postmenopausal women prescribed very-low-dose vaginal estrogen (VLDVE) products, including IMVEXXY®. The FDA reviewed the final study report submitted by Mayne Pharma and concluded that the requirement has been fulfilled. With this outcome, Mayne Pharma has no remaining post-marketing requirements with the FDA for IMVEXXY®. Largest real-world analysis of very-low-dose vaginal estrogen safety The study was conducted by independent research organisation RTI Health Solutions using two large US health-insurance claims databases spanning commercial and Medicare Advantage populations. As previously announced to ASX on 20 August 2026, the results were presented at the International Society for Pharmacoepidemiology (ISPE) 2026 annual meeting in Milan, Italy. The analysis included more than 9.5 million postmenopausal women, of whom approximately 86,700 used VLDVE products. In propensity score-matched comparative analyses, and in the pooled meta-analysis across both data sources, there was no evidence of an association between
ASX Announcement Page 2 use of VLDVE products as prescribed and endometrial cancer risk relative to non-use. The pooled hazard ratio was 1.00 (95% confidence interval 0.69–1.45), indicating that the risk of endometrial cancer was approximately the same for VLDVE users as for nonusers.1 The study also found that approximately 89% of VLDVE treatment episodes involved no concomitant systemic estrogen use, consistent with the targeted, local mode of action of very- low-dose vaginal therapy. Mr Aaron Gray, CEO of Mayne Pharma said “Receipt of the FDA’s confirmation that we have fulfilled the IMVEXXY® post-marketing requirement is an important milestone for Mayne Pharma and for the women who rely on vaginal estrogen therapy. The study is one of the largest real-world safety analyses of very-low-dose vaginal estrogen ever undertaken and its conclusion shows no association with endometrial cancer when used as prescribed. Together with the removal of the black box warning from certain menopausal hormone therapy labelling, including BIJUVA® and growing evidence of the broader health benefits of local estrogen therapy, this strengthens the confidence of prescribers and patients in IMVEXXY® and potentially supports its black box warning removal in the future. Menopause remains one of the largest and most under-served markets in US women’s health, and with IMVEXXY® delivering continued prescription and sales growth, we are well positioned for growth across our Women’s Health portfolio.” Dr Frank Casty, Global Head of R&D and Chief Medical Officer of Mayne Pharma said “This study adds high-quality real-world evidence to the benefit–risk assessment of very-low-dose vaginal estrogen, drawing on data from more than nine and a half million women. It directly addresses a long-standing concern among clinicians and patients regarding endometrial safety and complements a growing body of evidence and guideline support for local vaginal estrogen in the management of genitourinary syndrome of menopause.” Growing evidence for local vaginal estrogen in genitourinary health Recently published real-world evidence reinforces the substantial clinical burden of recurrent urinary tract infections (rUTIs) in women and the potential role of local vaginal estrogen therapy. In an observational analysis of approximately 1.9 million women with rUTIs published in the journal Urology in 2026, women with a documented vaginal estrogen prescription within two months of rUTI diagnosis had lower observed rates of sepsis, hospital admission and all-cause mortality across all age groups than women without a recorded vaginal estrogen prescription. Sepsis occurred in 4.2%–10.4% of vaginal estrogen recipients compared with 8.5%–24.1% of nonrecipients, hospitalisation in 7.5%–12.0% compared with 15.7%–27.5% with mortality lower among estrogen recipients at 0.3%-3.9% vs 0.8%-9.6%.2 The study was retrospective and observational, its findings demonstrate association rather than causation, and they were not specific to IMVEXXY®; however, this study highlights the value of vaginal estrogens, including IMVEXXY®. The findings are consistent with US clinical guidelines. The joint American Urological Association Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction and the American Urogynecologic Society Guideline on Genitourinary Syndrome of Menopause (GSM) recommends local low-dose vaginal estrogen for appropriate patients with GSM and rUTIs to reduce the risk of future UTIs, and states that local low-dose vaginal estrogen does not increase the risk of endometrial hyperplasia with atypia or endometrial cancer.3
ASX Announcement Page 3 Collectively, the completed FDA post-marketing requirement, established US guideline support and growing real-world evidence underscore the importance of continued research, education and access to local vaginal estrogen therapy for women in menopause. IMVEXXY® and the US menopause opportunity IMVEXXY® is a core product in Mayne Pharma’s US Women’s Health portfolio, alongside BIJUVA®, NEXTSTELLIS® and ANNOVERA®. In FY26, IMVEXXY® total prescriptions grew 6% and net sales increased 8% to US$29.3 million. Approximately 75 million US women are now in peri- or post- menopause, and the US menopause market is forecast to reach US$15–25 billion by 2030.4 Prescriber and patient confidence in hormone therapy continues to strengthen following the FDA’s removal of the boxed warning from menopausal hormone therapy labelling, including for BIJUVA® in February 2026. Click here to view this announcement on Mayne Pharma’s Investor Hub. IMVEXXY® (estradiol) is a vaginal insert indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. The most common adverse reaction with Imvexxy (≥3%) was headache. Serious adverse reactions associated with estrogen-alone therapy include endometrial cancer, cardiovascular disorders, and probable dementia among others. Please see full prescribing information here.
- ENDS -
ASX Announcement
MAYNE PHARMA REPORTS FY26 FINANCIAL RESULTS
Key Points 1
• Solid growth in the Women’s Health menopause portfolio with FY26 total prescriptions (TRx)
2
for BIJUVA
®
up
26% versus the pcp and IMVEXXY TRx up 6%, driven by refreshed sales and marketing initiatives
• Contraception portfolio mixed with strong NEXTSTELLIS
®
demand cycle growth of 15% versus the pcp, driven
by higher sales investment, new PBM relationships and insurance coverage; ANNOVERA
®
TRx up 2%
• FY26 revenue of $383.7 million (-6% on pcp), gross margin of 64.7% (+410bps), direct contribution of $107.1
million (-2%) underlying EBITDA
3
, of $34.2 million (-27% on pcp)
• New automated Adelaide Apothecary facility lease executed, build out to lift capacity approx. seven-fold to
over 2.5 million prescriptions per annum, supporting DistributeRx growth from early 2027
• Cash and marketable securities of $80.0 million at 30 June 2026
Mayne Pharma CEO Mr Aaron Gray and CFO Mr Griffin Buchanan will host a webcast of the FY26 results at
9.30am AEST today (7.30pm US Eastern Time on 26 August 2026) – Details Below
27 August 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX), today announces its financial results for the 12 months ended 30 June 2026 (FY26).
Group Financial Overview
$ million FY26 FY25
Change vs
FY25
% Change vs
FY25
Revenue 383.7 408.1 (24.4) -6%
Gross Profit 248.1 247.3 0.8 0%
Direct Contribution 107.1 109.7 (2.6) -2%
Reported EBITDA 141.4 18.4 123.0 668%
Underlying EBITDA 34.2 47.0 (12.8) -27%
Reported Net Profit (Loss) After Tax 31.2 (90.1) 121.3 135%
Operating cash flow from continuing operations
4
24.9 25.4 (0.5) -2%
Adjusted Operating Cash Flow Continuing Ops
5
34.5 45.4 (10.9) -24%
Mr Aaron Gray, CEO of Mayne Pharma commented “FY26 was a year in which we strengthened the foundations of the business and positioned the business for long term growth. While the Cosette transaction process and subsequent legal matters placed real demands on management focus and caused general disruption, we used the year to invest with conviction by increasing our Women's Health sales and promotional capability to capture the strong momentum we are seeing across the portfolio, particularly in menopause. The successful launch of DistributeRx in the second half is already delivering strong growth and
1 All amounts are expressed in Australian Dollar Terms (A$/AUD) unless otherwise indicated Amounts include FX effects. 2 TRx data includes IQVIA data, plus prescription volume through non-reporting pharmacies (including Mayne Pharma’s own distribution channel). 3 Underlying EBITDA excludes earn-out reassessments, litigation and restructuring charges, derivative fair value adjustments, other. 4 Total net operating cashflow excluding tax refund, outflows for discontinued operations, and class action settlement. Earnout payments recognised as financing cash outflows. 5 Excluding class action settlement and tax refund in FY25 and Scheme transaction and litigation costs in FY26
ASX Announcement
Page 2
reshaping the economics of our Dermatology segment, and our International segment is benefiting from the Salisbury manufacturing investment and the NEXTSTELLIS® PBS listing. We enter FY27 with clear commercial momentum, a refreshed leadership team and Board, and a disciplined plan to convert our opportunities into durable business performance and growing shareholder value.”
Financial and Operational Summary
FY26 revenue of $383.7 million was 6% below the prior year, with gross margin expanding 410 basis points to 64.7% on disciplined pricing, portfolio mix and channel execution. Total direct segment contribution of $107.1 million was down 2%, while underlying EBITDA of $34.2 million was 27% lower than FY25. The decline reflects the general business disruption arising from the Cosette transaction and a deliberate step- up in Women's Health sales and marketing in the second half. The Company reported a Net Profit after tax of $31.2 million ($90.1 million loss in FY25) driven by a $125.6 million earn-out liability re-assessment gain (non-cash).
Operating cash flow from continuing operations was $34.5 million, down 24% on FY25, before transaction and litigation costs. Cash and marketable securities closed at $80.0 million, down from $100.4 million at 30 June 2025. The $20.4 million reduction reflects $25.7 million of earn-out payments across royalties and the TWYNEO®/EPSOLAY® acquisition, $12.6 million of Cosette transaction and litigation costs (net of the $14.4 million in recovered costs from Cosette), $8.1 million of discontinued operations outflows, and $8.4 million of capital leases, net capex and other items.
Underlying EBITDA
FY26 underlying EBITDA of $34.2 million was down 27% on the pcp. On 31 July the Company anticipated FY26 underlying EBITDA of $31.7 million down 33% on the pcp. The 7.9% increase in underlying EBITDA announced today was attributable to the Company electing to treat the portion of share-based expense attributable to retention, as part of the continuing operations adjustments given the one-off nature of this expense.
The structural drivers of the year-on-year decline included:
• Foreign exchange: unfavourable movements of approximately $1.9 million, reflecting the appreciation of the Australian dollar against the US dollar during FY26 • Short-term incentives: no employee short-term incentives were paid in FY25, compared with approximately $7.1 million recognised in FY26 • Prior-period true-up: a managed care provider payment true-up benefit (accrual versus actual invoice received) of approximately $5.6 million recognised in FY25
The events surrounding the Cosette transaction placed considerable demands on management focus and organisational bandwidth, disrupting the business through the year. During FY26, several deliberate investment decisions were made: a step-up in Women's Health sales and marketing in 2H FY26, higher post-market approval study costs across the Women's Health portfolio and additional sales and marketing costs for NEXTSTELLIS® in Australia. These weighed on FY26 earnings while positioning the business to capture continued growth across the menopause and contraception categories.
ASX Announcement
Page 3
Women’s Health
Women's Health operated against a materially improved macro backdrop in FY26. The removal of the FDA black box warning for BIJUVA®, announced in February 2026, continues to support practitioner confidence and prescribing. This coincides with a sustained demographic tailwind, with approximately 75 million US women now in peri- or post-menopause and increasing by around 1.3 million annually, alongside destigmatisation of menopause care and expanding payer coverage. The category remains significantly underpenetrated, with the Company holding a very low single digit share of a menopause market which is forecast to reach US$15–25 billion by 2030 6
Growth in the US contraception portfolio was underpinned by improving access. Affordable Care Act benefits continue to encourage payer willingness to fund open, affordable contraceptive access, while rising adoption of telehealth prescribing, online pharmacies and delivery apps has broadened and streamlined the route to patients.
The Company stepped up commercial investment behind the US portfolio including field force expansion and national realignment that added menopause and contraceptive specialists in key metropolitan markets, supported by refreshed campaigns and increased insurance coverage. Higher post-market approval study costs were incurred as FDA-required studies across ANNOVERA® and IMVEXXY® advanced.
BIJUVA® and NEXTSTELLIS® led the growth in the portfolio. As mentioned, BIJUVA® benefited from sales force changes and the FDA label change. NEXTSTELLIS ® growth was attributable to new Pharmacy Benefit Manager (PBM) relationships which drove volumes with a small offset in the net sales profile from additional rebates negotiated, with an additional 15 million covered lives were added in FY26 (where the patient has open access at zero cost). ANNOVERA® growth was disappointing with net sales constrained by persistent product returns. In response the Company has shifted to alternate sales channels with a more favourable returns profile and improved product economics
Key FY26 financials include:
• Revenue of $174.3 million (-2% versus pcp)
o NEXTSTELLIS® demand cycles up 15% and net sales of US$45.2 million (+6%);
o BIJUVA® TRx +26% and net sales of US$15.0 million (+20%)
o IMVEXXY® TRx +6% and net sales of US$29.3 million (+8%)
o ANNOVERA® total prescriptions (TRx) +2% and net sales of US$25.7 million (-13%)
• Gross profit of $138.0 million (-3% versus pcp) and gross margin of 79% (-1% versus pcp) • Direct contribution of $57.9 million (-7% versus pcp)
Dermatology / DistributeRx
Within the Mayne Pharma Dermatology portfolio, gACCUTANE® closed the quarter at approximately 62% category share 7 , while DORYX® ceded share amid increased competitor activity, and a generic RHOFADE® launched in July 2026. Mayne Pharma is anticipating some loss of market share and volumes moving forward for RHOFADE®.
6 PWC - Unlocking the menopause opportunity: A defining category in women’s health 7 Market share is based on current NRx (new prescription) volume from IQVIA measured against MYX defined set of competitors per brand.
ASX Announcement
Page 4
Mayne Pharma's disintermediation strategy culminated with the launch of DistributeRx, the Company's direct-to-patient distribution platform, in March 2026. DistributeRx addresses high friction points within the US pharmaceutical distribution system in which high copayments, complex prior authorisations, formulary exclusions and intermediary fees drive prescription abandonment and erode economics, and in which patients increasingly seek lower cost alternatives outside traditional insurance channels. Mayne Pharma sales representatives were onboarded into DistributeRx, with Adelaide Apothecary serving as its licensed pharmacy arm.
On 18 May 2026 the Company announced that Adelaide Apothecary will relocate and expand to a new automated facility in Lexington, Kentucky, lifting capacity over two phases to more than 2.5 million prescriptions per annum, with up to US$2 million to complete Phase 1 and operations expected to commence in early 2027.
In its first full quarter, DistributeRx (including Adelaide Apothecary scripts) generated 62k total prescriptions, an increase of 63% versus the pcp. New prescriptions increased to 42k, an increase of 104% versus the pcp. Specific to targeted sales team initiatives, DistributeRx drove a total of 5,042 unique prescribers. As at 30 June 2026, DistributeRx was in active discussions with seven pharmaceutical companies seeking to onboard their products into the DistributeRx channel to streamline prescription distribution, improve dispensing economics and expand patient access. Collectively, these discussions represent approximately 13 products, comprising approximately 11 dermatology and two non- dermatology products.
Disciplined pricing, mix and channel execution delivered margin expansion and direct contribution growth for the year despite lower segment revenue.
FY26 financials include:
• Revenue of $138.7 million (-10% versus pcp) • Gross profit of $88.7 million (+7% versus pcp) and gross margin of 64% (+19% versus pcp) • Direct contribution of $44.5 million (+11% versus pcp)
International
During FY26, International focused on converting infrastructure investment into new growth opportunities while in parallel transitioning from lower to higher margin products within the International portfolio, which has had a short-term impact on performance. The $18 million Salisbury facility upgrade, including $4.8 million from the Australian Government's Modern Manufacturing Initiative, was inaugurated during the year, expanding output capabilities and capacity significantly.
Delivered in full on time (DIFOT) performance increased to 97.4%, from 96.5% in FY25. Following completion of the upgrade the Company continues to explore new global partnerships for product manufacturing, with commercial discussions for certain Mayne Pharma products within Asian territories under development.
NEXTSTELLIS® received Pharmaceutical Benefits Scheme (PBS) approval in late September 2025, effective 1 October, and remains the first and only combined oral contraceptive pill available in Australia utilising a plant-derived, body-identical estrogen (estetrol). PBS approval, alongside increased sales and marketing investment, resulted in FY26 demand cycle growth of 127% versus the pcp and growth of 188%
ASX Announcement
Page 5
since the PBS approval to 30 June. Approximately 520,000 women accessed a comparable oral contraceptive in 2024, which provides a meaningful runway for further growth of NEXTSTELLIS® moving forward. KADIAN® in Canada also contributed under an expanded distribution agreement.
FY26 financials include:
• Revenue of $70.7 million (-7% versus pcp) • Gross profit of $21.3 million (+0% versus pcp) and gross margin of 30% • Direct contribution of $4.6 million (-38% versus pcp)
FY27 Outlook
Women’s Health: accelerate portfolio growth through a focused salesforce, refreshed marketing and improved prescriber access, underpinned by the macro tailwind from the removal of the HRT Black Box warning of the menopause category, in particular for BIJUVA®.
Dermatology/DistributeRx: continue to expand the DistributeRx platform on expectation of some loss of insurance coverage for TWYNEO® and generic entry into the RHOFADE® market. Strong opportunity to scale DistributeRx platform across additional products and therapeutic areas while leveraging Mayne Pharma’s established infrastructure.
International: build on NEXTSTELLIS® growth following the PBS listing, and leverage the Salisbury investment to deliver export growth and contract manufacturing revenues.
Corporate: continue to evaluate capital-efficient, synergistic acquisitions that can leverage our existing Women’s Health and Dermatology/DistributeRx ecosystems, alongside disciplined capital management.
Investor Webinar
Mayne Pharma’s CEO Mr Aaron Gray and CFO Mr Griffin Buchanan will host a webcast of the results at 9.30am AEST today, Thursday 27 August 2026 (7.30pm Eastern US Time on Wednesday, 26 August 2026).
Participants can register for the webcast / teleconference by navigating to:
https://s1.c-conf.com/diamondpass/10055595-h1qn7y.html
Click here to view the announcement on Investor Hub.
- ENDS -
ASX Announcement
Page 6
Released 26 Aug 2026 - 10:40 PM
Released 26 Aug 2026 - 10:40 PM
LikeFollowShare
27 August 2026 Manager, Company Announcements ASX Limited Level 27 39 Martin Place SYDNEY NSW 2000 Via E-Lodgement Dear Sir/Madam Mayne Pharma Group Limited Full Year Results – financial year ended 30 June 2026 Please find attached the following documents relating to the results for the year ended 30 June 2026: • Appendix 4E • Annual Report This announcement comprises the information required by ASX Listing Rule 4.3A. Yours faithfully, Mayne Pharma Group Limited Laura Loftus Company Secretary Please click here to visit view the announcement Investor Hub.
Ask a question
100%
/ 88
1 / 88
Announcement PDF 27 August 2026 Manager, Company Announcements ASX Limited Level 27 39 Martin Place SYDNEY NSW 2000 Via E-Lodgement Dear Sir/Madam Mayne Pharma Group Limited Full Year Results – financial year ended 30 June 2026 Please find attached the following documents relating to the results for the year ended 30 June 2026: • Appendix 4E • Annual Report This announcement comprises the information required by ASX Listing Rule 4.3A. Yours faithfully, Mayne Pharma Group Limited Laura Loftus Company Secretary Please click here to visit view the announcement Investor Hub. RESULTS FOR ANNOUNCEMENT TO THE MARKET APPENDIX 4E – PRELIMINARY FINAL REPORT % CHANGE 30 JUNE 2026 $’000 30 JUNE 2025 $’000 Revenue from ordinary activities (6) 383,676 408,095 Profit / (loss) from continuing operations before income tax expense 35,759 (83,296) Profit / (loss) from continuing operations after income tax expense 31,198 (90,071) Profit / (loss) from discontinued operations after income tax expense (6,725) (3,765) Profit / (loss) after income tax 24,473 (93,836) Attributable to: Equity holders of the parent Non-controlling interests 24,473 (93,836) - 24,473 (93,836) Other comprehensive profit/(loss) after income tax expense (8,396) 5,800 Total comprehensive profit/(loss) for the period 16,077 (88,036) Attributable to: Equity holders of the parent Non-controlling interests 16,077 (88,036) - 16,077 (88,036) 2026 $ 2025 $ Net tangible assets per ordinary share (1) ($0.90) ($2.22) Basic earnings per share $0.31 (1.19) Diluted earnings per share $0.21 (1.19) Final dividend in respect of the financial year ended 30 June per share Nil Nil Refer to the Review of Operations and Likely Developments and the accompanying ASX announcement dated 27 August 2026 for a brief commentary on the results. 1. Includes right-of-use lease assets. Annual Report 2026 Improving patient access to life‑enhancing medications What’s inside What we do 01 FY26 business highlights 02 Letter from the Chair and CEO 04 Directors’ Report 10 Remuneration Report 22 Auditor’s Independence Declaration 32 Corporate Governance Website 33 Consolidated Statement of Profit and Loss and other Comprehensive Income 34 Consolidated Statement of Financial Position 35 Consolidated Statement of Cash Flows 36 Consolidated Statement of Changes in Equity 37 Notes to the Consolidated Financial Statements 38 Consolidated Entity Disclosure Statement 73 Directors’ Declaration 74 Independent Auditor’s Report 75 ASX Additional Information 80 Intellectual Property & Glossary 81 Corporate Information iii At Mayne Pharma we are focused on keeping our promises to patients, for better medicines and a better tomorrow. We believe that everyone deserves medicines that are better, safe and more accessible. That’s why our people are determined to create innovative products and services for our changing world. Learn more at maynepharma.com Mayne Pharma Annual Report 2026 ii What we do Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. Mayne Pharma Annual Report 2026 1 FY26 business highlights Mayne Pharma at a glance $383.7m down 6% on FY25 64.7% FY26 gross margin, up from 60.6% in FY25 83% of group revenue from established brands, 17% generics $107.1m in direct contribution from business segments, down 2% versus FY25 $34.5m in adjusted operating cash flow from continuing operations down $10.9 million on FY25 $31.2m reported net profit after tax, versus a $90.1m net loss in FY25 >450 employees globally $248.2m gross profit, flat versus FY25 $34.2m in underlying EBITDA down 27% on FY25 5,042 unique prescribers joining DistributeRx platform since March 2026 launch $14.4m legal costs and interest recouped from Cosette Pharmaceuticals $80.0m cash and marketable securities at 30 June 2026 For further information visit the Group’s website at maynepharma.com Mayne Pharma Annual Report 2026 2 The 2026 financial year was a challenging year in which the Cosette transaction process and subsequent legal matters placed considerable demands on management focus and organisational bandwidth, including general disruption to our business. Against that backdrop, along with a planned leadership transition, our team delivered disciplined commercial execution, continued margin expansion and a landmark strategic initiative in the launch of DistributeRx. Mayne Pharma Annual Report 2026 3 Letter from the Chair & CEO Financial Performance FY26 Mayne Pharma generated $383.7 million in group revenue for FY26, with gross profit of $248.2 million and gross margin of 65%. Full year underlying EBITDA was $34.2 million, after absorbing increased investment in Women’s Health sales and marketing in 2H FY26 and higher post-market approval study costs in the Women’s Health portfolio. Several other structural drivers to the decline in EBITDA relative to FY25 were unfavourable foreign exchange movements, payments of short term incentives in FY26 compared to none being paid in FY25 and a managed care provider benefit being recognised in FY25. Across FY26, Mayne Pharma experienced general disruption and constraints in its business and operations as a result of the events around the Cosette transaction. Total direct segment contribution was $107.1 million in FY26, down 2% on the prior corresponding period (pcp), underpinned by strong Dermatology contribution growth of 11%. Operating expenses continued to reflect investment in promotional activities for Women’s Health, post approval studies for ANNOVERA® and IMVEXXY®, and the Cosette-related transaction and litigation costs, which are non-recurring in nature. Cash and marketable securities stood at $80.0 million at 30 June 2026. With three consecutive years of gross margin expansion and a strengthening cash position, Mayne Pharma enters FY27 with greater commercial momentum and a clearer pathway to sustained profitability. Dear Fellow Shareholders, The 2026 financial year (FY26) was a challenging year in which the Cosette transaction process and subsequent legal matters placed considerable demands on management focus and organisational bandwidth, including general disruption to our business. Against that backdrop, along with a planned leadership transition, our team delivered disciplined commercial execution, continued margin expansion and a landmark strategic initiative in the launch of DistributeRx. With three consecutive years of gross margin expansion and a strengthening cash position, Mayne Pharma enters FY27 with greater commercial momentum and a clearer pathway to sustained profitability. Mayne Pharma Annual Report 2026 4 The key highlights of FY26 were: • Underlying EBITDA: Underlying EBITDA was $34.2 million, primarily reflecting Cosette-related disruption and increased Women’s Health investment consistent with a strong outlook for the product portfolio. • Continued gross margin expansion: Group gross margin expanded to 64.7% in FY26, building on the 60.6% reported in FY25, reflecting a richer product mix, channel discipline and the growing contribution of branded products, which now represent 83% of net sales (up from 79% in FY25). • DistributeRx launch: In March 2026, Mayne Pharma launched DistributeRx — a transformational US direct- to-patient prescription distribution platform. Prescription demand exceeded our expectations in its first month of operation, validating our disintermediation strategy built over several years. • Women’s Health portfolio momentum: NEXTSTELLIS® demand cycles grew 15% in FY26, with strong double-digit growth across BIJUVA® (up 26% on the pcp) and continued growth in IMVEXXY® (up 6% on the pcp). The FDA’s removal of the Black Box warning for hormone replacement therapies represents a material positive macro tailwind for our menopause franchise. • Dermatology direct contribution surge: Dermatology direct contribution grew 11% in FY26 reflecting a shift in the dermatology product mix driving margin and contribution growth. Branded products increased as a share of the portfolio from 54% in FY25 to 58% in FY26, including from RHOFADE® and the successful launch of TWYNEO® and EPSOLAY®. • International transition: International segment revenue declined in FY26, driven by a transition from lower margin to higher margin products in the portfolio which has had a short term impact on performance, and additional investment into sales and marketing initiatives for NEXTSTELLIS® in Australia. NEXTSTELLIS® PBS listing (effective 1 October 2025) and expansion of KADIAN® supply in Canada were key positive contributors to the International result. The inauguration of the Salisbury facility in December 2025, following an $18 million capital investment, delivers a modernised manufacturing platform for sustainable export growth. • Cash position: Adjusted operating cash flows from continuing operations were down 24% in FY26, with cash and marketable securities of $80.0 million at 30 June 2026, providing balance sheet flexibility to reinvest into growth initiatives for the Company. • Leadership renewal: Professor Bruce Robinson was appointed Chair in January 2026, bringing deep clinical, scientific and governance expertise to the role. Aaron Gray was appointed Chief Executive Officer in February 2026, having served as CFO and playing a central role in delivering Mayne Pharma’s financial turnaround over the past two years. Mayne Pharma Annual Report 2026 5 Operational Achievements Women’s Health Our Women’s Health segment continued to build commercial momentum throughout FY26. NEXTSTELLIS®, which is the only oral contraceptive in the US containing estetrol, with Orange Book patent protection to 2043, delivered demand cycle growth of 15% in FY26, with US net sales of US$45.2 million (up 6% on the pcp). BIJUVA® delivered particularly strong performance, with total prescription (TRx) growth of 26% in FY26, reflecting removal of the FDA black box warning, targeted prescriber engagement and the effectiveness of our refreshed marketing materials launched across the portfolio in FY26. IMVEXXY® TRx grew 6% in FY26, also benefiting from the momentum in menopause and ANNOVERA® delivered steady volumes with expanded prescriber reach. The macro environment for our menopause franchise is improving materially. The FDA’s removal of the Black Box warning from hormone replacement therapies is a significant positive development for Women’s Health broadly and one from which Mayne Pharma is uniquely positioned to benefit given the quality and IP strength of our menopause portfolio. This warning was removed from BIJUVA® in February 2026. Gross margin for the Women’s Health segment was 79% in FY26, underpinning the premium nature of this franchise. Dermatology In Dermatology, FY26 was a pivotal year for both portfolio enrichment and the continued evolution of our disintermediation strategy. We launched TWYNEO® (tretinoin and ivermectin cream for acne) and EPSOLAY® (benzoyl peroxide cream for rosacea) in the US during 1H FY26, adding two differentiated, FDA-approved branded products to a franchise that has been strategically reshaped over the past two years. Dermatology gross margin reached 64% in FY26, up 10 percentage points on the pcp, reflecting the positive mix impact of new brand launches and the structural improvement in gross-to-net profiles achieved through channel optimisation. Direct contribution from Dermatology grew 15% in FY26, which demonstrates that the channel strategy is delivering tangible financial returns. Adelaide Apothecary, our specialist mail-order pharmacy, grew direct-to-patient revenues significantly in FY26. The channel ecosystem encompassing over 400 specialty pharmacies, Adelaide Apothecary and GoodRx-enabled prescribing access is now a genuine strategic asset and the foundation for the next phase of our disintermediation ambitions through DistributeRx. Letter from the Chair & CEO continued DistributeRx — A New Growth Platform The launch of DistributeRx in March 2026 marks a defining strategic milestone for Mayne Pharma. DistributeRx is a US- focused healthcare solutions business that creates a direct- to-patient prescription distribution channel, simplifying the pathway from prescription to patient through digital workflows, transparent cash-pay pricing and fulfilment via Adelaide Apothecary. By reducing reliance on traditional intermediaries, pharmacy benefit managers, wholesalers and large retail chains, DistributeRx improves patient affordability and access while substantially improving product economics for Mayne Pharma. The platform also provides manufacturer services including co-pay program optimisation, enhanced fulfilment solutions and direct-to-pharmacy contracting, opening a B2B revenue stream for third-party pharmaceutical clients. Early commercial results have exceeded expectations. Prescription demand through DistributeRx was ahead of internal forecasts in its first month of operation, with volumes continuing to build as new prescribers onboard. Daniel Moore, formerly General Manager of Mayne Pharma’s Dermatology business, has transitioned to President of DistributeRx, bringing over 20 years of healthcare commercial experience to the role. DistributeRx is positioned as a scalable ecosystem that can extend into adjacent therapeutic areas beyond Women’s Health and Dermatology. The platform taps into the rapidly expanding US digital pharmacy and direct-to-patient market, which represents a structural shift in how Americans access prescription medicines and builds on the infrastructure Mayne Pharma has developed over several years. Our objective is for DistributeRx to be a meaningful value driver for shareholders over the medium term. During FY26 we also moved to scale the platform’s infrastructure and reach. In May 2026, Mayne Pharma announced that Adelaide Apothecary will relocate and expand its US fulfilment operations into a new, automated facility in Lexington, Kentucky. This new facility is approximately four times Adelaide Apothecary’s current footprint and will increase annual capacity over two phases to more than 2.5 million prescriptions (an approximate seven-fold increase) to support the next phase of DistributeRx growth. Operations are expected to commence in early 2027. In June 2026, DistributeRx secured its first third-party manufacturer partnership, an exclusive US distribution agreement with Resilia Pharmaceuticals for RECEDO® topical silicone gel for scar management; the first product onboarded from outside Mayne Pharma’s own portfolio and early validation of the platform’s manufacturer-services model. Mayne Pharma Annual Report 2026 6 The launch of DistributeRx in March 2026 marks a defining strategic milestone for Mayne Pharma. DistributeRx is a US-focused healthcare solutions business that creates a direct-to-patient prescription distribution channel, simplifying the pathway from prescription to patient through digital workflows, transparent cash-pay pricing and fulfilment via Adelaide Apothecary. Mayne Pharma Annual Report 2026 7 Letter from the Chair & CEO continued International The$18millionSalisburyfacilityupgradewasformallyinaugurated inDecember2025,withthemodernisedplantreceivingrecognition acrossnationalandstateexportandbusinessawards.The completionofthisinvestmentdeliversenhancedmanufacturing capability,capacityfornewproductlaunchesandastepchangein operationalreliability—withon-time,in-fulldeliveryratesreaching 97.4%asat30June2026. NEXTSTELLIS®achievedalandmarkmilestoneinAustralia,withPBS listingeffective1October2025,broadeningpatientaccesstothis novelestrogen-containingcontraceptive.NEXTSTELLIS®achieved strongyear-on-yearprescriptiongrowthinAustralia,demonstrating thevalueofaccess-enablingmilestonesforcommercially matureproducts. Internationalsegmentrevenuedeclined7%inFY26,drivenby atransitionfromlowermargintohighermarginproductsinthe portfoliowhichhashadashorttermimpactonperformance,along withadditionalinvestmentintosalesandmarketinginitiativesfor NEXTSTELLIS®inAustralia.NEXTSTELLIS®PBSlistingandexpansion ofKADIAN®supplyinCanadawerekeypositivecontributorstothe Internationalresult.Wecontinuetopursuecontractdevelopment andmanufacturingopportunitiesthroughtheSalisburyfacilityto drivecapacityutilisationandmarginimprovement. Corporate Matters — Cosette Transaction In February 2025, the Board unanimously recommended a Scheme of Arrangement with Cosette Pharmaceuticals, Inc. at A$7.40 per share, representing a premium of approximately 50% to the 90-day VWAP of Mayne Pharma’s share price at announcement. At the Scheme Meeting in June 2025, shareholders voted overwhelmingly in favour of the Scheme, with 99.06% of votes cast in support. However, Cosette subsequently failed to satisfy its obligations under the Scheme Implementation Deed, and the matter proceeded to litigation in the Supreme Court of New South Wales. In October 2025, the Court found that Cosette had not validly terminated the Scheme Implementation Deed, vindicating the Company’s position, and subsequently awarded costs in Mayne Pharma’s favour. On 5 June 2026, the Company received $14.4 million from Cosette in full satisfaction of those court-ordered legal costs and interest. Cosette has appealed the October 2025 judgment and that appeal was heard by the New South Wales Court of Appeal on 2 and 3 June 2026, with the Court reserving its decision. Separately, in February 2026 Mayne Pharma commenced proceedings seeking substantial damages from Cosette and associated parties for breach of, and inducing breach of, the Scheme Implementation Deed, and those proceedings continue. The Board and management team maintained focus throughout this period on operational execution. Board and Leadership Renewal FY26 brought meaningful renewal at both board and management level. Mr Frank Condella retired as Non-Executive Director and Chair with effect from 14 January 2026, following almost eight years of dedicated service including over four years as Chair. On behalf of the Board and all shareholders, we thank Frank for his leadership and the considerable value he contributed to Mayne Pharma through significant business transformation. Professor Bruce Robinson was appointed Chair in January 2026, bringing extensive clinical, scientific and governance credentials including his role as a Non-Executive Director of Cochlear Limited and former Dean of the University of Sydney Medical School. Mr Patrick Blake and Mrs Anne Lockwood stepped down as Non-Executive Directors following the release of 1H FY26 results in February 2026, and Dr Katie MacFarlane stepped down at the end of May 2026. The Board thanks Pat, Anne and Katie for their contributions. At the management level, Mr Shawn Patrick O’Brien stepped down as Managing Director and Chief Executive Officer on 20 February 2026, in a planned and orderly transition. Shawn led the business through a defining period of transformation — from a complex multi-segment business to a focused specialty pharmaceutical company with a clear Women’s Health and Dermatology identity — and we thank him for his commitment and leadership. Mr Aaron Gray was appointed Chief Executive Officer in February 2026 with immediate effect. Aaron joined Mayne Pharma as Chief Financial Officer in 2022 and has been central to the financial and strategic transformation of the Company, including the Cosette transaction process, the margin expansion program and the development of DistributeRx. In July 2026, the Company announced the appointment of Mr Griffin D. Buchanan as Chief Financial Officer from 1 August 2026. Mr Buchanan is a senior finance executive with extensive experience in global medical technology and healthcare who understands the global medical technology and women’s health markets first-hand. Mayne Pharma Annual Report 2026 8 In June 2026, the Board further strengthened its composition with the appointment of Ms Meghan Rivera as a Non-Executive Director. Ms Rivera has more than 25 years’ experience in the US pharmaceutical industry across multiple therapeutic areas including women’s health. Ms Rivera currently serves as Vice President and Global Commercial Lead for ViiV Healthcare, a leading biopharmaceutical organisation focussed on the prevention, treatment and cure of HIV. Her prior roles include US Market President at Organon & Co (NYSE: OGN), Chief Marketing Officer and Head of Commercial at Akili Interactive and Senior Vice President of Women’s Health at AMAG Pharmaceuticals. Ms Rivera’s appointment adds deep US commercial and Women’s Health expertise to the Board as Mayne Pharma scales its branded franchises and the DistributeRx platform. On 14 August 2026, Mr Jacob Ma-Weaver joined the Board. Mr Ma-Weaver, a US resident, is the Managing Member of Cable Car Capital, LP (Cable Car), an investment adviser he founded in 2013. Cable Car is the General Partner of Funicular Funds, LP, a hedge fund which holds 9.90% of the fully paid ordinary shares in the Company. Mr Ma-Weaver was an investment analyst at Amici Capital LLC, where he focused on healthcare. He previously worked as an equity research associate at Dodge & Cox and a corporate finance business analyst at McKinsey & Company. Jacob brings extensive experience as an investor and analyst in the life sciences and healthcare industries. Outlook Mayne Pharma enters FY27 with operational momentum, a strong balance sheet and a clear strategic agenda. In Women’s Health, the priority is to accelerate portfolio growth through a focused salesforce, refreshed marketing and improved prescriber access, underpinned by the macro tailwind from the removal of the HRT Black Box warning of the menopause category, in particular for BIJUVA®. In Dermatology, we will continue to extend the disintermediation model while expecting some loss of insurance coverage for TWYNEO® during the year and generic entry into the RHOFADE® market. The DistributeRx platform will be a significant area of focus. With prescription volumes already materially exceeding our internal forecasts, we see an opportunity to scale this platform across additional products and therapeutic areas while leveraging Mayne Pharma’s established infrastructure. Internationally, we will build on NEXTSTELLIS® growth following the PBS listing in Australia, and leverage the Salisbury investment to deliver export growth and contract manufacturing revenues. We will also continue to evaluate capital-efficient, synergistic acquisitions that can leverage our existing Women’s Health and Dermatology ecosystems, alongside disciplined capital management. On behalf of the Board, we wish to express our sincere thanks to all Mayne Pharma employees for their dedication and commitment during what was a challenging year of external uncertainty. Their focus on operational execution and patient outcomes has been the foundation of the commercial progress we are reporting. We also thank our shareholders for their continued support and for their patience through the Cosette transaction process. We are encouraged by the underlying strength of this business with solid gross margins, an expanding branded portfolio, strengthening cash generation and a genuinely innovative new platform in DistributeRx. We look forward to demonstrating continued progress. Thank you for your continued support. Professor Bruce Robinson Chair Aaron Gray Chief Executive Officer Mayne Pharma Annual Report 2026 9 Mayne Pharma Annual Report 2026 10 Directors’ Report Mayne Pharma Group Limited Financial Statements for the year ended 30 June 2026 2 DIRECTORS’ REPORT The Directors of Mayne Pharma Group Limited (‘the Company’) present their report together with the financial report of the Company and its controlled entities (collectively the ‘Group’ or ‘Consolidated Entity’ or ‘Mayne Pharma’) for the year ended 30 June 2026 and the Auditor’s Report thereon. The information set out below is to be read in conjunction with the Remuneration Report set out on pages 22 to 31, which forms part of this Directors’ Report. DIRECTORS The Directors of the Company during the financial year and up to the date of this report are set out below. Directors were in office for this entire period unless otherwise noted. Prof Bruce Robinson, AC, Chair (Chair effective from 14 January 2026) Ms Ann Custin Mr David Petrie Ms Meghan Rivera (appointed 26 June 2026) Mr Jacob Ma-Weaver (appointed 14 August 2026) Mr Frank Condella (retired from the Board and Chair role effective 14 January 2026) Mr Shawn Patrick O’Brien (stepped down as CEO and Managing Director effective 20 February 2026 US time) Mr Patrick Blake (resigned 28 February 2026) Mrs Anne Lockwood (resigned 28 February 2026) Dr Kathryn MacFarlane (resigned 31 May 2026) The Directors’ qualifications, other listed company directorships, experience and special responsibilities are detailed on pages 19 of this report. The qualifications and experience of the Company Secretary are detailed on page 19 of this report. DIRECTORS’ MEETINGS The number of Directors’ meetings (including meetings of committees of Directors) and number of meetings attended by each of the Directors of the Company during the 2026 financial year are: BOARD AUDIT & RISK COMMITTEE NOMINATION COMMITTEE REMUNERATION & PEOPLE COMMITTEE SCIENCE, TECHNOLOGY & MEDICAL COMMITTEE HELD1 ATTENDED2 HELD1 ATTENDED2 HELD1 ATTENDED2 HELD1 ATTENDED2 HELD1 ATTENDED2 Prof B Robinson 32 28 1 1 1 1 1 1 2 2 Ms A Custin4 32 32 6 6 1 1 5 6 - - Mr D Petrie 32 32 6 6 1 1 9 9 - 1 Ms M Rivera 1 1 - - - - - - - Mr F Condella3 22 22 - 2 4 4 - - Mr S O’Brien3,4 25 25 - 5 - 5 - - Mr P Blake 25 22 5 4 6 6 - - Mrs A Lockwood 25 22 5 5 - - - - Dr K MacFarlane 31 31 - - 1 1 3 2 2 2 1. This column shows the number of meetings held during the period the Director was a member of the Board or Committee. 2. This column shows the number of meetings attended. 3. Mr O’Brien and Mr Condella are not members of the Audit and Risk Committee however they attend meetings at the Chair’s invitation. 4. Mr O’Brien was not a member of the Remuneration and People Committee however he attended meetings at the Chair’s invitation. 5. Ms Custin was not a member of the Remuneration and People Committee until January 2026, however she attended meetings at the Chair’s invitation. 6. Mr Petrie is not a member of the Science, Technology and Medical Committee, however he attends meetings at the Chair’s invitation. SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS The Group continues to develop and invest in existing assets as well as expand its disintermediation strategy to enhance growth opportunities. This included the launch of DistributeRx in March 2026 and the new automated facility to deliver a seven-fold increase in capacity over two phases. Work on the Salisbury modernisation project, partly funded by a federal government grant, was completed during the period. Official inauguration of the upgrade occurred in December 2025. Pharmaceutical Benefits Scheme (PBS) approval for NEXTSTELLIS® in Australia was received in September 2025. TWYNEO® and EPSOLAY® were launched in the United States during the year. Cosette litigation As announced on 5 June 2026 Mayne Pharma received a total of $14.4 million from Cosette, comprising recovery of the Company’s legal costs of the proceedings, the costs associated with its application for costs, and interest. In January 2026, Cosette appealed the Court’s October 2025 judgment. The appeal was heard by the Supreme Court of New South Wales, Court of Appeal on 2 and 3 June 2026 and the decision has been reserved. On 18 February 2026, Mayne Pharma commenced proceedings in the Supreme Court of New South Wales against Cosette Pharmaceuticals, Inc, Cosette Pharmaceuticals Holdings, Inc, Avista Capital Holdings, LP trading as Avista Healthcare Partners (Avista) and David Burgstahler (the Managing Partner and CEO of Avista) seeking substantial damages on behalf of Mayne Pharma shareholders against Cosette for breach of the Scheme Implementation Deed (SID) and against the other defendants for inducing Cosette’s breach of the SID. Mayne Pharma is also seeking substantial damages on its own behalf against the defendants. Mayne Pharma Annual Report 2026 11 Mayne Pharma Group Limited Financial Statements for the year ended 30 June 2026 3 PRINCIPAL ACTIVITIES Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising branded women’s health and dermatology pharmaceuticals. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that continue to be marketed around the world. Mayne Pharma has a product development and manufacturing facility based in Salisbury, Australia with expertise in the formulation of complex oral and topical dose forms including modified-release products and poorly soluble compounds. REVIEW OF OPERATIONS AND LIKELY DEVELOPMENTS Summary of financial performance Set out below is a summary of the financial performance attributable to Mayne Pharma shareholders for the 2026 financial year (FY26) compared to the prior corresponding period (pcp). This summary includes non-IFRS Accounting financial information that is stated excluding certain non-operating income and expense items. The results are set out this way as the Directors consider them to be a meaningful comparison from period to period that are useful for the users of this financial report as they provide additional and relevant information that reflect the underlying performance of the business. Key measures of earnings considered by management in operating the business and assessing performanc
Open panelView summary and Q&As
Summary
Professor Bruce Robinson, Chairman of Mayne Pharma said "The 2026 financial year was a challenging year in which the Cosette transaction process and subsequent legal matters placed considerable demands on management focus and organisational bandwidth, including general disruption to our business. Against that backdrop, along with a planned leadership transition, our team delivered disciplined commercial execution, continued margin expansion and a landmark strategic initiative in the launch of DistributeRx."
Share your feedback
How likely is it that you would recommend Mayne Pharma Group Limited to another investor?
Likely
Neutral
Unlikely
0 responses
Questions (0)
Post question
Your question will be sent privately to Mayne Pharma Group Limited. The company may choose to make this question public.
Start the conversation
Ask Mayne Pharma Group Limited a question about this announcement.
Discover
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:04 AM](https://investors.maynepharma.com/announcements/69glBo-notification-regarding-unquoted-securities-myx)
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:03 AM](https://investors.maynepharma.com/announcements/RQVGgB-notification-regarding-unquoted-securities-myx)
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:02 AM](https://investors.maynepharma.com/announcements/46zl4q-notification-regarding-unquoted-securities-myx)
Summary
Professor Bruce Robinson, Chairman of Mayne Pharma said "The 2026 financial year was a challenging year in which the Cosette transaction process and subsequent legal matters placed considerable demands on management focus and organisational bandwidth, including general disruption to our business. Against that backdrop, along with a planned leadership transition, our team delivered disciplined commercial execution, continued margin expansion and a landmark strategic initiative in the launch of DistributeRx."
Summary
Professor Bruce Robinson, Chairman of Mayne Pharma said "The 2026 financial year was a challenging year in which the Cosette transaction process and subsequent legal matters placed considerable demands on management focus and organisational bandwidth, including general disruption to our business. Against that backdrop, along with a planned leadership transition, our team delivered disciplined commercial execution, continued margin expansion and a landmark strategic initiative in the launch of DistributeRx."
Questions (0)
Provide feedback to Mayne Pharma Group Limited. Complete survey to view results.
How likely is it that you would recommend Mayne Pharma Group Limited to another investor?
Likely
Neutral
Unlikely
0 responses
Post question
Your question will be sent privately to Mayne Pharma Group Limited. The company may choose to make this question public.
Start the conversation
Ask Mayne Pharma Group Limited a question about this announcement.
Share your feedback
How likely is it that you would recommend Mayne Pharma Group Limited to another investor?
Likely
Neutral
Unlikely
0 responses
Discover
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:04 AM](https://investors.maynepharma.com/announcements/69glBo-notification-regarding-unquoted-securities-myx)
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:03 AM](https://investors.maynepharma.com/announcements/RQVGgB-notification-regarding-unquoted-securities-myx)
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:02 AM](https://investors.maynepharma.com/announcements/46zl4q-notification-regarding-unquoted-securities-myx)
We value your privacy
We use cookies, including those from select third parties, to enhance your experience on our website and to help improve our services as specified in our Privacy Policy.
By clicking "Accept all", you consent to our use of cookies.
Our cookie notice lists every cookie we set, what it does and how long it lasts.
Closing this window accepts our default settings. You can change them at any time from cookie settings.
Accept allReject allCustomise settings
ASX Announcement
MAYNE PHARMA REPORTS 1H FY26 FINANCIAL RESULTS
Highlights 1
• Reported revenue of $212.1 million (-0.5% pcp) with gross margin of 65.3% (+390 bps pcp), reflecting
disciplined pricing, mix and channel execution
• Underlying EBITDA of $28.6 million (-8% pcp) with total direct segment contribution
2
of $68.1 million
(+5% pcp), underpinned by strong Dermatology contribution growth (+35% pcp)
• Adjusted operating cash flow from continuing operations
3
of $16.9 million (-41% pcp)
• Cash and marketable securities of $67.3 million at 31 December 2025.
Mayne Pharma CEO Mr Aaron Gray will host a webcast of the 1H FY26 results at 9.30am AEDT today (5.30pm
Eastern US Time on 22 February 2026) – Details Below
23 February 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX), today announces its audited financial results for the 6 months ended 31 December 2025 (1H FY26).
Group Financial Overview
$ million
1H FY26 1H FY25
Change vs
1H FY25
% Change vs
1H FY25
Reported Revenue 212.1
213.1
-1.0 Down 0.5%
Reported Gross Profit 138.6
130.9
7.7 Up 6%
Direct Contribution 68.1
65.0
3.1 Up 5%
Reported EBITDA 63.0
26.1
36.9 Up 141%
Underlying EBITDA
4
28.6
31.0
-2.4 Down 8%
Reported Net Loss After Tax (12.1)
(20.0)
7.9 Improved 40%
Adjusted cash flow from
continuing operations
16.9
28.8
-11.9 Down 41%
Mayne Pharma’s CEO, Mr Aaron Gray said “In the first half of FY26 we delivered resilient earnings, with disciplined margin management supporting a meaningful improvement in group gross margin, despite obvious uncertainty from the Cosette transaction process. Dermatology delivered a strong uplift in direct contribution, reflecting channel execution and favourable mix, while we continued to invest in Women’s Health sales and promotional activity to support growth across our portfolio. As previously disclosed, Scheme‑related legal costs and scheduled earn-out payments weighed on cash flow during the half, and we remain focused on balancing disciplined investment with cost control and shareholder value. Looking forward, we continue to evaluate a variety of capital allocation priorities including share repurchases, targeted asset acquisitions, and expanding our promotional activities across our segments.”
1 All amounts are expressed in Australian Dollar Terms (A$/AUD) unless otherwise indicated. 2 Direct contribution calculated as gross margin less direct opex. 3 Total net operating cashflow excluding outflows for discontinued operations and legal expenses (Scheme). Earnout payments recognised as financing cash outflows. 4 Refer to 1H FY26 Results Presentations for adjustments from reported to underlying EBITDA.
ASX Announcement
Page 2
Financial and Operational Summary
Women’s Health
The Women’s Health segment distributes branded products, including NEXTSTELLIS®, ANNOVERA®, IMVEXXY®, and BIJUVA®. Women’s Health delivered a strong first half, with continued momentum across the portfolio translating into sustained demand and share gains. The team has improved the cadence and effectiveness of prescriber engagement, by building awareness and supporting demand generation. Updated messaging and access solutions are translating intent into higher prescription volumes. Mayne Pharma benefits from its IP strength underpinning the franchise and operating discipline as well as improving cost leverage as volumes build.
Key 1H FY26 highlights include:
• Revenue of $96.5 million (up 2% versus pcp) with gross profit of $76.2 million (down 1%
versus pcp) and gross margin of 79% (down 3% versus pcp)
• Direct contribution of $36.2 million (down 8% versus pcp), reflecting higher direct operating
expense (+6% versus pcp) due to targeted investment in sales activities
• NEXTSTELLIS® demand cycles up 16% and net sales of US$23.4 million (+4%); ANNOVERA®
total prescriptions (TRx) up 2% and net sales of US$14.4 million (-9%); IMVEXXY® TRx up 3%
and net sales of US$15.6 million (+2%); BIJUVA® TRx up 26% and net sales of US$8.2 million
(+23%)
• FDA’s planned removal of the ‘Black Box’ warning for certain hormone replacement
therapies (HRTs) is a positive macro tailwind
• Mayne Pharma refreshed and launched new marketing materials and optimised the
salesforce to support portfolio momentum
Dermatology
Dermatology benefitted from contribution of new products & continued to prove the power of Mayne Pharma’s disintermediation strategy in the first half, demonstrating that simplifying the pathway from prescription to patient can drive both access and outcomes. The ecosystem that has been built is now becoming a strategic asset and one that can be scaled, optimised, and extended thereby improving patient experience while strengthening the economics of the channel. With a clear plan to take the next step in this model and expand into adjacent therapeutic areas, the first half provides momentum and validation with the objective of seizing a much larger opportunity
Key 1H FY26 highlights include:
• Revenue of $78.6 million (down 3% versus pcp) with gross profit of $51.1 million (up 18% versus pcp) and gross margin of 65.0% (+12% versus pcp) • Direct contribution of $29.8 million (up 35% versus pcp), supported by beneficial mix effects and operating leverage • Direct to patient revenues through Adelaide Apothecary grew 63% on pcp • TWYNEO® and EPSOLAY® launched, with a new disintermediation strategy planned for late Q3 FY26
ASX Announcement
Page 3
International
Mayne Pharma International’s revenue and gross profit are derived from the Australian manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. International advanced from investment phase to value realisation in the first half, with focused execution aimed at unlocking the returns from the platform that has been built. The combination of the NEXTSELLIS® PBS listing, completion of the significant capital investment, and strengthening supply arrangements is translating into a more capable, better-positioned international business. As these building blocks convert into sustainable volumes and broadened access, International is well positioned to further deliver the strategic value embedded in the portfolio.
Key 1H FY26 highlights include:
• Revenue of $36.9 million (down 1% versus pcp) with gross profit of $11.3 million (up 7% versus pcp) and gross margin of 30.5% (+3 percentage points versus pcp) • Direct contribution of $2.1 million (down 42% versus pcp) impacted by higher direct operating expense (+32% versus pcp) associated with investment following NEXTSTELLIS® PBS approval in Australia • Operational milestones during the half included inauguration of the completed Salisbury facility ($18 million capital investment) and recognition across national and state export and business awards
Expenses
Mayne Pharma continues to focus on cost efficiencies to sustainably improve cost leverage:
• Research, development, medical and regulatory affairs expenses of $12.7 million (up 29%
versus pcp) reflecting FDA required Post-Authorisation Safety Studies for ANNOVERA® and
IMVEXXY®
• Marketing and distribution expenses were $69.5 million (up 5% versus the pcp)
• Administration and other expenses increased 28% to $82.1 million; however, adjusting for a
mark to market loss of the derivative related to the convertible note in 1H FY26(+$6.8 million)
and diligence, business development and related litigation expenses (-$21.3 million), core
admin and other expenses was up 10% compared to pcp
• Total direct operating expenses of $70.5 million (up 7% versus pcp), increased as a % of
revenue to 33% in 1H FY26 (31% in pcp)
No impairments were recorded in the current or prior period.
Cash Flow
Key 1H FY26 highlights include:
• Closing cash and marketable securities (“cash”) was $67.3 million at 31 December 2025 (30 June 2025: $100.4 million) • Reported EBITDA and operating cash flow for the half were significantly impacted by Scheme‑related legal and transaction costs, including litigation
ASX Announcement
Page 4
• Cash for continuing operations (excluding transaction and litigation costs) was +$16.9 million, offset by Scheme transaction and subsequent litigation costs of -$20.7 million, earn‑out payments (royalties) of -$7.3 million and TWYNEO® and EPSOLAY® acquisition- related earn‑out payments of -$10.3 million • Additional cash outflows included discontinued operations (-$8.2 million), capital leases (- $1.7 million), and net capex (-$1.3 million)
Mayne Pharma continues to focus on disciplined cash generation and active working capital management. As the Company progresses its structured plan to deliver ongoing operational and financial performance improvements across the business, underlying EBITDA strength is translating into improved cash flow conversion, which should enable flexibility to reinvest in growth priorities while preserving balance sheet resilience as revenue continues to grow.
Strategic Growth Initiatives
Mayne Pharma is preparing to scale its integrated digital platform, leveraging the Company’s existing GoodRx-enabled prescribing access, Adelaide Apothecary cash pay capability, and partnerships with specialty pharmacies to unify prescriber, patient and fulfillment pathways. This next-generation disintermediation ecosystem will capitalize on growing US direct-to-patient behaviour shifts, broaden patient access, and accelerate prescription fulfilment while providing improved data visibility and conversion benefits across the portfolio and beyond.
Mayne Pharma anticipates the launch of this in late Q3 FY26 and will update the market accordingly.
Outlook
Mayne Pharma’s strategy is focused on driving profitable growth across its core platforms while building scale and resilience.
In Women’s Health, the priority is to continue growing market share through our dedicated sales team, refreshed marketing, and improved product access solutions underpinned by strong intellectual property for best-in-class brands, while delivering cost leverage through ongoing growth and disciplined cost optimisation.
In Dermatology, the next phase is to deepen the disintermediation strategy by fully leveraging the ecosystem already built to improve access and patient outcomes, with a pathway to expand the model into other therapeutic areas.
Internationally, the focus is on unlocking the value of prior investments, including the NEXTSELLIS® PBS listing, targeted capex, and international supply agreements.
Complementing this, Mayne Pharma will continue to pursue synergistic, capital-efficient acquisitions that enhance scale across the portfolio and capital allocation strategies generally, which may include a share buy-back. In addition, Mayne Pharma remains committed to enforcing its legal rights in a way that balances cost with shareholder value.
ASX Announcement
Page 5
Investor Webcast
Mayne Pharma will host a webcast of the results at 9.30am AEDT on Monday, 23 February 2026 (5.30pm Eastern US Time on Sunday, 22 February 2026).
Participants can register for the webcast by navigating to:
https://ccmediaframe.com/?id=C6LzkOZC
ASX Announcement
MAYNE PHARMA MANAGEMENT CHANGES
23 February 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX), today announces a planned leadership transition. On 20 February 2026 (US time) Mr Shawn Patrick O’Brien stepped down as Chief Executive Officer and Managing Director, and Mr Aaron Gray, currently Mayne Pharma’s Chief Financial Officer, was appointed Chief Executive Officer.
Mr O’Brien joined Mayne Pharma as CEO and Managing Director in October 2022 and will remain available to the Board in an advisory capacity until 1 May 2026 to support an orderly transition to Mr Gray as part of Mayne Pharma’s structured succession process.
Aaron Gray joined Mayne Pharma in July 2022 and has been the Chief Financial Officer since 29 August 2022. He brings over 20 years of experience to the role. Prior to joining Mayne Pharma, Aaron held senior finance roles at Siemens Healthineers, a leading global medical technology company with €20 billion in revenues and 48,000 employees globally. Most recently, he was Senior Vice President, USA Customer Finance with €5 billion in revenues. Prior to joining Siemens Healthineers, he spent 15 years in finance roles at Siemens, AG energy divisions. Aaron has significant expertise in the areas of financial planning and analysis, strategy, digitisation, sales operations, manufacturing, risk management and operational excellence.
Professor Bruce Robinson, Chair of Mayne Pharma said “On behalf of the Board, I would like to sincerely thank Shawn for his leadership and contribution to Mayne Pharma. Shawn has guided the Company through a period of meaningful change with professionalism, energy and a clear focus on execution. The Board welcomes Aaron to the role of Chief Executive Officer of Mayne Pharma. Aaron brings deep knowledge of Mayne Pharma and strong strategic and operational capability, and the Board is confident he is well placed to lead the Company as we continue to execute our strategy and create long-term value for shareholders. This is a planned and orderly leadership transition that reflects our focus on maintaining momentum and execution. The business has strong leadership depth, and the Board is confident in the continuity of strategy, operational delivery and financial discipline.”
Mr Aaron Gray, CEO of Mayne Pharma commented “I am honoured to be appointed to this role by the Board. This is a business with a strong portfolio, talented people, significant future opportunities and I am excited to lead the next phase of execution and performance delivery. I also want to acknowledge and thank Shawn for his leadership and contribution to Mayne Pharma. Shawn has navigated the Company through a complex period with determination and integrity and I am pleased Shawn will be available to support this transition. I deeply appreciate the support and collaboration and wish Shawn nothing but the best.”
Mr Shawn Patrick O’Brien said “This is the right time for me to transition leadership to Aaron as we enter the next phase of execution. I’m proud of the progress the team has made, and I’m committed to supporting a smooth handover. Through all of the changes made to the Mayne Pharma business, Aaron has demonstrated his knowledge and capabilities within the business and the industry. I have every confidence in Aaron’s leadership and Mayne Pharma’s strategy and future.”
ASX Announcement
Page 2
The Company has commenced a formal process to appoint a suitably qualified Chief Financial Officer to support the next phase of execution and performance delivery with Mr Gray moving into the CEO role. In the interim, financial governance and reporting continuity will be maintained through appropriate internal arrangements, within the finance team, with ongoing oversight from the Board.
Existing incentive awards held by Mr O’Brien will be treated in accordance with the relevant plan rules and their original terms. The FY26 incentive awards approved by shareholders at the Annual General Meeting on 29 January 2026 will not be issued to Mr O’Brien.
Summary of key terms of Aaron Gray’s employment agreement
Commencement
date
20 February 2026
Term Appointment on an on-going basis until terminated by either party in
accordance with the terms and conditions of the employment
contract.
Fixed annual
remuneration (FAR)
Fixed annual remuneration of US$600,000 per annum (subject to
annual review).
Sign-on bonus Sign on bonus of US$300,000, to be provided in the form of Restricted
Stock Units (RSUs), subject to immediate vesting as a service-based
award.
Short term incentive
(STI)
Eligible to receive an annual STI award with a target payment of 50%
of FAR if specified annual performance objectives determined by the
Board are met. Annual STI achievement can range between 0% and
130% of the target STI percentage (ie between 0% and 65% of FAR)
based on achievement of performance objectives.
Participation for FY26 will be pro-rated between Mr Gray’s time in the CFO role and the CEO role. Long term incentive (LTI) Eligible to receive an LTI of up to 150% of FAR in the Company’s long- term incentive program. Vesting will be subject to performance targets determined by the Board.
Participation for FY26 will be pro-rated between Mr Gray’s time in the
CFO role and the CEO role.
Notice period The parties may mutually agree to terminate the employment
contract, or Mr Gray may voluntarily resign from his employment, by
providing 90 days’ notice.
The Company may terminate the employment without 'cause', or Mr
Gray may resign for 'good reason', in which case the employment
terminates on the date specified in the notice (and Mr Gray is entitled
to the termination benefits described below).
The Company may terminate immediately for 'cause'.
Termination benefits Nil if termination is for 'cause'. Otherwise, 12 months’ base salary and
reimbursement of premiums under the Company's medical benefits
planif termination is without 'cause' or for 'good reason'.
ASX Announcement
Page 3
Other The Company will maintain life insurance coverage for Mr Gray in the amount of US$1.2 million during the term of his employment agreement.
Mr Gray’s employment agreement otherwise contains standard terms and conditions for agreements of this nature such as post-employment restraints for 12 months.
- ENDS -
2026 Half Year Media Release
Released 22 Feb 2026 - 10:35 PM
Released 22 Feb 2026 - 10:35 PM
LikeFollowShare
ASX Announcement MAYNE PHARMA REPORTS 1H FY26 FINANCIAL RESULTS Highlights1 • Reported revenue of $212.1 million (-0.5% pcp) with gross margin of 65.3% (+390 bps pcp), reflecting disciplined pricing, mix and channel execution • Underlying EBITDA of $28.6 million (-8% pcp) with total direct segment contribution2 of $68.1 million (+5% pcp), underpinned by strong Dermatology contribution growth (+35% pcp) • Adjusted operating cash flow from continuing operations3 of $16.9 million (-41% pcp) • Cash and marketable securities of $67.3 million at 31 December 2025. Mayne Pharma CEO Mr Aaron Gray will host a webcast of the 1H FY26 results at 9.30am AEDT today (5.30pm Eastern US Time on 22 February 2026) – Details Below 23 February 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX), today announces its audited financial results for the 6 months ended 31 December 2025 (1H FY26). Group Financial Overview $ million 1H FY26 1H FY25 Change vs 1H FY25 % Change vs 1H FY25 Reported Revenue 212.1 213.1 -1.0 Down 0.5% Reported Gross Profit 138.6 130.9 7.7 Up 6% Direct Contribution 68.1 65.0 3.1 Up 5% Reported EBITDA 63.0 26.1 36.9 Up 141% Underlying EBITDA4 28.6 31.0 -2.4 Down 8% Reported Net Loss After Tax (12.1) (20.0) 7.9 Improved 40% Adjusted cash flow from continuing operations 16.9 28.8 -11.9 Down 41% Mayne Pharma’s CEO, Mr Aaron Gray said “In the first half of FY26 we delivered resilient earnings, with disciplined margin management supporting a meaningful improvement in group gross margin, despite obvious uncertainty from the Cosette transaction process. Dermatology delivered a strong uplift in direct contribution, reflecting channel execution and favourable mix, while we continued to invest in Women’s Health sales and promotional activity to support growth across our portfolio. As previously disclosed, Scheme ‑related legal costs and scheduled earn -out payments weighed on cash flow during the half, and we remain focused on balancing disciplined investment with cost control and shareholder value. Looking forward, we continue to evaluate a variety of capital allocation priorities including share repurchases, targeted asset acquisitions, and expanding our promotional activities across our segments.” 1 All amounts are expressed in Australian Dollar Terms (A$/AUD) unless otherwise indicated. 2 Direct contribution calculated as gross margin less direct opex. 3 Total net operating cashflow excluding outflows for discontinued operations and legal expenses (Scheme). Earnout payments recognised as financing cash outflows. 4 Refer to 1H FY26 Results Presentations for adjustments from reported to underlying EBITDA.
ASX Announcement Page 2 Financial and Operational Summary Women’s Health The Women’s Health segment distributes branded products, including NEXTSTELLIS®, ANNOVERA®, IMVEXXY®, and BIJUVA®. Women’s Health delivered a strong first half, with continued momentum across the portfolio translating into sustained demand and share gains. The team has improved the cadence and effectiveness of prescriber engagement, by building awareness and supporting demand generation. Updated messaging and access solutions are translating intent into higher prescription volumes. Mayne Pharma benefits from its IP strength underpinning the franchise and operating discipline as well as improving cost leverage as volumes build. Key 1H FY26 highlights include: • Revenue of $96.5 million (up 2% versus pcp) with gross profit of $76.2 million (down 1% versus pcp) and gross margin of 79% (down 3% versus pcp) • Direct contribution of $36.2 million (down 8% versus pcp), reflecting higher direct operating expense (+6% versus pcp) due to targeted investment in sales activities • NEXTSTELLIS® demand cycles up 16% and net sales of US$23.4 million (+4%); ANNOVERA® total prescriptions (TRx) up 2% and net sales of US$14.4 million (-9%); IMVEXXY® TRx up 3% and net sales of US$15.6 million (+2%); BIJUVA® TRx up 26% and net sales of US$8.2 million (+23%) • FDA’s planned removal of the ‘Black Box’ warning for certain hormone replacement therapies (HRTs) is a positive macro tailwind • Mayne Pharma refreshed and launched new marketing materials and optimised the salesforce to support portfolio momentum Dermatology Dermatology benefitted from contribution of new products & continued to prove the power of Mayne Pharma’s disintermediation strategy in the first half, demonstrating that simplifying the pathway from prescription to patient can drive both access and outcomes. The ecosystem that has been built is now becoming a strategic asset and one that can be scaled, optimised, and extended thereby improving patient experience while strengthening the economics of the channel. With a clear plan to take the next step in this model and expand into adjacent therapeutic areas, the first half provides momentum and validation with the objective of seizing a much larger opportunity Key 1H FY26 highlights include: • Revenue of $78.6 million (down 3% versus pcp) with gross profit of $51.1 million (up 18% versus pcp) and gross margin of 65.0% (+12% versus pcp) • Direct contribution of $29.8 million (up 35% versus pcp), supported by beneficial mix effects and operating leverage • Direct to patient revenues through Adelaide Apothecary grew 63% on pcp • TWYNEO® and EPSOLAY® launched, with a new disintermediation strategy planned for late Q3 FY26
ASX Announcement Page 3 International Mayne Pharma International’s revenue and gross profit are derived from the Australian manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. International advanced from investment phase to value realisation in the first half, with focused execution aimed at unlocking the returns from the platform that has been built. The combination of the NEXTSELLIS® PBS listing, completion of the significant capital investment, and strengthening supply arrangements is translating into a more capable, better-positioned international business. As these building blocks convert into sustainable volumes and broadened access, International is well positioned to further deliver the strategic value embedded in the portfolio. Key 1H FY26 highlights include: • Revenue of $36.9 million (down 1% versus pcp) with gross profit of $11.3 million (up 7% versus pcp) and gross margin of 30.5% (+3 percentage points versus pcp) • Direct contribution of $2.1 million (down 42% versus pcp) impacted by higher direct operating expense (+32% versus pcp) associated with investment following NEXTSTELLIS® PBS approval in Australia • Operational milestones during the half included inauguration of the completed Salisbury facility ($18 million capital investment) and recognition across national and state export and business awards Expenses Mayne Pharma continues to focus on cost efficiencies to sustainably improve cost leverage: • Research, development, medical and regulatory affairs expenses of $12.7 million (up 29% versus pcp) reflecting FDA required Post-Authorisation Safety Studies for ANNOVERA® and IMVEXXY® • Marketing and distribution expenses were $69.5 million (up 5% versus the pcp) • Administration and other expenses increased 28% to $82.1 million; however, adjusting for a mark to market loss of the derivative related to the convertible note in 1H FY26(+$6.8 million) and diligence, business development and related litigation expenses (-$21.3 million), core admin and other expenses was up 10% compared to pcp • Total direct operating expenses of $70.5 million (up 7% versus pcp), increased as a % of revenue to 33% in 1H FY26 (31% in pcp) No impairments were recorded in the current or prior period. Cash Flow Key 1H FY26 highlights include: • Closing cash and marketable securities (“cash”) was $67.3 million at 31 December 2025 (30 June 2025: $100.4 million) • Reported EBITDA and operating cash flow for the half were significantly impacted by Scheme‑related legal and transaction costs, including litigation
ASX Announcement Page 4 • Cash for continuing operations (excluding transaction and litigation costs) was +$16.9 million, offset by Scheme transaction and subsequent litigation costs of -$20.7 million, earn‑out payments (royalties) of -$7.3 million and TWYNEO® and EPSOLAY® acquisition- related earn‑out payments of -$10.3 million • Additional cash outflows included discontinued operations (-$8.2 million), capital leases (- $1.7 million), and net capex (-$1.3 million) Mayne Pharma continues to focus on disciplined cash generation and active working capital management. As the Company progresses its structured plan to deliver ongoing operational and financial performance improvements across the business, underlying EBITDA strength is translating into improved cash flow conversion, which should enable flexibility to reinvest in growth priorities while preserving balance sheet resilience as revenue continues to grow. Strategic Growth Initiatives Mayne Pharma is preparing to scale its integrated digital platform, leveraging the Company’s existing GoodRx-enabled prescribing access, Adelaide Apothecary cash pay capability, and partnerships with specialty pharmacies to unify prescriber, patient and fulfillment pathways. This next-generation disintermediation ecosystem will capitalize on growing US direct-to-patient behaviour shifts, broaden patient access, and accelerate prescription fulfilment while providing improved data visibility and conversion benefits across the portfolio and beyond. Mayne Pharma anticipates the launch of this in late Q3 FY26 and will update the market accordingly. Outlook Mayne Pharma’s strategy is focused on driving profitable growth across its core platforms while building scale and resilience. In Women’s Health, the priority is to continue growing market share through our dedicated sales team, refreshed marketing, and improved product access solutions underpinned by strong intellectual property for best-in-class brands, while delivering cost leverage through ongoing growth and disciplined cost optimisation. In Dermatology, the next phase is to deepen the disintermediation strategy by fully leveraging the ecosystem already built to improve access and patient outcomes, with a pathway to expand the model into other therapeutic areas. Internationally, the focus is on unlocking the value of prior investments, including the NEXTSELLIS® PBS listing, targeted capex, and international supply agreements. Complementing this, Mayne Pharma will continue to pursue synergistic, capital-efficient acquisitions that enhance scale across the portfolio and capital allocation strategies generally, which may include a share buy-back. In addition, Mayne Pharma remains committed to enforcing its legal rights in a way that balances cost with shareholder value.
ASX Announcement Page 5 Investor Webcast Mayne Pharma will host a webcast of the results at 9.30am AEDT on Monday, 23 February 2026 (5.30pm Eastern US Time on Sunday, 22 February 2026). Participants can register for the webcast by navigating to: https://ccmediaframe.com/?id=C6LzkOZC
2026 Half Year Investor Presentation
Released 22 Feb 2026 - 10:38 PM
Released 22 Feb 2026 - 10:38 PM
LikeFollowShare
Mayne Pharma Group Limited 1H FY26 Results Presentation Aaron Gray CEO 23 February 2026
Ask a question
100%
/ 35
1 / 35
Announcement PDF Mayne Pharma Group Limited 1H FY26 Results Presentation Aaron Gray CEO 23 February 2026 2 Disclaimer The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited Financial Statements and market disclosures. This material is not intended to be relied upon as advice to investors or potential investors. Non-IFRS information ● Other than as indicated, the financial information contained in this document is directly extracted or calculated from the audited Financial Statements. Throughout this document some non-IFRS financial information is stated, excluding certain specified income and expenses. Results excluding such items are considered by the Directors to provide a meaningful basis for comparison from period to period. ● Earnings before interest, tax, impairment, depreciation and amortisation (EBITDA) – a non-IFRS term – is considered by Directors to be a meaningful measure of the operating earnings and performance of the Group and this information may be useful for investors as it provides additional and relevant information that reflects the underlying performance of the business. ● The non-IFRS financial information has not been audited by the Group’s auditors. Forward looking statements ● This presentation contains forward-looking statements that involve subjective judgement and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to the Company. These forward looking statements use words such as ‘potential’, ‘expect’, ‘anticipate’, ‘intend’, ‘plan’ and ‘may’, and other words of similar meaning. No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including the Company). Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based. Given these uncertainties, readers are cautioned not to place undue reliance on such forward looking statements. Subject to the Company’s continuous disclosure obligations at law and under the listing rules of the Australian Securities Exchange, the Company disclaims any obligation to update or revise any forward looking statements. The factors that may affect the Company’s future performance include, among others: changes in economic conditions, changes in the legal and regulatory regimes in which the Company operates, litigation or government investigations, decisions by regulatory authorities, changes in behaviour of major customers, suppliers and competitors, interruptions to manufacturing or distribution, the success of research and development activities and research collaborations and the Company’s ability to protect its intellectual property. Other ● A glossary of industry terminology is contained in the Mayne Pharma Annual Report which can be accessed at maynepharma.com/investor-relations/results-reports and product descriptions are detailed at maynepharma.com/us-products and maynepharma.com/au-products. ● DORYX®, FABIOR®, LEXETTE®, SORILUX®, and RHOFADE® are trademarks of Mayne Pharma. ANNOVERA®, BIJUVA®, EPSOLAY®, IMVEXXY®, KADIAN®, NEXTSTELLIS®, ORACEA®, TWYNEO® and WYNZORA® and are trademarks of third parties. 3 1H FY26 Financial Results1 1. All numbers are expressed in AUD/A$ terms unless otherwise stated. 2. Underlying EBITDA is a non-IFRS measure and excludes earn-out reassessments, restructuring charges, class action settlement costs, derivative fair value adjustments and litigation expense. 3. Total net operating cashflow excluding outflows for discontinued operations and legal expenses (Scheme). Earnout payments recognised as financing cash outflows. 1H FY26 delivered resilient earnings, with margin discipline underpinning performance $212.1m Revenue down 0.5% 1H FY25 65.3% Gross margin up from 61.4% 1H FY25 $28.6m Underlying EBITDA2 down 8% from 1H FY25 $68.1m Total direct segment contribution up 5% from $65.0m 1H FY25 $16.9m Adjusted operating cashflow from continuing operations3 down 38% from $28.8m 1H FY25 $67.3m Cash and marketable securities at 31 Dec 2025 down from $100.4m FY25 1H FY26 Group Financial Performance 5 Group Continuing Operations Overview 1. Attributable to members. EBITDA excludes asset impairments. 2. Underlying EBITDA excludes ($54.5m) of earn-out reassessments, $21.3m diligence/business development, litigation and restructuring charges $4.2m, and ($6.8m) derivative fair value adjustments and other +$1.4m 3. Excluding class action settlement, Scheme transaction costs (1H FY25) / Scheme transaction costs and litigation costs (1H FY26) A$ million1 1H FY26 1H FY25 Change vs 1H FY25 ($) Change vs 1H FY25 (%) Reported Revenue 212.1 213.1 (1.0) 0% Reported Gross Profit 138.6 130.9 7.7 6% Gross Margin 65.3% 61.4% N/A 390 bps Reported Direct Contribution 68.1 65.0 3.1 5% Reported EBITDA 63.0 26.1 36.9 141% Underlying EBITDA2 28.6 31.0 (2.4) -8% Reported Net Loss After Tax (12.1) (20.0) 7.9 40% Operating Cash Flow Continuing Ops (3.8) (7.4) 3.6 49% Adjusted Operating Cash Flow Continuing Ops3 16.9 28.8 (11.9) -41% Resilient underlying EBITDA, with disciplined margin management, despite obvious uncertainty from the Cosette transaction process 6 Targeted investments to drive growth and sustainable cost leverage 1H FY26 Commentary2 • Improvement in gross profit by 6% driven by positive mix effect in Dermatology • Direct operating expenses increased by 7% reflecting increases in Women’s Health promotional activities and International sales and marketing expense following NEXTSTELLIS® PBS approval • Direct opex as % of revenue 33% in 1HFY26 v 31% in 1H FY25 Segment Performance1 (A$ million) 1H FY26 1H FY25 Change Revenue 212.1 213.1 0% Gross Profit 138.6 130.9 6% Direct Operating Expenses (70.5) (65.9) 7% Direct Contribution 68.1 65.0 5% 1. Refer Note 2 of the financial statements for additional detail on segment performance. 2. Refer P&L statement and Note 3 of the financial statements for additional detail on opex. Continued improvements in cost leverage (A$m) 213.1 212.1 100.0 150.0 200.0 1H FY25 1H FY26 Revenue flat 0% (-$1.0m) 65.9 70.5 0.0 50.0 100.0 150.0 1H FY25 1H FY26 65.0 68.1 -50.0 0.0 50.0 Direct opex up 7% (+$4.6m) Direct Contribution up 5% (+$3.1m) 1H FY25 1H FY26 7 1H FY26 EBITDA & Cash Flow Reconciliation (cont.) 1. Underlying EBITDA is a non-IFRS measure and is unaudited; 2. Certain items that are excluded from underlying EBITDA (ex. restructuring and certain litigation matters) are included in continuing operations as cash outflows in the figures shown above Scheme Legal Costs (inc. Litigation) had a Significant Impact on EBITDA and Cash Flow A$ million 1H FY26 1H FY25 Change vs 1H FY25 ($) Change vs 1H FY25 (%) Reported EBITDA 63.0 26.1 36.9 141% Scheme legal fees (inc. litigation) 21.3 2.5 18.8 752% Earn-out Reassessments (54.5) (1.0) (53.5) -5350% Fair Value Adjustment of Convertible Note Derivative (6.8) (0.2) (6.6) -3300% Other Litigation and Restructuring 4.2 3.6 0.6 17% Other Adjustments 1.4 0.0 1.4 100% Underlying EBITDA1 28.6 31.0 (2.4) -8% 16.9 -20.7 -7.3 -10.3 -5.1 -3.1 -1.7 -1.3 -0.5 100.4 79.0 70.8 67.3 EBITDA Cash Flow 30 Jun 2025 Cash balance 31 Dec 2025 Cash balance • Reported EBITDA driven by: • Scheme related legal costs, inc. litigation • Non-cash earn-out reassessment for Women’s Health portfolio • Underlying EBITDA driven by: • Down 8% versus pcp • Lower contribution from Women’s Health: additional investment into sales activities • Higher Direct Contribution from Dermatology: strong margin growth Investing & Financing (10% net cash used) Continuing operations2 (65% net cash used) Discontinued operations (25% net cash used) • Cash for continuing operations (excl. transaction & litigation costs): +$16.9m • Transaction & litigation costs (Scheme related): -$20.7m • Earn out payments (royalties): -$7.3m • Earn out payments (TWYNEO® & EPSOLAY® intangible acquisition cost): -$10.3m • Earn out payments: -$3.1m • Other cash outflows: -$5.1m • Capital Leases: -$1.7m • Capex (net): -$1.3m • Other: -0.5m Transaction & litigation costs Earn-outs TWYNEO ® & EPSOLAY ® payments Underlying cash flow from continuing operations Discontinued operations Earn out payment (disc.ops.) Capital leases Capex (net) Other Segment Performance 9 Continued Improvement with Growth in FY25 Direct Contribution1 $3.1m increase in direct contribution driven by 35% increase in Dermatology 1. Direct contribution calculated as gross margin less direct opex. $68.1m 1HFY26 Total Direct Contribution $36.2m $29.8m $2.1m • Acquired April 2025 • Re-launched Q1 FY26 1H FY25 Total Direct Contribution $22.1m $39.3m $3.6m $65.0m Dermatology Women’s Health International +$3.1m Women’s Health 11 Women’s Health: solid demand growth 1H FY26 Operating Highlights • Women’s Health delivered a solid first half, with continued momentum across the portfolio translating into sustained demand and share gains • Team has improved the cadence and effectiveness of prescriber engagement, by building awareness and supporting demand generation • Menopause awareness leading to strong growth in menopause market, positive tailwinds for BIJUVA® and IMVEXXY ® • FDA’s planned removal of the ‘Black Box’ warning for certain hormone replacement therapies (HRTs) is a positive macro tailwind • Investing for future growth, driving higher opex and lower contribution versus the pcp • NEXTSTELLIS®, BIJUVA® and IMVEXXY® demand hit record highs in Dec 2025 1H FY26 Financial Highlights • Revenue $96.5 million (+2% versus pcp) o NEXTSTELLIS®: +16% Demand Cycles1, +4% growth in net sales to US$23.4m o ANNOVERA®: +2% TRx2, -9% growth in net sales to US$14.4m o IMVEXXY®: +3% TRx, +2% growth in net sales to US$15.6m o BIJUVA®: +26% TRx, +23% growth in net sales to US$8.2m • Direct Opex3 $40.0 million (+6% versus pcp) • Gross Profit $76.2 million (-1% versus pcp) • Gross Margin %: 79.0% (-3% versus pcp) • Direct Contribution: $36.2 million (-8% pcp) 1. Demand Cycles - calculated as IQVIA reported TRx (converted to units/cycles) plus non-reporting pharmacies (including Mayne Pharma’s own distribution channel). TRx converted to units by taking number of pills in the TRx divided by 28 (number of NEXTSTELLIS® pills included in 1 month of therapy). NEXTSTELLIS® prescriptions can be prescribed in 1-month and 3-month increments. On average 1 TRx equals 2.0 units/cycles. 2. TRx – total prescriptions. The data includes IQVIA data, plus prescription volume through non-reporting pharmacies (including Mayne Pharma’s own distribution channel). 3. Direct opex includes lease depreciation, which is largely related to motor vehicles of salesforce 12 7.1 7.1 13.8 16.3 22.4 20.1 23.4 0.0 5.0 10.0 15.0 20.0 25.0 1H FY23 2H FY23 1H FY24 2H FY24 1H FY25 2H FY25 1H FY26 NEXTSTELLIS® Quarterly US Demand Cycles (thousands) • Demand cycle growth of 16% on the pcp • All-time high demand cycles achieved • New marketing materials, sales force optimisation 1H FY26 NEXTSTELLIS® demand cycles up 16%1 1H FY26 Commentary NEXTSTELLIS ® Net Sales (US$m) and growth (pcp) • 4% net sales growth for NEXTSTELLIS® in US market vs pcp • Net Selling Price (NSP) holding steady with continued volume growth • New coverage decisions 1 January – 25m additional covered lives 1H FY26 Commentary Sequential Q Growth (%) 18% 96% 0% 38% 45 58 71 89 106 118 125 138 146 152 155 168 171 176 28.9% 22.4% 25.4% 19.1% 11.3% 5.9% 10.4% 5.8% 4.1% 2.0% 8.4% 1.8% 2.9% 0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% 70.0% 80.0% 90.0% 100.0% 0.0 20.0 40.0 60.0 80.0 100.0 120.0 140.0 160.0 180.0 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Cycles (thousands) -10% 16% 13 1. TRx data includes IQVIA data, plus prescription volume through non-reporting pharmacies (including Mayne Pharma’s own distribution channel) 2. ANNOVERA® net sales in 1HFY26 impacted by US$1.7m of returns due to the lingering effects of legacy inventory returns Licensed Portfolio Demand TRx (thousands)1 ANNOVERA® 107 137 169 177 168 183 80 100 120 140 160 180 200 2HFY23 1HFY24 2HFY24 1HFY25 2HFY25 1HFY26 IMVEXXY® BIJUVA® TRx +3% on pcp Net Sales: US$15.6m Driving demand with IMVEXXY® and BIJUVA® for menopausal patients TRx +2% on pcp Net Sales: US$14.4m2 38 45 53 61 67 77 - 10 20 30 40 50 60 70 80 90 2HFY23 1HFY24 2HFY24 1HFY25 2HFY25 1HFY26 12 12 14 14 14 14 - 2 4 6 8 10 12 14 2HFY23 1HFY24 2HFY24 1HFY25 2HFY25 1HFY26 TRx +26% on pcp Net Sales: US$8.2m 14 Women’s Health: solid portfolio growth Future growth drivers for Women’s Health • Drive Market Penetration – increase low single digit market share (versus competitive set – iQVIA1) + solid market growth • Strong defence of portfolio economics – long dated patent life to protect value, support pricing power, and sustain investment through remaining patent life • Commercial execution – upgraded/refreshed marketing, optimised field-force effectiveness, and tighter targeting of high-value prescribers/segments • Improving Access and Coverage – through payer contracting and patient access programs that reduce friction at the pharmacy counter and drive higher fill rates ~2% ~1% ~3% ~3% 1. As of Dec 2025; Market share is based on current NRx (new prescription) volume from IQVIA measured against our defined set of competitors per brand. Sample US promotional flyer only Dermatology 16 Dermatology: Improved product mix, solid channel growth from disintermediation strategy 1H FY26 Financial Highlights • Substantial margin improvement via beneficial mix effects, due to a higher percentage of branded sales, relative to pcp • Channel/disintermediation execution continued to scale, with >70% of Mayne Pharma Rx outside the traditional channel and ongoing mix/price management supporting portfolio margin • Direct-to-patient momentum: Adelaide Apothecary direct-to-patient revenues grew 63% pcp • Portfolio expansion and launch execution: TWYNEO® and EPSOLAY® acquired from Sol-Gel Technologies and launched in Q1 FY26. • Set up the next leg of disintermediation with a new disintermediation strategy and launch planned for Q3 FY26 1. As per IQVIA NSP MAT Dec 2024 1H FY26 Operating Highlights • Revenue $78.6 million (-3% versus pcp) • Direct Opex $21.3 million (+0% versus pcp) • Gross Profit $51.1 million (+18% versus pcp) • Gross Margin 65.0% (+12% versus pcp) • Direct Contribution: $29.8 million (+35% pcp) 17 Dermatology portfolio mix shift drives margins & contribution growth 1H FY25 Revenue by Category – TOTAL $81.4 million 1H FY26 Revenue by Category – TOTAL $78.6 million Total Revenue Growth: -3% $51.2, 65% $27.4, 35% Branded All Other $44.5, 55% $36.9, 45% Branded All Other 43.4 39.5 51.1 53.0% 54.0% 65.0% 0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% 25 30 35 40 45 50 55 1HFY25 2HFY25 1HFY26 Gross Profit (A$m) Margin (%) Gross Margin Growth +1200 bps Gross Profit Growth +29% Contribution Growth +35% 18 Dermatology: Improved product mix, solid channel growth from disintermediation strategy Future growth drivers for Dermatology • Scale the disintermediation/channel strategy (specialty pharmacy ecosystem) to reduce friction for prescribers/patients and lift direct contribution as mix improves • Expand and refresh the dermatology portfolio via capital-efficient, accretive business arrangements and targeted BD (new FDA-approved brands/products) to broaden addressable segments • Drive prescriptions (Rx) through stronger commercial execution—sales force capability upgrades plus refreshed marketing materials to rebuild/accelerate demand and support launches. • Improve gross margin through product mix and channel shift (higher-value brands and more favourable channel economics) even when top-line is pressured by generics International 20 1H FY26 Operating Highlights International: investing to create new opportunities • Pharmaceutical Benefits Scheme (PBS) approval for NEXTSTELLIS® in Australia: investment into promotion commenced post PBS approval • Inauguration of completed Salisbury facility ($18m investment including $4.8m from the Modern Manufacturing Initiative (MMI) government grant) • External recognition for export performance: finalist in the 2025 Australian Export Awards and multiple SA Premier’s Business & Export Awards (incl. SA Business of the Year). 1H FY26 Financial Highlights • Revenue $36.9 million (-1% versus pcp) • Direct Opex $9.2 million (+32% versus pcp) • Gross Profit $11.3 million (+7% versus pcp) • Gross Margin %: 30.5% (+3% versus pcp) • Direct Contribution: $2.1 million (-42% pcp) 21 International: investing to create new opportunities Future growth drivers for International • More capacity and reliability from Salisbury (post-upgrade) enabling higher output, better service levels and improved DIFOT1 to support growth in export and partner demand • NEXTSTELLIS® PBS listing tailwind driving Australian Rx growth as affordability/ access improves promotion accelerates: 118% growth in 3 pack volumes in Dec 2025 (post PBS) v Jul 2025 (pre PBS) • Unlock value from significant infrastructure investment, drive operating leverage and improved utilisation at the facility • International supply agreements / expanded partnerships to grow exports and increase third-party volume through the network. 1. DIFOT – Delivered In full on Time 22 FY26 focus and outlook • Women’s Health: continue market share growth with dedicated people who are 100% focused on women’s health, refreshed marketing, product access solutions, strong intellectual property for our best-in-class products. Targeted investments to drive growth and sustainable cost leverage. • Dermatology: take the next step in our disintermediation strategy – fully leverage the ecosystem we have built to improve access and patient outcomes for dermatology, pursue expansion into other therapeutic areas. • International: focused activities to unlock the value created by the investments that have been made in the international business (NEXTSELLIS® PBS listing, capex infusion, international supply agreements). • Legal: enforce agreements and reserve all of Mayne Pharma’s rights, balancing costs with shareholder value in mind. • Capital: acquire synergistic, capital efficient assets to improve scale and capital allocation strategies generally, which may include a share buy-back. 23 You deserve tomorrow. Q&A For further information contact: Dr Tom Duthy Investor Relations +61 402 493 727 [email protected] Sign up for our ASX email alerts at: https://www.maynepharma.com/investor-relations/email-alerts Appendix 25 Segment Performance 1. Gross Profit includes depreciation, which is included in COGS (refer to “cost of sales” depreciation amount in Note 3 of the financial statements). 2. Direct opex includes lease depreciation, which is largely related to motor vehicles of salesforce (refer to “marketing and distribution expenses” depreciation amount in Note 3 of the financial statements). Reported results (A$million) 1HFY26 1HFY25 2HFY25 FY25 Change vs 1HFY25 1HFY26 1HFY25 2HFY25 FY25 Change vs 1HFY25 Revenue Gross profit1 Women's Health 96.5 94.3 84.1 178.4 2% Women's Health 76.2 76.9 66.0 142.9 -1% Dermatology 78.6 81.4 72.7 154.1 -3% Dermatology 51.1 43.4 39.5 82.8 18% International 36.9 37.4 38.3 75.6 -1% International 11.3 10.6 10.9 21.5 7% Total 212.1 213.1 195.0 408.1 0% Total 138.6 130.9 116.5 247.3 6% Operating expenses 2 Direct Contribution Women's Health 40.0 37.6 43.3 80.9 6% Women's Health 36.2 39.3 22.7 62.0 -8% Dermatology 21.3 21.4 21.2 42.6 0% Dermatology 29.8 22.1 18.2 40.2 35% International 9.2 6.9 7.1 14.1 32% International 2.1 3.6 3.8 7.4 -42% Total 70.5 65.9 71.7 137.6 7% Total 68.1 65.0 44.8 109.7 5% Investment in Women’s Health Sales & Marketing, Branded Dermatology / Disintermediation, NEXTSTELLIS® in AU Major Focus Areas in 1HFY26 26 Women’s Health: portfolio performance (USD and AUD) * Direct contribution calculated as gross profit less direct opex – includes depreciation of motor vehicle leases in direct opex ** Cash contribution calculated as direct contribution plus add-back for depreciation and less proportional earn-out liability : portion of earnout liability related to revenues for the period independent of timing / capitalised amount Women's Health in US$'000 1HFY26 1HFY25 2HFY25 FY25 Total Revenue 63,246 62,342 53,169 115,510 Total Gross Profit 49,946 50,824 41,720 92,545 Total Gross Profit % of Revenue 79% 82% 78% 80% Direct OPEX (26,198) (24,864) (27,525) (52,389) Direct Contribution 23,748 25,960 14,195 40,155 Depreciation Add-Back 519 583 535 1,118 Earn-out liability (4,342) (4,466) (3,731) (8,197) "Cash" Contribution** 19,926 22,077 10,999 33,076 Women's Health in A$'000 1HFY26 1HFY25 2HFY25 FY25 Reported Revenue 96,529 94,286 84,081 178,367 Reported Gross Profit 76,230 76,867 66,037 142,904 Total Gross Profit % of Revenue 79% 82% 79% 80% Direct OPEX (39,984) (37,605) (43,293) (80,898) Direct Contribution* 36,246 39,262 22,744 62,006 Depreciation Add-Back 792 882 844 1,726 Earn-out liability (6,626) (6,754) (5,903) (12,657) "Cash" Contribution** 30,411 33,389 17,686 51,075 27 Dermatology: Improvements in product mix delivers strong contribution (USD & AUD) * Direct contribution calculated as gross margin less direct opex – includes depreciation and allocation of shared functions & overhead within COGS and depreciation of motor vehicle leases in direct opex ** Cash contribution calculated as direct contribution plus add-back for depreciation and less proportional earn-out liability: portion of earnout liability related to revenues for the period independent of timing / capitalised amount Dermatology in US$'000 1HFY26 1HFY25 2HFY25 FY25 Total Revenue 51,510 53,813 45,973 99,786 Total Gross Profit 33,468 28,699 24,946 53,645 Total Gross Profit % of Revenue 65% 53% 54% 54% Direct OPEX (13,956) (14,119) (13,464) (27,582) Direct Contribution* 19,512 14,581 11,482 26,063 Depreciation Add-Back 469 491 463 954 Earn-out liability (551) (611) (77) (688) "Cash" Contribution** 19,430 14,461 11,867 26,328 Dermatology in A$'000 1HFY26 1HFY25 2HFY25 FY25 Reported Revenue 78,618 81,386 72,699 154,085 Reported Gross Profit 51,081 43,405 39,432 82,837 Total Gross Profit % of Revenue 65% 53% 54% 54% Direct OPEX (21,300) (21,353) (21,238) (42,592) Direct Contribution* 29,781 22,052 18,193 40,245 Depreciation Add-Back 715 742 730 1,473 Earn-out liability (841) (924) (139) (1,063) "Cash" Contribution** 29,655 21,870 18,785 40,655 28 International: strategic and operational levers building momentum (AUD) * Direct contribution calculated as gross margin less direct opex – includes depreciation and allocation of shared functions & overhead. Corresponds to 4D segment note ** Cash contribution calculated as direct contribution plus add-back for depreciation and less proportional earn-out liability: portion of earnout liability related to revenues for the period independent of timing / capitalised amount International in A$'000 1HFY26 1HFY25 2HFY25 FY25 Reported Revenue 36,923 37,382 38,261 75,643 Reported Gross Profit 11,268 10,587 10,946 21,533 Total Gross Profit % of Revenue 31% 28% 29% 28% Direct OPEX (9,211) (6,945) (7,147) (14,092) Direct Contribution* 2,057 3,642 3,799 7,441 Depreciation Add-Back 1,930 1,907 1,916 3,823 Earn-out liability - - - - "Cash" Contribution** 3,988 5,549 5,715 11,264 29 Reported EBITDA to Underlying Bridge ● Underlying EBITDA delivering steady operational improvements resulting from higher revenue and operational execution ● Underlying EBITDA excludes non-cash items, including: • Earn out reassessment +$54.5m • Fair Value Adjustment of Convertible Note Derivative (as a result of share price movement across the year) +$6.8m • Litigation and restructuring expenses, other ($4.2m) • Diligence & Business Development ($21.3m) • Other Adjustment ($1.4m) 1. Statutory accounts include amounts relating to depreciation which are added back to reconcile to EBITDA. 1HFY25 Depreciation: Gross Profit ($2.2m), Direct opex ($1.4m), Indirect opex ($0.6m). FY25 Depreciation: Gross Profit ($4.3m), Direct opex ($2.7m), Indirect opex ($1.2m). 1HFY26 Depreciation: Gross Profit ($2.2m), Direct opex ($1.2m), Indirect opex ($0.6m). A$million 1HFY26 1HFY25 2HFY25 FY25 Reported Revenue 212.1 213.1 195.0 408.1 Reported Gross Profit 138.6 130.9 116.4 247.3 Total Gross Profit % of Revenue 65% 61% 60% 61% Direct OPEX (70.5) (66.0) (71.6) (137.6) Direct Contribution* 68.1 65.0 44.8 109.7 Indirect OPEX (63.8) (45.4) (39.4) (84.7) Other Income 0.2 1.3 0.4 1.7 Earn-out Reassessments 54.5 1.0 (17.6) (16.6) Depreciation Add-Back 4.0 4.2 4.1 8.3 Reported EBITDA 63.0 26.1 (7.6) 18.4 Earn-out Reassessments (54.5) (1.0) 17.6 16.6 Fair Value Adjustment of Convertible Note Derivative (6.8) (0.2) (1.5) (1.7) Scheme legal fees (inc. litigation) 21.3 2.5 6.0 8.5 Litigation and Restructuring Expenses 4.2 3.6 1.6 5.2 Other Adjustment 1.4 - - - Underlying EBITDA 28.6 31.0 16.1 47.0 30 Consolidated Balance Sheet 31-Dec-25 30-Jun-25 Change Balance Sheet Extract A$m A$m A$m Cash 67.3 59.8 7.5 Marketable securities 0.1 42.9 (42.8) Receivables 191.4 180.6 10.8 Inventory 47.5 50.6 (3.1) Income tax receivable 1.1 1.3 (0.2) PP&E 52.1 53.1 (1.0) Intangible assets including goodwill 503.1 545.8 (42.7) Other assets 77.9 80.5 (2.6) Total assets 940.5 1,014.6 (74.1) Interest-bearing debt (including lease liabilities) 39.9 38.8 1.1 Trade and other payables 200.1 244.5 (44.4) Other financial liabilities 416.3 381.8 34.5 Other liabilities 28.2 23.9 4.3 Total liabilities 684.5 689.0 (4.5) Equity 446.2 454.1 (7.9) 31 $23.4, 37% $14.4, 23% $15.6, 25% $8.2, 13% $1.6, 2% Women’s Health: revenue, margin and contribution summary $20.1, 38% $13.6, 26% $12.0, 22% $5.9, 11% $1.6, 3% Gross Margin: 78% Direct opex: US$27.5m Direct Cont.: US$14.2m / A$22.7m $22.4, 36% $15.8, 25% $15.3, 25% $6.6, 11% $2.2, 3% 1HFY25 Total Revenue US$62.3m +34.3% v 2HFY24 2HFY25 Total Revenue US$53.2m +14.7% v pcp, -14.6% seq. Gross Margin: 82% Direct opex: US$24.9m Direct Cont.: US$26.0m / A$39.3m 1HFY26 Total Revenue US$63.2m +1.4% v pcp, +18.8% seq. Gross Margin: 79% Direct opex: US$26.2m Direct Cont.: US$23.7m / A$36.2m 1. All figures in the charts shown in USD 32 Women’s Health – favourable macro trends positions Mayne Pharma well • Affordable Care Act - In all 50 states, the ACA guarantees coverage of women's preventive services for individuals and covered dependents • 3 executive orders by President Biden on strengthening access to contraception • Biden’s US$2bn investment in Women’s Health research & education • Global menopause market hit US$15.4bn in 2021 and is projected to reach US$24.4bn by 20301 • Increased need for contraception options post Roe v Wade in the US • Greater emphasis on education and training (Obs/Gyn) (historically, lack of clinical education in menopause – only 31% of Obs/Gyn report receiving menopause curriculum during residency)2 • Increased awareness of the impact of menopause (e.g. published articles, celebrities drawing awareness) Key macro trends in Women’s Health Mayne Pharma • Participate in efforts to provide information and feedback to lawmakers on ACA • Working to develop programs that will benefit from the US$2bn Women’s Health program • BIJUVA® – only available, FDA approved bioidentical combination treatment for vasomotor symptoms associated with menopause • NEXTSTELLIS® and ANNOVERA® are unique contraceptive solutions • Investment in Medical Science Liaisons to raise product scientific awareness • Supporting education programs on the use of hormones for contraception and menopause • Sales team of 85 able to reach target customers Growing addressable Women’s Health market Increased awareness and education Government Support / Initiatives 1. https://www.grandviewresearch.com/press-release/global-menopause-market 2. Allen JT et al, 2023, Menopause. 1;30(10):1002-1005. 33 Dermatology: Mayne Pharma can fill 1 in 3 retail prescriptions for medical dermatology1 • Health insurance benefit design has shifted large cost burden to patients in dermatology • Large retailers often carry limited dermatologic agents due to high costs and often call back prescribers to switch patients’ prescriptions to older, cheaper options • Rising incidence of skin diseases, and a growing awareness and increased spend on personal care (e.g. Acne – 50m people in the US)2 • Patient preference for consultation with specialist dermatologists for chronic skin conditions supports continued growth • Few products in development for the treatment of common dermatology conditions, introducing a longer life cycle for currently available dermatology products Key Macro trends in Dermatology Mayne Pharma • Leverage existing 400+ speciality pharmacies, convenient for repeat prescriptions across brands and generics • Uninsured patients receive the prescribed product at a reasonable and predictable cost with limited special assistance from their dermatologist required • Increasing number of patients are treatable via Mayne Pharma’s portfolio • Portfolio of branded (EPSOLAY®, DORYX®, FABIOR®, LEXETTE®, RHOFADE®, SORILUX®, TWYNEO® and WYNZORA®) and generic (n=20) gives focus and presence to dermatology prescribers • Opportunity to expand our portfolio offering in near term via capital light transactions Expanding treatable population Retreat by Big Pharma from medical dermatology Disintermediation 1. IQVIA recent 12-month TRx totals by molecule. 2. American Academy of Dermatology Association. 34 Earn-Out and Deferred Consideration Liabilities - Update Dermatology Women’s Health International 8% Net Sales on all TXMD Licensed Products (ANNOVERA®, IMVEXXY®, BIJUVA®) N/M2 N/M Royalties Milestones 10% Net Sales to Population Council (ANNOVERA®)1 Population Council: US$40.0m (cumulative sales of US$400m: ANNOVERA®) Population Council: US$40.0m (cumulative sales of US$1
Open panelView summary and Q&As
Share your feedback
How likely is it that you would recommend Mayne Pharma Group Limited to another investor?
Likely
Neutral
Unlikely
0 responses
Questions (0)
Post question
Your question will be sent privately to Mayne Pharma Group Limited. The company may choose to make this question public.
Start the conversation
Ask Mayne Pharma Group Limited a question about this announcement.
Discover
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:04 AM](https://investors.maynepharma.com/announcements/69glBo-notification-regarding-unquoted-securities-myx)
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:03 AM](https://investors.maynepharma.com/announcements/RQVGgB-notification-regarding-unquoted-securities-myx)
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:02 AM](https://investors.maynepharma.com/announcements/46zl4q-notification-regarding-unquoted-securities-myx)
Summary
Summary
Questions (0)
Provide feedback to Mayne Pharma Group Limited. Complete survey to view results.
How likely is it that you would recommend Mayne Pharma Group Limited to another investor?
Likely
Neutral
Unlikely
0 responses
Post question
Your question will be sent privately to Mayne Pharma Group Limited. The company may choose to make this question public.
Start the conversation
Ask Mayne Pharma Group Limited a question about this announcement.
Share your feedback
How likely is it that you would recommend Mayne Pharma Group Limited to another investor?
Likely
Neutral
Unlikely
0 responses
Discover
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:04 AM](https://investors.maynepharma.com/announcements/69glBo-notification-regarding-unquoted-securities-myx)
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:03 AM](https://investors.maynepharma.com/announcements/RQVGgB-notification-regarding-unquoted-securities-myx)
[![]()
Notification regarding unquoted securities - MYX
Released 29 Oct 2026 - 8:02 AM](https://investors.maynepharma.com/announcements/46zl4q-notification-regarding-unquoted-securities-myx)
We value your privacy
We use cookies, including those from select third parties, to enhance your experience on our website and to help improve our services as specified in our Privacy Policy.
By clicking "Accept all", you consent to our use of cookies.
Our cookie notice lists every cookie we set, what it does and how long it lasts.
Closing this window accepts our default settings. You can change them at any time from cookie settings.
Accept allReject allCustomise settings
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Mayne Pharma Group Limited
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| DFIS | 0.00% | 54,599 | $ 126.047K | Nov 12, 2026 |
| DFIC | 0.00% | 52,725 | $ 121.72K | Nov 12, 2026 |
| DFAX | 0.00% | 4,930 | $ 11.381K | Nov 12, 2026 |
| DFAI | 0.00% | 4,979 | $ 11.494K | Nov 12, 2026 |
| AVDE | 0.00% | 42,015 | $ 90.396K | Nov 16, 2026 |
| AVDV | 0.00% | 147,610 | $ 317.585K | Nov 16, 2026 |
| AVSD | 0.00% | 5,977 | $ 12.86K | Nov 16, 2026 |
| AVDS | 0.00% | 5,894 | $ 12.681K | Nov 16, 2026 |